

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 February 2004 (26.02.2004)

PCT

(10) International Publication Number
WO 2004/016636 A1

(51) International Patent Classification⁷: **C07H 21/00**

104-1, Moongi-dong, Yuseong-gu, Taejeon 305-380 (KR).
SONG, Si Young [KR/KR]; College of Medicine, Yonsei
University, 134, Sinchon-dong, Seodaemun-gu, Seoul
120-749 (KR).

(21) International Application Number:
PCT/KR2003/001653

(22) International Filing Date: 14 August 2003 (14.08.2003)

(74) Agent: **CHOI, Kyu Pal**; Halla Classic Building 4F,
824-11, Yeoksam-dong, Kangnam-ku, Seoul 135-080
(KR).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/402,904	14 August 2002 (14.08.2002)	US
60/404,408	20 August 2002 (20.08.2002)	US
60/405,304	23 August 2002 (23.08.2002)	US
60/421,582	28 October 2002 (28.10.2002)	US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **LG LIFE
SCIENCES LTD.** [KR/KR]; LG Twin Tower, East Tower,
20, Yoido-Dong, Youngdungpo-Ku, Seoul 150-010 (KR).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **KOH, Sang Seok**
[KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1,
Moongi-dong, Yuseong-gu, Taejeon 305-380 (KR). **LIU,
Qing** [US/US]; 708 Quince Orchard Road, Gaithers-
burg, Maryland, MD 20878 (US). **CHUNG, Hyun-Ho**
[KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1,
Moongi-dong, Yuseong-gu, Taejeon 305-380 (KR).
ZENG, Wen [US/US]; 708 Quince Orchard Road,
Gaithersburg, Maryland, MD 20878 (US). **LEE, Bog-
man** [KR/KR]; R & D Park, LG Life Sciences Ltd.,

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: GENE FAMILIES ASSOCIATED WITH STOMACH CANCER

(57) Abstract: The invention relates generally to the changes in gene expression in stomach cancer. The invention relates specifically to human gene families that correspond to mRNA species that are differentially expressed in cancerous stomach tissue compared to normal stomach tissue.

WO 2004/016636 A1

GENE FAMILIES ASSOCIATED WITH STOMACH CANCER

TECHNICAL FIELD

5 The invention relates generally to the changes in gene expression in stomach tissue from stomach cancer patients compared to normal stomach tissue. The invention specifically relates to human gene families which are differentially expressed in advanced gastric cancers and other malignant neoplasms compared to normal tissue.

BACKGROUND ART

Stomach Cancer

10 In the United States, approximately 24,000 new cases of stomach cancer, or gastric cancer, are diagnosed every year. Although the incidence of stomach cancer has declined significantly in the last 60 years, it is still a serious disease caused by factors that remain elusive. Under similar circumstances, some people develop stomach cancer and others do not.

15 Stomach cancer usually occurs in people over the age of 55 and is twice as common in men as in women. This type of cancer is not prevalent in the United States, but it is much more prevalent in Japan, Korea, Latin America and parts of Eastern Europe, where people eat more foods that are preserved by drying, pickling, smoking or salting. Conversely, consuming fresh fruits and vegetables may protect against this disease.

20 Stomach cancer can develop in any part of the stomach and spread throughout the stomach and/or to other organs. The cancer may also grow along the stomach wall and spread to the esophagus or small intestine. If the cancer grows through the stomach wall, it can extend to nearby lymph nodes, the liver and the pancreas and the colon. Stomach cancer can spread even farther, to the ovaries, lungs and distant lymph nodes. When stomach cancer metastasizes to another part of the body, these tumor cells are of the same

10 / 524258
BT01 Rec'd PCT/PTC 11 FEB 2005

type as those in the original tumor. In other words, metastasized cells in the liver are still stomach tumor cells. Such tumor cells that spread to an ovary, establishing one or more ovarian tumors, are known as Krukenberg tumors and are composed of transformed stomach cells, not ovarian cells.

5 Because the symptoms of stomach cancer are non-specific, this cancer is difficult to detect in its early stages. Symptoms include indigestion, heartburn, abdominal pain, nausea and vomiting, diarrhea or constipation, loss of appetite, weakness and fatigue, and bleeding which is detected by blood in the stool or by the affected person vomiting blood. Diagnosis is usually performed by x-rays of the upper gastrointestinal tract and esophagus, 10 the x-rays taken after the patient has consumed a liquid barium tracer. Endoscopy of the stomach and esophagus, with a gastroscope, can also be performed. If abnormal tissue is found, it can be biopsied through the gastroscope. Should the biopsy specimen show cancerous cells, surrounding lymph nodes are then biopsied, and surrounding organs, such as the liver and pancreas, are examined via CT scan to determine the extent or stage of the 15 disease. Treatment methods for stomach cancer are similar to those employed in other types of cancer- removal of the affected organ (partial or total gastrectomy), possibly with removal of nearby lymph nodes as well, chemotherapy, radiation therapy and immunotherapy (stimulating immune system components that attack cancer cells) (<http://cancernet.nci.nih.gov/cancertypes.html>). As early stomach cancer causes few 20 symptoms, diagnosis is not usually made before the advanced stages of the disease, where treatments are less effective.

Molecular Changes in Stomach Cancer

25 Little is known about the molecular changes in stomach cells associated with the development and progression of stomach cancer. Accordingly, there exists a need for the investigation of the changes in gene expression levels, as well as the need for the identification of new molecular markers associated with the development and progression of stomach cancer. Furthermore, if intervention is expected to be successful in halting or

slowing the progression of stomach cancer, means of accurately assessing the early manifestations of this disease need to be established. One way to accurately assess the early manifestations of stomach cancer is to identify markers which are uniquely associated with disease progression (see for example Kim *et al.* (2001), *Oncogene* 20: 4568-4575). Likewise, the development of therapeutics to prevent or stop the progression of stomach cancer relies on the identification of genes responsible for cancerous transformation and growth in the stomach.

DISCLOSURE OF THE INVENTION

The present invention is based on the discovery of new gene families that are differentially expressed in advanced gastric cancer (AGC) and other malignant neoplasms compared to normal tissue. The invention includes an isolated nucleic acid molecule comprising SEQ ID NO: 3, 5, 7, 9, 11, 13, 17 or 19; an isolated nucleic acid molecule that encodes the amino acid sequence of SEQ ID NO: 4, 14 or 18; an isolated nucleic acid molecule that encodes a protein that is expressed in stomach cancer and that exhibits at least about 92% nucleotide sequence identity over the entire length of SEQ ID NO: 3 or 17, an isolated nucleic acid molecule that encodes a protein that is expressed in stomach cancer and that exhibits at least about 95% nucleotide sequence identity over the entire length of SEQ ID NO: 13, and an isolated nucleic acid molecule comprising the complement of any of the aforementioned nucleic acid molecules.

The present invention further includes the nucleic acid molecules operably linked to one or more expression control elements, including vectors comprising the isolated nucleic acid molecules. The invention further includes host cells transformed to contain the nucleic acid molecules of the invention and methods for producing a protein comprising the step of culturing a host cell transformed with a nucleic acid molecule of the invention under conditions in which the protein is expressed.

The invention further provides an isolated polypeptide selected from the group

consisting of an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 4, 6, 8, 10, 12, 14 or 18, an isolated polypeptide comprising a fragment of at least 10 amino acids of SEQ ID NO: 6, 8, 10 or 12, an isolated polypeptide comprising conservative amino acid substitutions of SEQ ID NO: 6, 8, 10 or 12 and an isolated polypeptide comprising naturally occurring amino acid sequence variants of SEQ ID NO: 6, 8, 10 or 12. Polypeptides of the invention also include polypeptides with an amino acid sequence having at least about 90% amino acid sequence identity with the sequence set forth in SEQ ID NO: 4, preferably at least about 92-95%, and more preferably at least about 95-98% sequence identity with the sequence set forth in SEQ ID NO: 4. Polypeptides of the invention also include polypeptides with an amino acid sequence having at least about 50%, 60%, 70% or 75% amino acid sequence identity with the sequence set forth in SEQ ID NO: 6, 8, 10 or 12, preferably at least about 80%, more preferably at least about 90-95%, and most preferably at least about 95-98% sequence identity with the sequence set forth in SEQ ID NO: 6, 8, 10 or 12. Polypeptides of the invention also include polypeptides with an amino acid sequence having at least about 95% and at least about 92% amino acid sequence identity with the sequence set forth in SEQ ID NO: 14 and SEQ ID NO: 18, respectively.

The invention further provides an isolated antibody or antigen-binding antibody fragment that specifically binds to a polypeptide of the invention, including monoclonal and polyclonal antibodies.

The invention further provides methods of identifying an agent which modulates the expression of a nucleic acid molecule encoding a protein of the invention, comprising: exposing cells which express the nucleic acid molecule to the agent; and determining whether the agent modulates expression of said nucleic acid molecule, thereby identifying an agent which modulates the expression of a nucleic acid molecule encoding the protein.

The invention further provides methods of identifying an agent which modulates the level of or at least one activity of a protein of the invention, comprising: exposing cells which express the protein to the agent; and determining whether the agent modulates the

level of or at least one activity of said protein, thereby identifying an agent which modulates the level of or at least one activity of the protein.

The invention further provides methods of identifying binding partners for a protein of the invention, comprising the steps of exposing said protein to a potential binding partner; and determining if the potential binding partner binds to said protein, thereby identifying binding partners for the protein.

The present invention further provides methods of modulating the expression of a nucleic acid molecule encoding a protein of the invention, comprising the step of administering an effective amount of an agent which modulates the expression of a nucleic acid molecule encoding the protein. The invention also provides methods of modulating at least one activity of a protein of the invention, comprising the step of administering an effective amount of an agent which modulates at least one activity of the protein of the invention.

The present invention further includes non-human transgenic animals modified to contain the nucleic acid molecules of the invention, or non-human transgenic animals modified to contain the mutated nucleic acid molecules such that expression of the encoded polypeptides of the invention is prevented.

The present invention also includes non-human transgenic animals in which all or a portion of a gene comprising all or a portion of SEQ ID NO: 3, 5, 7, 9, 11, 13 or 17 has been knocked out or deleted from the genome of the animal.

The invention further provides methods of diagnosing stomach cancer or other malignant neoplasms, comprising the steps of acquiring a tissue, blood, urine or other sample from a subject and determining the level of expression of a nucleic acid molecule of the invention or polypeptide of the invention.

The invention further includes compositions comprising a diluent and a polypeptide or protein selected from the group consisting of an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 4, 6, 8, 10, 12, 14 or 18, an isolated polypeptide with an amino acid sequence having at least about 90% amino acid sequence

identity with the sequence set forth in SEQ ID NO: 4, preferably at least about 92-95%, and more preferably at least about 95-98% sequence identity with the sequence set forth in SEQ ID NO: 4, an isolated polypeptide comprising a fragment of at least 10 amino acids of SEQ ID NO: 6, 8, 10 or 12, an isolated polypeptide comprising conservative amino acid substitutions of SEQ ID NO: 6, 8, 10 or 12, naturally occurring amino acid sequence variants of SEQ ID NO: 6, 8, 10 or 12, an isolated polypeptide with an amino acid sequence having at least about 50%, 60%, 70% or 75% amino acid sequence identity with the sequence set forth in SEQ ID NO: 6, 8, 10 or 12, preferably at least about 80%, more preferably at least about 90-95%, and most preferably at least about 95-98% sequence identity with the sequence set forth in SEQ ID NO: 6, 8, 10 or 12, an isolated polypeptide with at least about 95% amino acid sequence identity with the sequence set forth in SEQ ID NO: 14, or an isolated polypeptide with at least about 92% amino acid sequence identity with the sequence set forth in SEQ ID NO: 18.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 Figure 1 is a diagram showing the sequence differences between SEQ ID NO: 1 (clone AD12) and SEQ ID NO: 3 (clone CH4), which are splice variants of the gene designated LBFL301.

Figure 2 Figure 2 is a hydrophobicity plot of the protein encoded by the open reading frame of LBFL301, variant AD12 (SEQ ID NO: 2). Analysis was performed according to the methods of Kyte-Doolittle and Goldman *et al.*

Figure 3 Figure 3 is a hydrophobicity plot of the protein encoded by the open reading frame of LBFL301, variant CH4 (SEQ ID NO: 4). Analysis was performed according to the methods of Kyte-Doolittle and Goldman *et al.*

Figure 4 Figure 4 is a hydrophobicity plot of the protein encoded by the longest of the open reading frames of LBFL304 (SEQ ID NO: 6). Analysis was performed according to the methods of Kyte-Doolittle and Goldman *et al.*

5 Figure 5 Figure 5 is a hydrophobicity plot of the protein encoded by the open reading frame of LBFL305 (SEQ ID NO: 14). Analysis was performed according to the methods of Kyte-Doolittle and Goldman *et al.*

Figure 6 Figure 6 shows the relative alignment positions of the three
10 LBFL306 clones.

Figure 7 Figure 7 is a hydrophobicity plot of the protein encoded by the open reading frame of clone no. LBFL306-EF3 (SEQ ID NO: 18). Analysis was performed according to the methods of Kyte-Doolittle and Goldman *et al.*

15 Figure 8 Figure 8 is a hydrophobicity plot of the protein encoded by the open reading frame of clone no. LBFL306-GC7 (SEQ ID NO: 20). Analysis was performed according to the methods of Kyte-Doolittle and Goldman *et al.*

20 Figure 9 Figure 9 is a hydrophobicity plot of the protein encoded by the open reading frame of clone no. LBFL306-GE2 (SEQ ID NO: 22). Analysis was performed according to the methods of Kyte-Doolittle and Goldman *et al.*

BEST MODE FOR CARRYING OUT THE INVENTION

I. General Description

25 The present invention is based in part on the identification of new gene families that are differentially expressed in cancerous human stomach tissue and other malignant

neoplasms compared to normal human tissue. These gene families include the human cDNA of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 17, 19 and 21.

The genes and proteins of the invention may be used as diagnostic agents or markers to detect stomach cancer or to monitor the progression of stomach cancer in a sample. They can also serve as a target for agents that modulate gene expression or activity. For example, agents may be identified that modulate biological processes associated with tumor growth, including the hyperplastic process of stomach cancer.

II. Specific Embodiments

A. The Proteins Associated with Stomach Cancer

The present invention provides isolated proteins, allelic variants of the proteins, and conservative amino acid substitutions of the proteins. As used herein, the "protein" or "polypeptide" refers, in part, to a protein that has the human amino acid sequence depicted in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 18. The terms also refer to naturally occurring allelic variants and proteins that have a slightly different amino acid sequence than that specifically recited above. Allelic variants, though possessing a slightly different amino acid sequence than those recited above, will still have the same or similar biological functions associated with these proteins.

As used herein, the families of proteins related to the human amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 18 include proteins that have been isolated from organisms in addition to humans. The methods used to identify and isolate other members of the family of proteins related to these proteins are described below.

The proteins of the present invention are preferably in isolated form. As used herein, a protein is said to be isolated when physical, mechanical or chemical methods are employed to remove the protein from cellular constituents that are normally associated with the protein. A skilled artisan can readily employ standard purification methods to obtain an isolated protein.

The proteins of the present invention further include splice variants and insertion,

deletion or conservative amino acid substitution variants of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 18. As used herein, a conservative variant refers to alterations in the amino acid sequence that do not adversely affect the biological functions of the protein. A substitution, insertion or deletion is said to adversely affect the protein when the altered sequence prevents or disrupts a biological function associated with the protein. For example, the overall charge, structure or hydrophobic/hydrophilic properties of the protein, in certain instances, may be altered without adversely affecting a biological activity. Accordingly, the amino acid sequence can be altered, for example to render the peptide more hydrophobic or hydrophilic, without adversely affecting the biological activities of the protein.

Ordinarily, the allelic variants, the conservative substitution variants, and the members of the protein family encoded by LBFL301, will have an amino acid sequence having at least about 50%, 60%, 70% or 75% amino acid sequence identity with the sequence set forth in SEQ ID NO: 2 or 4, more preferably at least about 80-90%, even more preferably at least about 92-95%, and most preferably at least about 95-98% sequence identity. The allelic variants, the conservative substitution variants, and the members of the protein family encoded by LBFL304, will have an amino acid sequence having at least about 50%, 60%, 70% or 75% amino acid sequence identity with the sequence set forth in SEQ ID NO: 6, 8, 10 or 12, more preferably at least about 80%, even more preferably at least about 90-95%, and most preferably at least about 99 or 99.5% sequence identity. The allelic variants, the conservative substitution variants, and the members of the protein family encoded by LBFL305 or LBFL306, will have an amino acid sequence having at least about 50%, 60%, 70% or 75% amino acid sequence identity with the sequence set forth in SEQ ID NO: 14 or 18, more preferably at least about 80-90%, even more preferably at least about 92-94%, and most preferably at least about 95%, 98% or 99% sequence identity. Identity or homology with respect to such sequences is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 18 after aligning the sequences and introducing

gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity (see section B for the relevant parameters). Fusion proteins, or N-terminal, C-terminal or internal extensions, deletions, or insertions into the peptide sequence shall not be construed as affecting homology.

5 Thus, the proteins of the present invention include molecules having the amino acid sequence disclosed in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 18; fragments thereof having a consecutive sequence of at least about 3, 4, 5, 6, 10, 15, 20, 25, 30, 35 or more amino acid residues of these proteins; amino acid sequence variants wherein one or more amino acid residues has been inserted N- or C-terminal to, or within, the disclosed coding
10 sequence; and amino acid sequence variants of the disclosed sequence, or their fragments as defined above, that have been substituted by at least one residue. Such fragments, also referred to as peptides or polypeptides, may contain antigenic regions, functional regions of the protein identified as regions of the amino acid sequence which correspond to known protein domains, as well as regions of pronounced hydrophilicity. The regions are all
15 easily identifiable by using commonly available protein sequence analysis software such as MacVector (Oxford Molecular).

 Contemplated variants further include those containing predetermined mutations by, *e.g.*, homologous recombination, site-directed or PCR mutagenesis, and the corresponding proteins of other animal species, including but not limited to rabbit, mouse,
20 rat, porcine, bovine, ovine, equine and non-human primate species, and the alleles or other naturally occurring variants of the families of proteins (for example, a mouse homolog that shows similarity to the mouse protein corresponding to GenBank Accession No. XM_128002, XM_129365, NM_021420, NM_133971 (DNA sequence) and NP_598732 (protein sequence), all of which are incorporated herein by reference.) Additional
25 variants include derivatives wherein the protein has been covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid (for example a detectable moiety such as an enzyme or radioisotope).

The present invention further provides compositions comprising a protein or polypeptide of the invention and a diluent. Suitable diluents can be aqueous or non-aqueous solvents or a combination thereof, and can comprise additional components, for example water-soluble salts or glycerol, that contribute to the stability, solubility, activity, and/or storage of the protein or polypeptide.

As described below, members of the families of proteins can be used: (1) to identify agents which modulate the level of or at least one activity of the protein, (2) to identify binding partners for the protein, (3) as an antigen to raise polyclonal or monoclonal antibodies, (4) as a therapeutic agent or target and (5) as a diagnostic agent or marker of stomach cancer and other hyperplastic diseases.

B. Nucleic Acid Molecules

The present invention further provides nucleic acid molecules that encode the protein having SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 18 and the related proteins herein described, preferably in isolated form. As used herein, "nucleic acid" is defined as RNA or DNA that encodes a protein or peptide as defined above; is complementary to a nucleic acid sequence encoding such peptides; hybridizes to the nucleic acid of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 or 17 and remains stably bound to it under appropriate stringency conditions; encodes a polypeptide sharing at least about 50%, 60%, 70% or 75%, preferably at least about 80-90%, more preferably at least about 92-95%, and most preferably at least about 95-98% or more identity with the peptide sequence of SEQ ID NO: 2 or 4; exhibits at least 50%, 60%, 70% or 75%, preferably at least about 80-90%, more preferably at least about 92-95%, and even more preferably at least about 95-98% or more nucleotide sequence identity over the open reading frames of SEQ ID NO: 1 or 3; encodes a polypeptide sharing at least about 50%, 60%, 70% or 75%, preferably at least about 80%, more preferably at least about 85%, and most preferably at least about 90%, 95%, 98%, 99%, 99.5% or more identity with the peptide sequence of SEQ ID NO: 6, 8, 10 or 12; exhibits at least 50%, 60%, 70% or 75%, preferably at least about 80%, more preferably at least

about 85%, and even more preferably at least about 90%, 95%, 98%, 99%, 99.5% or more nucleotide sequence identity over the open reading frames of SEQ ID NO: 5, 7, 9 or 11; encodes a polypeptide sharing at least about 50%, 60%, 70% or 75%, preferably at least about 80-90%, more preferably at least about 92-94%, and most preferably at least about 95%, 98%, 99% or more identity with the peptide sequence of SEQ ID NO: 14 or 18; or exhibits at least 50%, 60%, 70% or 75%, preferably at least about 80-90%, more preferably at least about 92-94%, and even more preferably at least about 95%, 98%, 99% or more nucleotide sequence identity over the open reading frame of SEQ ID NO: 13 or 17.

The present invention further includes isolated nucleic acid molecules that specifically hybridize to the complement of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 or 17, particularly molecules that specifically hybridize over the open reading frame. Such molecules that specifically hybridize to the complement of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 or 17 typically do so under stringent hybridization conditions.

Specifically contemplated are genomic DNA, cDNA, mRNA and antisense molecules, as well as nucleic acids based on alternative backbones or including alternative bases, whether derived from natural sources or synthesized. Such hybridizing or complementary nucleic acids, however, are defined further as being novel and unobvious over any prior art nucleic acid including that which encodes, hybridizes under appropriate stringency conditions, or is complementary to nucleic acid encoding a protein according to the present invention.

Homology or identity at the nucleotide or amino acid sequence level is determined by **BLAST** (Basic Local Alignment Search Tool) analysis using the algorithm employed by the programs **blastp**, **blastn**, **blastx**, **tblastn** and **tblastx** (Altschul *et al.*, (1997) *Nucleic Acids Res* 25:3389-3402, and Karlin *et al.*, (1990) *Proc Natl Acad Sci USA* 87:2264-2268, both fully incorporated by reference) which are tailored for sequence similarity searching. The approach used by the **BLAST** program is to first consider similar segments, with and without gaps, between a query sequence and a database sequence, then to evaluate the statistical significance of all matches that are identified and finally to summarize only

those matches which satisfy a preselected threshold of significance. For a discussion of basic issues in similarity searching of sequence databases, see Altschul *et al.*, (1994) *Nature Genetics* 6: 119-129 which is fully incorporated by reference. The search parameters for **histogram**, **descriptions**, **alignments**, **expect** (*i.e.*, the statistical significance threshold for reporting matches against database sequences), **cutoff**, **matrix** and **filter** (low complexity) are at the default settings. The default scoring matrix used by **blastp**, **blastx**, **tblastn**, and **tblastx** is the **BLOSUM62** matrix (Henikoff *et al.*, (1992) *Proc Natl Acad Sci USA* 89:10915-10919, fully incorporated by reference), recommended for query sequences over 85 nucleotides or amino acids in length.

For **blastn**, the scoring matrix is set by the ratios of **M** (*i.e.*, the reward score for a pair of matching residues) to **N** (*i.e.*, the penalty score for mismatching residues), wherein the default values for **M** and **N** are 5 and -4, respectively. Four **blastn** parameters were adjusted as follows: **Q**=10 (gap creation penalty); **R**=10 (gap extension penalty); **wink**=1 (generates word hits at every **wink**th position along the query); and **gapw**=16 (sets the window width within which gapped alignments are generated). The equivalent **Blastp** parameter settings were **Q**=9; **R**=2; **wink**=1; and **gapw**=32. A **Bestfit** comparison between sequences, available in the GCG package version 10.0, uses DNA parameters **GAP**=50 (gap creation penalty) and **LEN**=3 (gap extension penalty) and the equivalent settings in protein comparisons are **GAP**=8 and **LEN**=2.

“Stringent conditions” are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl/0.0015 M sodium citrate/0.1% SDS at 50 °C , or (2) employ during hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42 °C . Another example is hybridization in 50% formamide, 5× SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt’s solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42 °C , with washes at 42 °C in 0.2× SSC and 0.1%

SDS. A skilled artisan can readily determine and vary the stringency conditions appropriately to obtain a clear and detectable hybridization signal. Preferred molecules are those that hybridize under the above conditions to the complement of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 or 17 and which encode a functional or full-length protein. Even more preferred hybridizing molecules are those that hybridize under the above conditions to the complement strand of the open reading frame of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 or 17.

As used herein, a nucleic acid molecule is said to be "isolated" when the nucleic acid molecule is substantially separated from contaminant nucleic acid molecules encoding other polypeptides.

The present invention further provides fragments of the disclosed nucleic acid molecules. As used herein, a fragment of a nucleic acid molecule refers to a small portion of the coding or non-coding sequence. The size of the fragment will be determined by the intended use. For example, if the fragment is chosen so as to encode an active portion of the protein, the fragment will need to be large enough to encode the functional region(s) of the protein. For instance, fragments which encode peptides corresponding to predicted antigenic regions may be prepared. If the fragment is to be used as a nucleic acid probe or PCR primer, then the fragment length is chosen so as to obtain a relatively small number of false positives during probing/priming (see the discussion in Section H).

Fragments of the nucleic acid molecules of the present invention (*i.e.*, synthetic oligonucleotides) that are used as probes or specific primers for the polymerase chain reaction (PCR), or to synthesize gene sequences encoding proteins of the invention, can easily be synthesized by chemical techniques, for example, the phosphoramidite method of Matteucci *et al.*, ((1981) *J Am Chem Soc* 103:3185-3191) or using automated synthesis methods. In addition, larger DNA segments can readily be prepared by well known methods, such as synthesis of a group of oligonucleotides that define various modular segments of the gene, followed by ligation of oligonucleotides to build the complete modified gene.

The nucleic acid molecules of the present invention may further be modified so as

to contain a detectable label for diagnostic and probe purposes. A variety of such labels are known in the art and can readily be employed with the encoding molecules herein described. Suitable labels include, but are not limited to, biotin, radiolabeled or fluorescently labeled nucleotides and the like. A skilled artisan can readily employ any such label to obtain labeled variants of the nucleic acid molecules of the invention.

C. Isolation of Other Related Nucleic Acid Molecules

As described above, the identification and characterization of the nucleic acid molecule having SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 or 17 allows a skilled artisan to isolate nucleic acid molecules that encode other members of the protein families in addition to the sequences herein described. Further, the presently disclosed nucleic acid molecules allow a skilled artisan to isolate nucleic acid molecules that encode other members of the families of proteins in addition to the proteins having SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 18.

For instance, a skilled artisan can readily use the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 18 to generate antibody probes to screen expression libraries prepared from appropriate cells. Typically, polyclonal antiserum from mammals such as rabbits immunized with the purified protein (as described below) or monoclonal antibodies can be used to probe a mammalian cDNA or genomic expression library, such as lambda gt11 library, to obtain the appropriate coding sequence for other members of the protein families. The cloned cDNA sequence can be expressed as a fusion protein, expressed directly using its own control sequences, or expressed by constructions using control sequences appropriate to the particular host used for expression of the enzyme.

Alternatively, a portion of the coding sequence herein described can be synthesized and used as a probe to retrieve DNA encoding a member of the protein family from any mammalian organism. Oligomers containing approximately 18-20 nucleotides (encoding about a 6-7 amino acid stretch) are prepared and used to screen genomic DNA or cDNA libraries to obtain hybridization under stringent conditions or conditions of sufficient stringency to eliminate an undue level of false positives.

Additionally, pairs of oligonucleotide primers can be prepared for use in a polymerase chain reaction (PCR) to selectively clone an encoding nucleic acid molecule. A PCR denature/anneal/extend cycle for using such PCR primers is well known in the art and can readily be adapted for use in isolating other encoding nucleic acid molecules.

5 Nucleic acid molecules encoding other members of the protein families may also be identified in existing genomic or other sequence information using any available computational method, including but not limited to: PSI-BLAST (Altschul *et al.*, (1997) *Nucleic Acids Res* 25:3389-3402); PHI-BLAST (Zhang *et al.*, (1998) *Nucleic Acids Res* 26:3986-3990), 3D-PSSM (Kelly *et al.*, (2000) *J Mol Biol* 299(2):499-520); and other
10 computational analysis methods (Shi *et al.*, (1999) *Biochem Biophys Res Commun* 262(1):132-138 and Matsunami *et. al.*, (2000) *Nature* 404(6778):601-604.

D. rDNA molecules Containing a Nucleic Acid Molecule

The present invention further provides recombinant DNA molecules (rDNAs) that
15 contain a coding sequence. As used herein, a rDNA molecule is a DNA molecule that has been subjected to molecular manipulation *in situ*. Methods for generating rDNA molecules are well known in the art, for example, see Sambrook *et al.*, Molecular Cloning - A Laboratory Manual, Third Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001. In the preferred rDNA molecules, a coding DNA sequence is
20 operably linked to expression control sequences and/or vector sequences.

The choice of vector and/or expression control sequences to which one of the protein family encoding sequences of the present invention is operably linked depends directly, as is well known in the art, on the functional properties desired, *e.g.*, protein expression, and the host cell to be transformed. A vector contemplated by the present
25 invention is at least capable of directing the replication or insertion into the host chromosome, and preferably also expression, of the structural gene included in the rDNA molecule.

Expression control elements that are used for regulating the expression of an

operably linked protein encoding sequence are known in the art and include, but are not limited to, inducible promoters, constitutive promoters, secretion signals, and other regulatory elements. Preferably, the inducible promoter is readily controlled, such as being responsive to a nutrient in the host cell's medium.

5 In one embodiment, the vector containing a coding nucleic acid molecule will include a prokaryotic replicon, *i.e.*, a DNA sequence having the ability to direct autonomous replication and maintenance of the recombinant DNA molecule extrachromosomally in a prokaryotic host cell, such as a bacterial host cell, transformed therewith. Such replicons are well known in the art. In addition, vectors that include a
10 prokaryotic replicon may also include a gene whose expression confers a detectable marker such as a drug resistance. Typical bacterial drug resistance genes are those that confer resistance to ampicillin, kanamycin, chloramphenicol or tetracycline.

Vectors that include a prokaryotic replicon can further include a prokaryotic or bacteriophage promoter capable of directing the expression (transcription and translation)
15 of the coding gene sequences in a bacterial host cell, such as *E. coli*. A promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur. Promoter sequences compatible with bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for insertion of a DNA segment of the present invention. Typical of such vector plasmids are
20 pUC8, pUC9, pBR322 and pBR329 available from BioRad Laboratories, (Richmond, CA), pPL and pKK223 available from Pharmacia (Piscataway, NJ).

Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, such as stomach cells, can also be used to form rDNA molecules that contain a coding sequence. Eukaryotic cell expression vectors, including viral vectors,
25 are well known in the art and are available from several commercial sources. Typically, such vectors are provided containing convenient restriction sites for insertion of the desired DNA segment. Typical of such vectors are pSVL and pKSV-10 (Pharmacia), pBPV-1/pML2d (International Biotechnologies, Inc.), pTDT1 (ATCC, #31255), the vector

pCDM8 described herein, and the like eukaryotic expression vectors. Vectors may be modified to include stomach cell specific promoters if needed.

Eukaryotic cell expression vectors used to construct the rDNA molecules of the present invention may further include a selectable marker that is effective in an eukaryotic cell, preferably a drug resistance selection marker. A preferred drug resistance marker is the gene whose expression results in neomycin resistance, *i.e.*, the neomycin phosphotransferase (*neo*) gene. (Southern *et al.*, (1982) *J Mol Anal Genet* 1:327-341) Alternatively, the selectable marker can be present on a separate plasmid, and the two vectors are introduced by co-transfection of the host cell, and selected by culturing in the appropriate drug for the selectable marker.

E. Host Cells Containing an Exogenously Supplied Coding Nucleic Acid Molecule

The present invention further provides host cells transformed with a nucleic acid molecule that encodes a protein of the present invention. The host cell can be either prokaryotic or eukaryotic. Eukaryotic cells useful for expression of a protein of the invention are not limited, so long as the cell line is compatible with cell culture methods and compatible with the propagation of the expression vector and expression of the gene product. Preferred eukaryotic host cells include, but are not limited to, yeast, insect and mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human cell line. Preferred eukaryotic host cells include Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells (NIH/3T3) available from the ATCC as CRL 1658, baby hamster kidney cells (BHK), and the like eukaryotic tissue culture cell lines.

Any prokaryotic host can be used to express a rDNA molecule encoding a protein of the invention. The preferred prokaryotic host is *E. coli*.

Transformation of appropriate cell hosts with a rDNA molecule of the present invention is accomplished by well known methods that typically depend on the type of vector used and host system employed. With regard to transformation of prokaryotic host

cells, electroporation and salt treatment methods are typically employed (see, for example, Cohen *et al.*, (1972) *Proc Natl Acad Sci USA* 69:2110; and Sambrook *et al.*, *supra*). With regard to transformation of vertebrate cells with vectors containing rDNAs, electroporation, cationic lipid or salt treatment methods are typically employed, see, for example, Graham *et al.*, (1973) *Virology* 52:456; Wigler *et al.*, (1979) *Proc Natl Acad Sci USA* 76:1373-1376.

Successfully transformed cells, *i.e.*, cells that contain a rDNA molecule of the present invention, can be identified by well known techniques including the selection for a selectable marker. For example, cells resulting from the introduction of an rDNA of the present invention can be cloned to produce single colonies. Cells from those colonies can be harvested, lysed and their DNA content examined for the presence of the rDNA using a method such as that described by Southern, (1975) *J Mol Biol* 98:503 or Berent *et al.*, (1985) *Biotech* 3:208, or the proteins produced from the cell assayed via an immunological method.

F. Production of Recombinant Proteins using a rDNA Molecule

The present invention further provides methods for producing a protein of the invention using nucleic acid molecules herein described. In general terms, the production of a recombinant form of a protein typically involves the following steps:

First, a nucleic acid molecule is obtained that encodes a protein of the invention, such as a nucleic acid molecule comprising, consisting essentially of or consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 17, nucleotides 131-862 or 131-859 of SEQ ID NO: 1, nucleotides 174-587 or 174-584 of SEQ ID NO: 3, nucleotides 38-892 or 38-895 of SEQ ID NO: 5, nucleotides 53-892 or 53-895 of SEQ ID NO: 7, nucleotides 65-892 or 65-895 of SEQ ID NO: 9, or nucleotides 92-892 or 92-895 of SEQ ID NO: 11, nucleotides 49-1437 or 49-1434 of SEQ ID NO: 13, or nucleotides 75-575 or 75-572 of SEQ ID NO: 17. If the encoding sequence is uninterrupted by introns, as are these open-reading-frames, it is directly suitable for expression in any host.

The nucleic acid molecule is then preferably placed in operable linkage with suitable control sequences, as described above, to form an expression unit containing the protein open reading frame. The expression unit is used to transform a suitable host and the transformed host is cultured under conditions that allow the production of the recombinant protein. Optionally the recombinant protein is isolated from the medium or from the cells; recovery and purification of the protein may not be necessary in some instances where some impurities may be tolerated.

Each of the foregoing steps can be done in a variety of ways. For example, the desired coding sequences may be obtained from genomic fragments and used directly in appropriate hosts. The construction of expression vectors that are operable in a variety of hosts is accomplished using appropriate replicons and control sequences, as set forth above. The control sequences, expression vectors, and transformation methods are dependent on the type of host cell used to express the gene and were discussed in detail earlier. Suitable restriction sites can, if not normally available, be added to the ends of the coding sequence so as to provide an excisable gene to insert into these vectors. A skilled artisan can readily adapt any host/expression system known in the art for use with the nucleic acid molecules of the invention to produce recombinant protein.

G. Methods to Identify Binding Partners

Another embodiment of the present invention provides methods for isolating and identifying binding partners of proteins of the invention. In general, a protein of the invention is mixed with a potential binding partner or an extract or fraction of a cell under conditions that allow the association of potential binding partners with the protein of the invention. After mixing, peptides, polypeptides, proteins or other molecules that have become associated with a protein of the invention are separated from the mixture. The binding partner that bound to the protein of the invention can then be removed and further analyzed. To identify and isolate a binding partner, the entire protein, for instance a protein comprising the entire amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or

18 can be used. Alternatively, a fragment of the protein can be used.

As used herein, a cellular extract refers to a preparation or fraction which is made from a lysed or disrupted cell. The preferred source of cellular extracts will be cells derived from human stomach tumors or transformed stomach cells, for instance, biopsy
5 tissue or tissue culture cells from gastric carcinomas. Alternatively, cellular extracts may be prepared from normal tissue or available cell lines, particularly stomach-derived cell lines.

A variety of methods can be used to obtain an extract of a cell. Cells can be disrupted using either physical or chemical disruption methods. Examples of physical
10 disruption methods include, but are not limited to, sonication and mechanical shearing. Examples of chemical lysis methods include, but are not limited to, detergent lysis and enzyme lysis. A skilled artisan can readily adapt methods for preparing cellular extracts in order to obtain extracts for use in the present methods.

Once an extract of a cell is prepared, the extract is mixed with the protein of the
15 invention under conditions in which association of the protein with the binding partner can occur. A variety of conditions can be used, the most preferred being conditions that closely resemble conditions found in the cytoplasm of a human cell. Features such as osmolarity, pH, temperature, and the concentration of cellular extract used, can be varied to optimize the association of the protein with the binding partner.

20 After mixing under appropriate conditions, the bound complex is separated from the mixture. A variety of techniques can be utilized to separate the mixture. For example, antibodies specific to a protein of the invention can be used to immunoprecipitate the binding partner complex. Alternatively, standard chemical separation techniques such as chromatography and density/sediment centrifugation can be used.

25 After removal of non-associated cellular constituents found in the extract, the binding partner can be dissociated from the complex using conventional methods. For example, dissociation can be accomplished by altering the salt concentration or pH of the mixture.

To aid in separating associated binding partner pairs from the mixed extract, the protein of the invention can be immobilized on a solid support. For example, the protein can be attached to a nitrocellulose matrix or acrylic beads. Attachment of the protein to a solid support aids in separating peptide/binding partner pairs from other constituents found in the extract. The identified binding partners can be either a single protein or a complex made up of two or more proteins. Alternatively, binding partners may be identified using a Far-Western assay according to the procedures of Takayama *et al.*, (1997) *Methods Mol Biol* 69:171-184 or Sauder *et al.*, (1996) *J Gen Virol* 77:991-996 or identified through the use of epitope tagged proteins or GST fusion proteins.

Alternatively, the nucleic acid molecules of the invention can be used in a yeast two-hybrid system or other *in vivo* protein-protein detection system. The yeast two-hybrid system has been used to identify other protein partner pairs and can readily be adapted to employ the nucleic acid molecules herein described.

H. Methods to Identify Agents that Modulate the Expression a Nucleic Acid Encoding the Genes Associated with Stomach Cancer

Another embodiment of the present invention provides methods for identifying agents that modulate the expression of a nucleic acid encoding a protein of the invention such as a protein having the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12 or 18, or a Mst1 protein or splice variant of the invention such as a protein having the amino acid sequence of SEQ ID NO: 14. The agents that modulate the expression of the nucleic acid encoding the Mst1 protein or splice variant will have particular use in the treatment of stomach cancer. Such assays may utilize any available means of monitoring for changes in the expression level of the nucleic acids of the invention. As used herein, an agent is said to modulate the expression of a nucleic acid of the invention if it is capable of up- or down-regulating expression of the nucleic acid in a cell.

In one assay format, cell lines that contain reporter gene fusions between nucleotides from within the open reading frame defined by nucleotides 131-862 of SEQ ID

NO: 1, or nucleotides 174-587 of SEQ ID NO: 3, nucleotides 38-895 of SEQ ID NO: 5, nucleotides 53-895 of SEQ ID NO: 7, nucleotides 65-895 of SEQ ID NO: 9, nucleotides 92-895 of SEQ ID NO: 11, nucleotides 49-1437 or 49-1434 of SEQ ID NO: 13, nucleotides 75-575 of SEQ ID NO: 17 and/or the 5' and/or 3' regulatory elements and any assayable fusion partner may be prepared. Numerous assayable fusion partners are known and readily available including the firefly luciferase gene and the gene encoding chloramphenicol acetyltransferase (Alam *et al.*, (1990) *Anal Biochem* 188:245-254). Cell lines containing the reporter gene fusions are then exposed to the agent to be tested under appropriate conditions and time. Differential expression of the reporter gene between samples exposed to the agent and control samples identifies agents which modulate the expression of a nucleic acid of the invention.

Additional assay formats may be used to monitor the ability of the agent to modulate the expression of a nucleic acid encoding a protein of the invention, such as the protein having SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 18. For instance, mRNA expression may be monitored directly by hybridization to the nucleic acids of the invention. Cell lines are exposed to the agent to be tested under appropriate conditions and time and total RNA or mRNA is isolated by standard procedures such those disclosed in Sambrook *et al.*, Molecular Cloning - A Laboratory Manual, Third Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001.

The preferred cells will be those derived from human stomach tissue, for instance, stomach biopsy tissue or cultured cells from patients with stomach cancer. Cell lines such as ATCC gastric carcinoma cell line Catalogue Nos. NCI-SNU-16, CRL-1863, HTB-103, CRL-1739 and CRL-1864 may be used. Alternatively, other available cells or cell lines may be used.

Probes to detect differences in RNA expression levels between cells exposed to the agent and control cells may be prepared from the nucleic acids of the invention. It is preferable, but not necessary, to design probes which hybridize only with target nucleic acids under conditions of high stringency. Only highly complementary nucleic acid

hybrids form under conditions of high stringency. Accordingly, the stringency of the assay conditions determines the amount of complementarity which should exist between two nucleic acid strands in order to form a hybrid. Stringency should be chosen to maximize the difference in stability between the probe:target hybrid and probe:non-target hybrids.

Probes may be designed from the nucleic acids of the invention through methods known in the art. For instance, the G+C content of the probe and the probe length can affect probe binding to its target sequence. Methods to optimize probe specificity are commonly available in Sambrook *et al.*, *supra*, or Ausubel *et al.*, Short Protocols in Molecular Biology, Fourth Ed., John Wiley & Sons, Inc., New York, 1999.

Hybridization conditions are modified using known methods, such as those described by Sambrook *et al.* and Ausubel *et al.* as required for each probe. Hybridization of total cellular RNA or RNA enriched for polyA RNA can be accomplished in any available format. For instance, total cellular RNA or RNA enriched for polyA RNA can be affixed to a solid support and the solid support exposed to at least one probe comprising at least one, or part of one of the sequences of the invention under conditions in which the probe will specifically hybridize. Alternatively, nucleic acid fragments comprising at least one, or part of one of the sequences of the invention can be affixed to a solid support, such as a silicon chip, porous glass wafer or membrane. The solid support can then be exposed to total cellular RNA or polyA RNA from a sample under conditions in which the affixed sequences will specifically hybridize. Such solid supports and hybridization methods are widely available, for example, those disclosed by Beattie, (1995) WO 95/11755. By examining for the ability of a given probe to specifically hybridize to an RNA sample from an untreated cell population and from a cell population exposed to the agent, agents which up- or down-regulate the expression of a nucleic acid encoding the protein having the sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 18 are identified.

Hybridization for qualitative and quantitative analysis of mRNAs may also be

carried out by using a RNase Protection Assay (*i.e.*, RPA, see Ma *et al.*, (1996) *Methods* 10:273-238). Briefly, an expression vehicle comprising cDNA encoding the gene product and a phage specific DNA dependent RNA polymerase promoter (*e.g.*, T7, T3 or SP6 RNA polymerase) is linearized at the 3' end of the cDNA molecule, downstream from the phage promoter, wherein such a linearized molecule is subsequently used as a template for synthesis of a labeled antisense transcript of the cDNA by *in vitro* transcription. The labeled transcript is then hybridized to a mixture of isolated RNA (*i.e.*, total or fractionated mRNA) by incubation at 45 °C overnight in a buffer comprising 80% formamide, 40 mM Pipes, pH 6.4, 0.4 M NaCl and 1 mM EDTA. The resulting hybrids are then digested in a buffer comprising 40 µg/ml ribonuclease A and 2 µg/ml ribonuclease. After deactivation and extraction of extraneous proteins, the samples are loaded onto urea/polyacrylamide gels for analysis.

In another assay, to identify agents which affect the expression of the instant gene products, cells or cell lines are first identified which express the gene products of the invention physiologically. Cell and/or cell lines so identified would be expected to comprise the necessary cellular machinery such that the fidelity of modulation of the transcriptional apparatus is maintained with regard to exogenous contact of agent with appropriate surface transduction mechanisms and/or the cytosolic cascades. Further, such cells or cell lines would be transduced or transfected with an expression vehicle (*e.g.*, a plasmid or viral vector) construct comprising an operable non-translated 5'promoter-containing end of the structural gene encoding the instant gene products fused to one or more antigenic fragments, which are peculiar to the instant gene products, wherein said fragments are under the transcriptional control of said promoter and are expressed as polypeptides whose molecular weight can be distinguished from the naturally occurring polypeptides or may further comprise an immunologically distinct tag or other detectable marker. Such a process is well known in the art (see Sambrook *et al.*, *supra*).

Cells or cell lines transduced or transfected as outlined above are then contacted with agents under appropriate conditions. For example, the agent in a pharmaceutically

acceptable excipient is contacted with cells in an aqueous physiological buffer such as phosphate buffered saline (PBS) at physiological pH, Eagles balanced salt solution (BSS) at physiological pH, PBS or BSS comprising serum or conditioned media comprising PBS or BSS and/or serum incubated at 37 °C. Said conditions may be modulated as deemed
5 necessary by one of skill in the art. Subsequent to contacting the cells with the agent, said cells will be disrupted and the polypeptides of the lysate are fractionated such that a polypeptide fraction is pooled and contacted with an antibody to be further processed by immunological assay (*e.g.*, ELISA, immunoprecipitation or Western blot). The pool of proteins isolated from the "agent-contacted" sample will be compared with a control
10 sample where only the excipient is contacted with the cells and an increase or decrease in the immunologically generated signal from the "agent-contacted" sample compared to the control will be used to distinguish the effectiveness of the agent.

**I. Methods to Identify Agents that Modulate the Level or at Least One Activity of
15 the Stomach Cancer Associated Proteins**

Another embodiment of the present invention provides methods for identifying agents that modulate the level or at least one activity of a protein of the invention such as the protein having the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12 or 18, or of a Mst1 protein or splice variant of the invention such as the protein having the amino acid
20 sequence of SEQ ID NO: 14. Such methods or assays may utilize any means of monitoring or detecting the desired activity.

In one format, the relative amounts of a protein of the invention between a cell population that has been exposed to the agent to be tested compared to an un-exposed control cell population may be assayed. In this format, probes such as specific antibodies
25 are used to monitor the differential expression of the protein in the different cell populations. Cell lines or populations are exposed to the agent to be tested under appropriate conditions and time. Cellular lysates may be prepared from the exposed cell line or population and a control, unexposed cell line or population. The cellular lysates

are then analyzed with the probe.

Antibody probes are prepared by immunizing suitable mammalian hosts in appropriate immunization protocols using the peptides, polypeptides or proteins of the invention if they are of sufficient length, or, if desired, or if required to enhance immunogenicity, conjugated to suitable carriers. Methods for preparing immunogenic conjugates with carriers such as BSA, KLH, or other carrier proteins are well known in the art. In some circumstances, direct conjugation using, for example, carbodiimide reagents may be effective; in other instances linking reagents such as those supplied by Pierce Chemical Co. (Rockford, IL), may be desirable to provide accessibility to the hapten.

The hapten peptides can be extended at either the amino or carboxy terminus with a cysteine residue or interspersed with cysteine residues, for example, to facilitate linking to a carrier. Administration of the immunogens is conducted generally by injection over a suitable time period and with use of suitable adjuvants, as is generally understood in the art. During the immunization schedule, titers of antibodies are taken to determine adequacy of antibody formation.

While the polyclonal antisera produced in this way may be satisfactory for some applications, for pharmaceutical compositions, use of monoclonal preparations is preferred. Immortalized cell lines which secrete the desired monoclonal antibodies may be prepared using the standard method of Kohler and Milstein ((1975) *Nature* 256:495-497) or modifications which effect immortalization of lymphocytes or spleen cells, as is generally known. The immortalized cell lines secreting the desired antibodies are screened by immunoassay in which the antigen is the peptide hapten, polypeptide or protein. When the appropriate immortalized cell culture secreting the desired antibody is identified, the cells can be cultured either *in vitro* or by production in ascites fluid.

The desired monoclonal antibodies are then recovered from the culture supernatant or from the ascites supernatant. Fragments of the monoclonal antibodies or the polyclonal antisera which contain the immunologically significant (antigen-binding) portion can be used as antagonists, as well as the intact antibodies. Use of

immunologically reactive (antigen-binding) antibody fragments, such as the Fab, Fab', or F(ab')₂ fragments is often preferable, especially in a therapeutic context, as these fragments are generally less immunogenic than the whole immunoglobulin.

The antibodies or antigen-binding fragments may also be produced, using current technology, by recombinant means. Antibody regions that bind specifically to the desired regions of the protein can also be produced in the context of chimeras with multiple species origin, such as humanized antibodies.

Agents that are assayed in the above method can be randomly selected or rationally selected or designed. As used herein, an agent is said to be randomly selected when the agent is chosen randomly without considering the specific sequences involved in the association of a protein of the invention alone or with its associated substrates, binding partners, etc. An example of randomly selected agents is the use a chemical library or a peptide combinatorial library, or a growth broth of an organism.

As used herein, an agent is said to be rationally selected or designed when the agent is chosen on a nonrandom basis which takes into account the sequence of the target site and/or its conformation in connection with the agent's action. Agents can be rationally selected or rationally designed by utilizing the peptide sequences that make up these sites. For example, a rationally selected peptide agent can be a peptide whose amino acid sequence is identical to or a derivative of any functional consensus site.

The agents of the present invention can be, as examples, peptides, small molecules, vitamin derivatives, as well as carbohydrates. Dominant negative proteins, DNAs encoding these proteins, antibodies to these proteins, peptide fragments of these proteins or mimics of these proteins may be introduced into cells to affect function. "Mimic" used herein refers to the modification of a region or several regions of a peptide molecule to provide a structure chemically different from the parent peptide but topographically and functionally similar to the parent peptide (see Grant in: Molecular Biology and Biotechnology, Meyers, ed., pp. 659-664, VCH Publishers, Inc., New York, 1995). A skilled artisan can readily recognize that there is no limit as to the structural nature of the

agents of the present invention.

The peptide agents of the invention can be prepared using standard solid phase (or solution phase) peptide synthesis methods, as is known in the art. In addition, the DNA encoding these peptides may be synthesized using commercially available oligonucleotide synthesis instrumentation and produced recombinantly using standard recombinant production systems. The production using solid phase peptide synthesis is necessitated if non-gene-encoded amino acids are to be included.

Another class of agents of the present invention are antibodies immunoreactive with critical positions of proteins of the invention. Antibody agents are obtained by immunization of suitable mammalian subjects with peptides, containing as antigenic regions, those portions of the protein intended to be targeted by the antibodies.

J. Uses for Agents that Modulate the Expression or at Least one Activity of the Proteins Associated with Stomach Cancer

As provided in the Examples, the proteins and nucleic acids of the invention, such as the proteins having the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12 or 18, and the Mst1 or Mst1 splice variant proteins and nucleic acids of the invention, such as the proteins having the amino acid sequence of SEQ ID NO: 14 are differentially expressed in cancerous stomach tissue. Agents that up- or down- regulate or modulate the expression of the protein or at least one activity of the protein, such as agonists or antagonists, of may be used to modulate biological and pathologic processes associated with the protein's function and activity.

For example, two types of drugs have been shown to act through Mst1 (*e.g.*, GenBank Accession No. NM_006282, the nucleic acid and protein sequences for which are given as SEQ ID NOS: 15 and 16, respectively), a gene related to SEQ ID NOS: 13 and 14. Firstly, it has been shown that bisphosphonates, drugs that are used to treat osteoporosis and other bone diseases, act directly on the osteoclast to induce caspase cleavage of Mst1 during apoptosis. Secondly, cytotrienin A is an antitumor drug that is

used to treat leukemia, breast cancer and lung cancer (U.S. Patent No. 6,251,885). Cytotrienin A has been shown to activate Mst1 during cytotrienin A-induced apoptosis (Watabe *et al.*, (2000) *J Biol Chem* 275:8766-8771).

As used herein, a subject can be any mammal, so long as the mammal is in need of modulation of a pathological or biological process mediated by a protein of the invention. The term "mammal" is defined as an individual belonging to the class Mammalia. The invention is particularly useful in the treatment of human subjects.

Pathological processes refer to a category of biological processes which produce a deleterious effect. For example, expression of a protein of the invention may be associated with stomach cell growth or hyperplasia. As used herein, an agent is said to modulate a pathological process when the agent reduces the degree or severity of the process. For instance, stomach cancer may be prevented or disease progression modulated by the administration of agents which up- or down-regulate or modulate in some way the expression or at least one activity of a protein of the invention.

The agents of the present invention can be provided alone, or in combination with other agents that modulate a particular pathological process. For example, an agent of the present invention can be administered in combination with other known drugs. As used herein, two agents are said to be administered in combination when the two agents are administered simultaneously or are administered independently in a fashion such that the agents will act at the same time.

The agents of the present invention can be administered via parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

The present invention further provides compositions containing one or more agents which modulate expression or at least one activity of a protein of the invention. While individual needs vary, determination of optimal ranges of effective amounts of each

component is within the skill of the art. Typical dosages comprise 0.1 to 100 $\mu\text{g/kg}$ body wt. The preferred dosages comprise 0.1 to 10 $\mu\text{g/kg}$ body wt. The most preferred dosages comprise 0.1 to 1 $\mu\text{g/kg}$ body wt.

In addition to the pharmacologically active agent, the compositions of the present invention may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically for delivery to the site of action. Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers. Liposomes can also be used to encapsulate the agent for delivery into the cell.

The pharmaceutical formulation for systemic administration according to the invention may be formulated for enteral, parenteral or topical administration. Indeed, all three types of formulations may be used simultaneously to achieve systemic administration of the active ingredient.

Suitable formulations for oral administration include hard or soft gelatin capsules, pills, tablets, including coated tablets, elixirs, suspensions, syrups or inhalations and controlled release forms thereof.

In practicing the methods of this invention, the compounds of this invention may be used alone or in combination, or in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of this invention may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice. The compounds of this invention can

be utilized *in vivo*, ordinarily in mammals, such as humans, sheep, horses, cattle, pigs, dogs, cats, rats and mice, or *in vitro*.

K. Transgenic Animals

5 Transgenic animals containing mutant, knock-out or modified genes corresponding to the cDNA sequence of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 or 17, or the open reading frame encoding the polypeptide sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 18 or fragments thereof having a consecutive sequence of at least about 3, 4, 5, 6, 10, 15, 20, 25, 30, 35 or more amino acid residues, are also included in the invention. Transgenic
10 animals are genetically modified animals into which recombinant, exogenous or cloned genetic material has been experimentally transferred. Such genetic material is often referred to as a "transgene." The nucleic acid sequence of the transgene, in this case a form of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 or 17 may be integrated either at a locus of a genome where that particular nucleic acid sequence is not otherwise normally found or at
15 the normal locus for the transgene. The transgene may consist of nucleic acid sequences derived from the genome of the same species or of a different species than the species of the target animal.

In some embodiments, transgenic animals in which all or a portion of a gene comprising SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 or 17 is deleted may be constructed. In those
20 cases where the gene corresponding to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 or 17 contains one or more introns, the entire gene- all exons, introns and the regulatory sequences- may be deleted. Alternatively, less than the entire gene may be deleted. For example, a single exon and/or intron may be deleted, so as to create an animal expressing a modified version of a protein of the invention.

25 The term "germ cell line transgenic animal" refers to a transgenic animal in which the genetic alteration or genetic information was introduced into a germ line cell, thereby conferring the ability of the transgenic animal to transfer the genetic information to offspring. If such offspring in fact possess some or all of that alteration or genetic

information, then they too are transgenic animals.

The alteration or genetic information may be foreign to the species of animal to which the recipient belongs, foreign only to the particular individual recipient, or may be genetic information already possessed by the recipient. In the last case, the altered or introduced gene may be expressed differently than the native gene.

Transgenic animals can be produced by a variety of different methods including transfection, electroporation, microinjection, gene targeting in embryonic stem cells and recombinant viral and retroviral infection (*see, e.g.*, U.S. Patent No. 4,736,866; U.S. Patent No. 5,602,307; Mullins *et al.*, (1993) *Hypertension* 22:630-633; Brenin *et al.*, (1997) *Surg Oncol* 6:99-110; Recombinant Gene Expression Protocols (Methods in Molecular Biology, Vol. 62), Tuan, ed., Humana Press, Totowa, NJ, 1997).

A number of recombinant or transgenic mice have been produced, including those which express an activated oncogene sequence (U.S. Patent No. 4,736,866); express simian SV40 T-antigen (U.S. Patent No. 5,728,915); lack the expression of interferon regulatory factor 1 (IRF-1) (U.S. Patent No. 5,731,490); exhibit dopaminergic dysfunction (U.S. Patent No. 5,723,719); express at least one human gene which participates in blood pressure control (U.S. Patent No. 5,731,489); display greater similarity to the conditions existing in naturally occurring Alzheimer's disease (U.S. Patent No. 5,720,936); have a reduced capacity to mediate cellular adhesion (U.S. Patent No. 5,602,307); possess a bovine growth hormone gene (Clutter *et al.*, (1996) *Genetics* 143:1753-1760); or, are capable of generating a fully human antibody response (McCarthy (1997) *Lancet* 349:405).

While mice and rats remain the animals of choice for most transgenic experimentation, in some instances it is preferable or even necessary to use alternative animal species. Transgenic procedures have been successfully utilized in a variety of non-murine animals, including sheep, goats, pigs, dogs, cats, monkeys, chimpanzees, hamsters, rabbits, cows and guinea pigs (*see, e.g.*, Kim *et al.*, (1997) *Mol Reprod Dev* 46:515-526; Houdebine, (1995) *Reprod Nutr Dev* 35:609-617; Petters (1994) *Reprod Fertil Dev* 6:643-645; Schnieke *et al.*, (1997) *Science* 278:2130-2133; and Amoah, (1997) *J*

Animal Science 75:578-585).

The method of introduction of nucleic acid fragments into recombination competent mammalian cells can be by any method which favors co-transformation of multiple nucleic acid molecules. Detailed procedures for producing transgenic animals are readily available to one skilled in the art, including the disclosures in U.S. Patent No. 5,489,743 and U.S. Patent No. 5,602,307.

L. Diagnostic Methods

As the genes and proteins of the invention are differentially expressed in cancerous stomach tissue and in other malignant neoplasms compared to non-cancerous tissues of the same type, the genes and proteins of the invention may be used to diagnose or monitor such cancers or to track disease progression. One means of diagnosing cancer, including stomach cancer, using the nucleic acid molecules or proteins of the invention involves obtaining tissue from living subjects, such as biopsy specimens.

The use of molecular biological tools has become routine in forensic technology. For example, nucleic acid probes comprising all or at least part of the sequence of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 or 17 may be used to determine the expression of a nucleic acid molecule in forensic/pathology specimens. Further, nucleic acid assays may be carried out by any means of conducting a transcriptional profiling analysis. In addition to nucleic acid analysis, forensic methods of the invention may target the proteins of the invention, particularly a protein comprising SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20, to determine up- or down-regulation of the genes (Shiverick *et al.*, (1975) *Biochim Biophys Acta* 393:124-133).

Methods of the invention may involve treatment of tissues with collagenases or other proteases to make the tissue amenable to cell lysis (Semenov *et al.*, (1987) *Biull Eksp Biol Med* 104:113-116). Further, it is possible to obtain biopsy samples from different regions of the stomach for analysis.

Assays to detect nucleic acid or protein molecules of the invention may be in any

available format. Typical assays for nucleic acid molecules include hybridization or PCR based formats. Typical assays for the detection of proteins, polypeptides or peptides of the invention include the use of antibody probes in any available format such as *in situ* binding assays, etc. (see Harlow & Lane, Antibodies - A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988. In preferred embodiments, assays are carried-out with appropriate controls.

The above methods may also be used in other diagnostic protocols, including protocols and methods to detect disease states in other tissues or organs, for example in tissues in which expression of a nucleic acid molecule of the invention is detected.

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

EXAMPLES

Example 1a

Identification of Differentially Expressed mRNA in Advanced Gastric Carcinoma

Materials and Methods

Patient tissue samples were derived from five Korean patients, aged 47 to 68, including four men and one woman, who had been diagnosed with advanced gastric cancer. For each patient, tissue was obtained from two areas of the stomach, from a stomach tumor and from a cancer-free area, to produce a set of biopsy samples. Histological analysis of each of the tissue samples was performed, and samples were segregated into either non-cancerous or cancerous categories.

With minor modifications, the sample preparation protocol followed the

Affymetrix GeneChip Expression Analysis Manual. Frozen tissue was first ground to powder using the Spex Certiprep 6800 Freezer Mill. Total RNA was then extracted using Trizol (Life Technologies). The total RNA yield for each sample (average tissue weight of 300 mg) was 200-500 µg. Next, mRNA was isolated using the Oligotex mRNA Midi kit (Qiagen). Since the mRNA was eluted in a final volume of 400 µl, an ethanol precipitation step was required to bring the concentration to 1 µg/µl. Using 1-5 µg of mRNA, double stranded cDNA was created using the SuperScript Choice system (Gibco-BRL). First strand cDNA synthesis was primed with a T7-(dT₂₄) oligonucleotide. The cDNA was then phenol-chloroform extracted and ethanol precipitated to a final concentration of 1 µg/µl.

From 2 µg of cDNA, cRNA was synthesized according to standard procedures. To biotin label the cRNA, nucleotides Bio-11-CTP and Bio-16-UTP (Enzo Diagnostics) were added to the reaction. After a 37 °C incubation for six hours, the labeled cRNA was cleaned up according to the RNeasy Mini kit protocol (Qiagen). The cRNA was then fragmented (5× fragmentation buffer: 200 mM Tris-Acetate (pH 8.1), 500 mM KOAc, 150 mM MgOAc) for thirty-five minutes at 94 °C.

55 µg of fragmented cRNA was hybridized on the Affymetrix Human Genome U95 and U133 set of arrays for twenty-four hours at 60 rpm in a 45 °C hybridization oven. The chips were washed and stained with Streptavidin Phycoerythrin (SAPE) (Molecular Probes) in Affymetrix fluidics stations. To amplify staining, SAPE solution was added twice with an anti-streptavidin biotinylated antibody (Vector Laboratories) staining step in between. Hybridization to the probe arrays was detected by fluorometric scanning (Hewlett Packard Gene Array Scanner). Following hybridization and scanning, the microarray images were analyzed for quality control, looking for major chip defects or abnormalities in hybridization signal. After all chips passed QC, the data was analyzed using Affymetrix Microarray Suite (v4.0), and LIMS (v1.5) for U95 or Affymetrix Microarray Suite (v5.0), and LIMS (v3.0) for U133.

Differential expression of genes between the cancerous and non-cancerous liver

samples was determined by using Affymetrix human GeneChip sets, U95 and U133, with the following statistical methods. (1) For each gene, Affymetrix GeneChip average difference values for U95 were determined by Affymetrix Microarray Suite (v4.0), which also made "Absent" (=not detected), "Present" (=detected) or "Marginal" (=not clearly Absent or Present) calls for each GeneChip element. Signal values for U133 were determined by Affymetrix Microarray Suite (v5.0), which also made Absent, Present or Marginal calls. (2) Using the criteria of at least 10% present call in both cancerous and non-cancerous liver samples and at least 40% present call in either cancerous or non-cancerous liver sample groups, a gene set was selected for further analysis. (3) Based on the average difference values of U95 data, the gene set was split into two groups, a high expression group and low expression group. The high expression group contained genes with average difference values greater than or equal to 5 in both cancerous and non-cancerous samples. The remainder of the genes were included in the low expression group. The average difference values were transformed to a logarithmic scale for the high expression group, but were not changed for the low expression group. For U133 data, all signal values were transformed to a logarithmic scale regardless of expression level. (4) The Analysis of Variance (ANOVA) method was used for data analysis (Steel et al., Principles and Procedures of Statistics: A Biometrical Approach, Third Ed., McGraw-Hill, 1997). Prior to the final analysis, a leave-one-out approach is used for outlier detection. One sample at a time was left out of the ANOVA analysis to determine whether or not omitting a specific sample from the analysis had any significant effect on the final result. If so, that particular sample was excluded from the final analysis. After outlier detection, a list of genes that are differentially expressed with a p-value of less than or equal to 0.05 was generated by ANOVA. Data from Affymetrix GeneChip U133 chip set was analyzed with a similar procedure. (5) Two additional criteria were used to reduce the number of genes in the gene list generated from U95. Firstly, geometric mean values were compared between the non-cancerous control group samples and the carcinoma disease group samples to obtain a set of genes showing at least 2.0-fold

increases or decreases in expression level. Secondly, the ratio of the fold-change value and the p-value had to be 400 or greater.

Results and Analyses

5 a) LBFL301 gene family:

Analysis of the chip data showed that the expression of the marker LBFL301 was significantly up-regulated (13.75-fold; $p = 0.0172$) in gastric carcinoma samples compared to samples from normal stomach tissue. These data indicate that up-regulation of LBFL301 may be diagnostic for stomach cancer.

- 10 The expression level of LBFL301 (SEQ ID NO: 1 or 3) can be measured by chip sequence fragment nos. 48774_at and 225681_at on Affymetrix GeneChips® U95 and U133, respectively. The expression levels of 48774_at and 225681_at in various malignant neoplasms, compared to normal control tissues, are shown in Table 1a, where the fold-change and the direction of the change (up- or down-regulation) are also indicated.
- 15 A fold-change greater than 1.5 was considered to be significant.

Table 1a

Affy ID	Tissue	Disease	Morphology	Fold Change	Dir	T-Stat
48774_at	BONES, NOS	MALIGNANT NEOPLASM OF BONE, NOS	GIANT CELL TUMOR OF BONE, NOS	5.7	Up	3.5
225681_at			INFILTRATING DUCT CARCINOMA	3.4	Up	12.1
225681_at	BREAST, NOS	MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING DUCT AND LOBULAR CARCINOMA	3.3	Up	3.3
225681_at			INFILTRATING LOBULAR CARCINOMA	2.8	Up	5.3
225681_at	CERVIX, NOS	MALIGNANT NEOPLASM OF UTERINE CERVIX	SQUAMOUS CELL CARCINOMA, NOS	3.6	Up	3.4
225681_at	COLON, NOS	MALIGNANT NEOPLASM OF COLON, NOS	MUCINOUS ADENOCARCINOMA	12.7	Up	2.5
225681_at			ADENOCARCINOMA, NOS	6.9	Up	7.9
225681_at	ENDOMETRIUM, NOS	MALIGNANT NEOPLASM OF ENDOMETRIUM	MULLERIAN MIXED TUMOR	11.0	Up	5.5
225681_at	ESOPHAGUS, NOS	MALIGNANT NEOPLASM OF ESOPHAGUS, NOS	ADENOCARCINOMA, NOS	2.2	Up	3.7
225681_at	KIDNEY, NOS	MALIGNANT NEOPLASM OF KIDNEY, NOS	CLEAR CELL ADENOCARCINOMA, NOS	7.2	Up	3.6
225681_at			WILMS' TUMOR	9.8	Up	5.4
225681_at	LARYNX, NOS	MALIGNANT NEOPLASM OF LARYNX, NOS	SQUAMOUS CELL CARCINOMA, NOS	7.2	Up	3.4
225681_at	LIVER, NOS	SECONDARY MALIGNANT NEOPLASM OF LIVER, NOS	ADENOCARCINOMA, NOS	6.8	Up	4.3
225681_at	LUNG, NOS	MALIGNANT NEOPLASM OF LUNG, NOS	SQUAMOUS CELL CARCINOMA, NOS	12.4	Up	3.5
225681_at			ADENOCARCINOMA, NOS	5.4	Up	5.4
225681_at	LYMPH NODE, NOS	SECONDARY MALIGNANT NEOPLASM OF LYMPH NODE, NOS	ADENOCARCINOMA, NOS	4.4	Up	5.1
225681_at		MALIGNANT NEOPLASM OF LYMPHOID AND HISTIOCYTIC TISSUE, NOS	SQUAMOUS CELL CARCINOMA, NOS	4.1	Up	2.7
225681_at	OMENTUM, NOS	MALIGNANT NEOPLASM OF THE OMENTUM	MALIGNANT LYMPHOMA, NOS	4.3	Down	3.2
225681_at			PAPILLARY SEROUS ADENOCARCINOMA	7.2	Up	4.1
225681_at			PAPILLARY SEROUS ADENOCARCINOMA	4.8	Up	4.3
225681_at			MULLERIAN MIXED TUMOR	4.7	Up	11.0
225681_at			ADENOCARCINOMA, NOS	13.8	Up	2.6
225681_at			SEROUS CYST ADENOCARCINOMA, NOS	10.7	Up	2.8
225681_at	OVARY, NOS	NEOPLASM OF UNCERTAIN BEHAVIOR OF OVARY	STRUMA OVARII, NOS	9.5	Up	6.4
225681_at			PAPILLARY SEROUS ADENOCARCINOMA	7.7	Up	3.7
225681_at			ADENOCARCINOMA, NOS	6.9	Up	3.7
225681_at			SEROUS CYSTADENOMA, BORDERLINE MALIGNANCY	5.3	Up	7.2
225681_at	PANCREAS, NOS	MALIGNANT NEOPLASM OF PANCREAS, NOS	ADENOCARCINOMA, NOS	7.8	Up	9.3
225681_at	RECTUM, NOS	MALIGNANT NEOPLASM OF RECTUM	ADENOCARCINOMA, NOS	7.7	Up	5.8

Table 1a

Affy ID	Tissue	Disease	Morphology	Fold Change	Dir	T-Stat
225681_at	SOFT TISSUES, NOS	NEOPLASM OF UNCERTAIN BEHAVIOR OF CONNECTIVE AND OTHER SOFT TISSUES, NOS	FIBROMATOSIS, NOS	12.5	Up	7.6
225681_at		SECONDARY MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUES, NOS	SQUAMOUS CELL CARCINOMA, NOS	5.3	Up	3.2
225681_at		MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUES, NOS	FIBROUS HISTIOCYTOMA, MALIGNANT	3.7	Up	3.1
225681_at			ADENOCARCINOMA, NOS	3.6	Up	3.5
225681_at	STOMACH, NOS	MALIGNANT NEOPLASM OF STOMACH, NOS	SIGNET RING CELL CARCINOMA	3.5	Up	4.5
225681_at	THYROID GLAND, NOS	MALIGNANT NEOPLASM OF THYROID GLAND	PAPILLARY CARCINOMA, NOS	4.5	Up	4.1

Table 2 summarizes the differential expression data collected from experiments

5 using Affymetrix GeneChips by tissue type. The chips were scanned and the data

analyzed by the GX Scan algorithm, which is described in related applications 60/331,182, 60/388,745 and 60/390,608, all entitled "An Automated Computer-based Algorithm for Organizing and Mining Gene Expression Data Derived from Biological Samples with Complex Clinical Attributes," and all of which are herein incorporated by reference in their entirety.

Table 2- LBFL301 (U95: 48774_at, U133: 225681_at): Clones AD12 & CH4

	<u>48774_at From U95 data</u>	<u>225681_at From U133 data</u>
1. Bone	UP	—
2. Breast	UP	UP
3. Cervix	UP	UP
4. Colon	UP	UP
5. Endometrium	UP	UP
6. Esophagus	UP	UP
7. Kidney	UP	UP
8. Larynx	UP	UP
9. Liver	UP	UP
10. Lung	UP	UP
11. Omentum	UP	UP
12. Ovary	UP	UP
13. Pancreas	UP	UP
14. Rectum	UP	UP
15. Soft tissues	UP	UP
16. Stomach	UP	UP
17. Thyroid Gland	UP	UP

The GeneChip expression results, determined by sample binding to chip sequence fragment no. 48774_at were validated by quantitative RT-PCR using Taqman® assay (Perkin-Elmer). PCR primers designed from the sequence of the specific Affymetrix fragment (48774_at) were used in the assay. The target gene in each RNA sample (ten ng of total RNA) was assayed relative to an exogenously spiked reference gene. For this purpose, the tetracycline resistance gene was used as the exogenously added spike. This approach provides the relative expression as measured by cycle threshold (Ct) value of the target mRNA relative to a constant amount of Tet spike Ct values. The sample panel included normal and advanced gastric cancer tissue RNAs that were analyzed on U95 GeneChips. In addition, several new samples that were not analyzed on the GeneChip were used for the expression validations by Quantitative RT-PCR. The Q-RT-PCR data

confirms the up-regulation of LBFL301 observed in advanced gastric cancer.

b) LBFL304 gene family:

Analysis of the chip data showed that the expression of the marker LBFL304 was significantly up-regulated (3.5-fold, $p = 2.54 \times 10^{-3}$ for U95; 6.13-fold, $p = 2.43 \times 10^{-4}$ for U133) in AGC samples compared to samples from normal stomach tissue. This data indicates that up-regulation of LBFL304 may be diagnostic for stomach cancer.

The expression level of LBFL304 (SEQ ID NO: 5, 7, 9 or 11) can be measured by chip sequence fragment nos. 35832_at on Affymetrix GeneChips® U95 and 212344_at, 212353_at, and 212354_at on Affymetrix GeneChips® U133. The expression levels of 51263_at, 212344_at, 212353_at, and 212354_at in various malignant neoplasms, compared to normal control tissues, are shown in Table 1b, where the fold-change and the direction of the change (up- or down-regulation) are also indicated. A fold-change greater than 1.5 was considered to be significant.

The GeneChip expression results, determined by sample binding to chip sequence fragment no. 35832_at, were validated by quantitative RT-PCR (Q-RT-PCR) using the Taqman® assay (Perkin-Elmer). PCR primers designed from the sequence information file of the specific Affymetrix fragment (35832_at) were used in the assay. The target gene in each RNA sample (10 ng of total RNA) was assayed relative to an exogenously spiked reference gene. For this purpose, the tetracycline resistance gene was used as the exogenously added spike. This approach provides the relative expression as measured by cycle threshold (Ct) value of the target mRNA relative to a constant amount of Tet spike Ct values. The sample panel included normal stomach (Normal) and advanced gastric cancer (AGC) tissue RNAs that were analyzed on U95 GeneChips. In addition, several new samples that were not analyzed on the GeneChip were used for the expression validations by Q-RT-PCR. The Q-RT-PCR data confirms the up-regulation of LBFL304 observed in AGC, compared to normal stomach biopsy samples.

Table 1b

TABLE I	Affy ID	Tissue	Disease	Morphology	Fold Change	Dir	T-Stat
212344_at		BONES, NOS	MALIGNANT NEOPLASM OF BONE, NOS	GIANT CELL TUMOR OF BONE, NOS	6.8	Up	6.9
212353_at			MALIGNANT NEOPLASM OF BONE, NOS	GIANT CELL TUMOR OF BONE, NOS	5.5	Up	5.7
212354_at			MALIGNANT NEOPLASM OF BONE, NOS	GIANT CELL TUMOR OF BONE, NOS	5.9	Up	7.1
35832_at			MALIGNANT NEOPLASM OF BONE, NOS	GIANT CELL TUMOR OF BONE, NOS	10.6	Up	5.7
212344_at		COLON, NOS	MALIGNANT NEOPLASM OF COLON, NOS	MUCINOUS ADENOCARCINOMA	3.7	Up	2.8
212344_at			MALIGNANT NEOPLASM OF COLON, NOS	ADENOCARCINOMA, NOS	2.7	Up	7.9
212353_at			MALIGNANT NEOPLASM OF COLON, NOS	MUCINOUS ADENOCARCINOMA	5.7	Up	3.7
212353_at			MALIGNANT NEOPLASM OF COLON, NOS	ADENOCARCINOMA, NOS	4.1	Up	9.0
212354_at			MALIGNANT NEOPLASM OF COLON, NOS	MUCINOUS ADENOCARCINOMA	4.7	Up	3.5
212354_at			MALIGNANT NEOPLASM OF COLON, NOS	ADENOCARCINOMA, NOS	3.0	Up	8.6
35832_at			MALIGNANT NEOPLASM OF COLON, NOS	MUCINOUS ADENOCARCINOMA	9.4	Up	3.8
35832_at			MALIGNANT NEOPLASM OF COLON, NOS	ADENOCARCINOMA, NOS	6.5	Up	10.2

Table 1b

TABLE 1 Affy ID	Tissue	Disease	Morphology	Fold Change	Dir	T-Stat
212344_at	SOFT TISSUES, NOS	MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUES, NOS	FIBROUS HISTIOCYTOMA, MALIGNANT	2.7	Up	3.2
212353_at		MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUES, NOS	FIBROUS HISTIOCYTOMA, MALIGNANT	2.1	Up	2.2
212353_at		MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUES, NOS	MYXOID LIPOSARCOMA	-2.7	Down	-2.4
212354_at		MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUES, NOS	FIBROUS HISTIOCYTOMA, MALIGNANT	2.2	Up	2.6
35832_at	ENDOMETRI UM, NOS	MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUES, NOS	FIBROUS HISTIOCYTOMA, MALIGNANT	3.5	Up	2.6
35832_at		MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUES, NOS	LIPOSARCOMA, NOS	4.8	Up	2.6
212344_at		MALIGNANT NEOPLASM OF ENDOMETRIUM	MULLERIAN MIXED TUMOR	2.4	Up	3.3
212344_at		MALIGNANT NEOPLASM OF ENDOMETRIUM	ADENOCARCINOMA, NOS	2.2	Up	5.5
212353_at		MALIGNANT NEOPLASM OF ENDOMETRIUM	MULLERIAN MIXED TUMOR	1.9	Up	2.9
212353_at		MALIGNANT NEOPLASM OF ENDOMETRIUM	ADENOCARCINOMA, NOS	2.0	Up	4.2

Table 1b

TABLE 1 Affy ID	Tissue	Disease	Morphology	Fold Change	Dir	T-Stat
212354_at		MALIGNANT NEOPLASM OF ENDOMETRIUM	MULLERIAN MIXED TUMOR	2.0	Up	2.7
212354_at		MALIGNANT NEOPLASM OF ENDOMETRIUM	ADENOCARCINOMA, NOS	1.9	Up	4.7
35832_at		MALIGNANT NEOPLASM OF ENDOMETRIUM	MULLERIAN MIXED TUMOR	3.0	Up	3.9
35832_at		MALIGNANT NEOPLASM OF ENDOMETRIUM	ADENOCARCINOMA, NOS	2.4	Up	4.7
212344_at	ESOPHAGUS , NOS	MALIGNANT NEOPLASM OF ESOPHAGUS, NOS	ADENOCARCINOMA, NOS	1.7	Up	2.3
212353_at		MALIGNANT NEOPLASM OF ESOPHAGUS, NOS	ADENOCARCINOMA, NOS	5.5	Up	3.2
212354_at		MALIGNANT NEOPLASM OF ESOPHAGUS, NOS	ADENOCARCINOMA, NOS	2.9	Up	3.1
35832_at		MALIGNANT NEOPLASM OF ESOPHAGUS, NOS	ADENOCARCINOMA, NOS	10.7	Up	3.2
212344_at	BREAST, NOS	MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	MUCINOUS ADENOCARCINOMA	3.3	Up	4.8
212344_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING LOBULAR CARCINOMA	1.6	Up	2.9
212344_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING DUCT CARCINOMA	2.5	Up	8.7
212344_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING DUCT AND LOBULAR CARCINOMA	2.6	Up	2.8
212353_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING LOBULAR CARCINOMA	2.8	Up	4.7

Table 1b

TABLE 1	Affy ID	Tissue	Disease	Morphology	Fold Change	Dir	T-Stat
	212353_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING DUCT CARCINOMA	3.9	Up	13.0
	212353_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING DUCT AND LOBULAR CARCINOMA	3.4	Up	3.7
	212354_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING LOBULAR CARCINOMA	1.7	Up	3.1
	212354_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING DUCT CARCINOMA	2.6	Up	8.5
	212354_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING DUCT AND LOBULAR CARCINOMA	2.7	Up	2.6
	35832_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	MUCINOUS ADENOCARCINOMA	4.0	Up	5.5
	35832_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING LOBULAR CARCINOMA	3.2	Up	4.4
	35832_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING DUCT CARCINOMA	4.5	Up	12.0
	35832_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING DUCT AND LOBULAR CARCINOMA	4.3	Up	4.5
	212353_at	KIDNEY, NOS	MALIGNANT NEOPLASM OF KIDNEY, NOS	CLEAR CELL ADENOCARCINOMA, NOS	2.8	Up	5.5
	212354_at		MALIGNANT NEOPLASM OF KIDNEY, NOS	CLEAR CELL ADENOCARCINOMA, NOS	2.4	Up	5.3
	35832_at		MALIGNANT NEOPLASM OF KIDNEY, NOS	CLEAR CELL ADENOCARCINOMA, NOS	6.1	Up	5.6
	212344_at	LARYNX, NOS	MALIGNANT NEOPLASM OF LARYNX, NOS	SQUAMOUS CELL CARCINOMA, NOS	3.0	Up	3.3

Table 1b

TABLE 1 Affy ID	Tissue	Disease	Morphology	Fold Change	Dir	T-Stat
212353_at		MALIGNANT NEOPLASM OF LARYNX, NOS	SQUAMOUS CELL CARCINOMA, NOS	5.1	Up	3.8
212354_at		MALIGNANT NEOPLASM OF LARYNX, NOS	SQUAMOUS CELL CARCINOMA, NOS	3.7	Up	3.6
35832_at		MALIGNANT NEOPLASM OF LARYNX, NOS	SQUAMOUS CELL CARCINOMA, NOS	7.2	Up	3.7
212344_at	LUNG, NOS	MALIGNANT NEOPLASM OF LUNG, NOS	CARCINOMA, NOS	4.1	Up	3.9
212344_at		MALIGNANT NEOPLASM OF LUNG, NOS	SQUAMOUS CELL CARCINOMA, NOS	3.1	Up	5.8
212344_at		MALIGNANT NEOPLASM OF LUNG, NOS	LARGE CELL CARCINOMA, NOS	2.7	Up	2.5
212344_at		MALIGNANT NEOPLASM OF LUNG, NOS	ADENOCARCINOMA, NOS	2.8	Up	6.2
212353_at		MALIGNANT NEOPLASM OF LUNG, NOS	CARCINOMA, NOS	4.1	Up	3.2
212353_at		MALIGNANT NEOPLASM OF LUNG, NOS	SQUAMOUS CELL CARCINOMA, NOS	3.6	Up	6.5
212353_at		MALIGNANT NEOPLASM OF LUNG, NOS	LARGE CELL CARCINOMA, NOS	3.8	Up	2.7
212353_at		MALIGNANT NEOPLASM OF LUNG, NOS	ADENOCARCINOMA, NOS	3.6	Up	6.9
212354_at		MALIGNANT NEOPLASM OF LUNG, NOS	CARCINOMA, NOS	3.5	Up	2.9
212354_at		MALIGNANT NEOPLASM OF LUNG, NOS	SQUAMOUS CELL CARCINOMA, NOS	3.1	Up	5.6

Table 1b

TABLE 1 Affy ID	Tissue	Disease	Morphology	Fold Change	Dir	T-Stat
212354_at		MALIGNANT NEOPLASM OF LUNG, NOS	LARGE CELL CARCINOMA, NOS	2.9	Up	2.6
212354_at		MALIGNANT NEOPLASM OF LUNG, NOS	ADENOCARCINOMA, NOS	2.9	Up	6.2
35832_at		MALIGNANT NEOPLASM OF LUNG, NOS	SQUAMOUS CELL CARCINOMA, NOS	8.8	Up	6.0
35832_at		MALIGNANT NEOPLASM OF LUNG, NOS	ADENOCARCINOMA, NOS	8.9	Up	7.2
212344_at	OVARY, NOS	MALIGNANT NEOPLASM OF OVARY	PAPILLARY SEROUS ADENOCARCINOMA	3.0	Up	3.9
212353_at		MALIGNANT NEOPLASM OF OVARY	PAPILLARY SEROUS ADENOCARCINOMA	3.6	Up	3.9
212354_at		MALIGNANT NEOPLASM OF OVARY	PAPILLARY SEROUS ADENOCARCINOMA	2.6	Up	3.4
212344_at	PANCREAS, NOS	MALIGNANT NEOPLASM OF PANCREAS, NOS	ADENOCARCINOMA, NOS	6.9	Up	9.0
212353_at		MALIGNANT NEOPLASM OF PANCREAS, NOS	ADENOCARCINOMA, NOS	7.8	Up	11.2
212354_at		MALIGNANT NEOPLASM OF PANCREAS, NOS	ADENOCARCINOMA, NOS	8.6	Up	11.0
35832_at		MALIGNANT NEOPLASM OF PANCREAS, NOS	ADENOCARCINOMA, NOS	99.8	Up	11.1
212353_at	PROSTATE, NOS	MALIGNANT NEOPLASM OF PROSTATE	ATYPIC SUSPICIOUS FOR MALIGNANCY	-2.2	Dow n	-4.7
212353_at		MALIGNANT NEOPLASM OF PROSTATE	ADENOCARCINOMA, NOS	-1.5	Dow n	-2.5

Table 1b

TABLE 1 Affy ID	Tissue	Disease	Morphology	Fold Change	Dir	T-Stat
212354_at		MALIGNANT NEOPLASM OF PROSTATE	ATYPIA SUSPICIOUS FOR MALIGNANCY	-1.8	Down	-3.8
212354_at		MALIGNANT NEOPLASM OF PROSTATE	ADENOCARCINOMA, NOS	-1.7	Down	-3.8
35832_at		MALIGNANT NEOPLASM OF PROSTATE	ATYPIA SUSPICIOUS FOR MALIGNANCY	-4.3	Down	-4.4
35832_at		MALIGNANT NEOPLASM OF PROSTATE	ADENOCARCINOMA, NOS	-1.7	Down	-2.6
212344_at	RECTUM, NOS	MALIGNANT NEOPLASM OF RECTUM	ADENOCARCINOMA, NOS	3.0	Up	6.9
212353_at		MALIGNANT NEOPLASM OF RECTUM	ADENOCARCINOMA, NOS	4.1	Up	7.6
212354_at		MALIGNANT NEOPLASM OF RECTUM	ADENOCARCINOMA, NOS	3.0	Up	7.2
35832_at		MALIGNANT NEOPLASM OF RECTUM	ADENOCARCINOMA, NOS	5.4	Up	8.8
212344_at	SKIN, NOS	MALIGNANT NEOPLASM OF SKIN, NOS	SQUAMOUS CELL CARCINOMA, NOS	2.8	Up	2.4
212353_at		MALIGNANT NEOPLASM OF SKIN, NOS	SQUAMOUS CELL CARCINOMA, NOS	3.5	Up	2.4
35832_at		MALIGNANT NEOPLASM OF SKIN, NOS	BASAL CELL CARCINOMA, NOS	3.6	Up	2.5
35832_at		MALIGNANT NEOPLASM OF SKIN, NOS	SQUAMOUS CELL CARCINOMA, NOS	5.5	Up	3.0
212344_at	STOMACH, NOS	MALIGNANT NEOPLASM OF STOMACH, NOS	MUCINOUS ADENOCARCINOMA	7.6	Up	3.1

Table 1b

TABLE 1 Affy ID	Tissue	Disease	Morphology	Fold Change	Dir	T-Stat
212344_at		MALIGNANT NEOPLASM OF STOMACH, NOS	SIGNET RING CELL CARCINOMA	3.9	Up	2.4
212344_at		MALIGNANT NEOPLASM OF STOMACH, NOS	ADENOCARCINOMA, NOS	2.5	Up	4.9
212353_at		MALIGNANT NEOPLASM OF STOMACH, NOS	MUCINOUS ADENOCARCINOMA	11.0	Up	3.7
212353_at		MALIGNANT NEOPLASM OF STOMACH, NOS	SIGNET RING CELL CARCINOMA	4.9	Up	2.9
212353_at		MALIGNANT NEOPLASM OF STOMACH, NOS	ADENOCARCINOMA, NOS	3.4	Up	5.6
212354_at		MALIGNANT NEOPLASM OF STOMACH, NOS	MUCINOUS ADENOCARCINOMA	7.5	Up	3.2
212354_at		MALIGNANT NEOPLASM OF STOMACH, NOS	SIGNET RING CELL CARCINOMA	3.7	Up	2.4
212354_at		MALIGNANT NEOPLASM OF STOMACH, NOS	ADENOCARCINOMA, NOS	2.7	Up	5.1
35832_at		MALIGNANT NEOPLASM OF STOMACH, NOS	SIGNET RING CELL CARCINOMA	8.4	Up	3.4
35832_at		MALIGNANT NEOPLASM OF STOMACH, NOS	ADENOCARCINOMA, NOS	8.6	Up	6.7
212344_at	TESTIS, NOS	MALIGNANT NEOPLASM OF TESTIS, NOS	MIXED GERM CELL TUMOR	2.0	Up	2.4
212353_at		MALIGNANT NEOPLASM OF TESTIS, NOS	MIXED GERM CELL TUMOR	4.1	Up	2.8
212354_at		MALIGNANT NEOPLASM OF TESTIS, NOS	MIXED GERM CELL TUMOR	3.4	Up	2.6

Table 1b

TABLE 1 Affy ID	Tissue	Disease	Morphology	Fold Change	Dir	T-Stat
212353_at	OMENTUM, NOS	MALIGNANT NEOPLASM OF THE OMENTUM	PAPILLARY SEROUS ADENOCARCINOMA	1.7	Up	2.6
35832_at	THYROID GLAND, NOS	MALIGNANT NEOPLASM OF THYROID GLAND	PAPILLARY CARCINOMA, NOS	2.5	Up	2.5
35832_at	CERVIX, NOS	MALIGNANT NEOPLASM OF UTERINE CERVIX	SQUAMOUS CELL CARCINOMA, NOS	3.5	Up	2.3

c) LBFL305 gene family:

Analysis of the chip data showed that the expression of the marker LBFL305 was significantly up-regulated (2.2-fold, $p = 0.0051$ using the U95 GeneChip; 2.14-fold, $p = 0.0109$ using the U133 GeneChip) in gastric carcinoma samples compared to samples from normal stomach tissue. These data indicate that up-regulation of LBFL305 may be diagnostic for stomach cancer.

The expression level of LBFL305 (SEQ ID NO: 13) can be measured by chip sequence fragment nos. 53858_at and 225364_at on Affymetrix GeneChips® U95 and U133, respectively. Differential expression data were collected from experiments using Affymetrix GeneChips® by tissue type and were analyzed by the GX Scan algorithm, which is described in related applications 60/331,182, 60/388,745 and 60/390,608, all entitled "An Automated Computer-based Algorithm for Organizing and Mining Gene Expression Data Derived from Biological Samples with Complex Clinical Attributes," and all of which are herein incorporated by reference in their entirety. The expression levels of 53858_at and 225364_at in various malignant neoplasms, compared to normal control tissues, are shown in Table 1c, where the fold-change and the direction of the change (up- or down-regulation) are also indicated. A fold-change greater than 1.5 was considered to be significant.

Table 1c

Affy ID	Tissue	Disease	Morphology	Fold Change	Dir	T-Stat
53858_at	BLADDER, NOS	MALIGNANT NEOPLASM OF BLADDER, NOS	TRANSITIONAL CELL CARCINOMA, NOS	1.691	Up	2.377
53858_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING DUCT CARCINOMA	1.538	Up	6.824
53858_at	BREAST, NOS	MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING DUCT & LOBULAR CARCINOMA	1.599	Up	2.408
225364_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING DUCT & LOBULAR CARCINOMA	1.525	Up	3.251
53858_at	CERVIX, NOS	MALIGNANT NEOPLASM OF UTERINE CERVIX	SQUAMOUS CELL CARCINOMA, NOS	1.637	Up	4.056
53858_at	ENDOMETRIUM, NOS	MALIGNANT NEOPLASM OF ENDOMETRIUM	MULLERIAN MIXED TUMOR	1.548	Up	2.647
53858_at	ESOPHAGUS, NOS	MALIGNANT NEOPLASM OF ESOPHAGUS, NOS	ADENOCARCINOMA, NOS	2.079	Up	3.145
225364_at		MALIGNANT NEOPLASM OF ESOPHAGUS, NOS	ADENOCARCINOMA, NOS	1.615	Up	2.915
53858_at		MALIGNANT NEOPLASM OF KIDNEY, NOS	RENAL CELL CARCINOMA	1.864	Up	6.093
53858_at	KIDNEY, NOS	MALIGNANT NEOPLASM OF KIDNEY, NOS	CLEAR CELL ADENOCARCINOMA, NOS	2.167	Up	6.877
225364_at		MALIGNANT NEOPLASM OF KIDNEY, NOS	RENAL CELL CARCINOMA	1.593	Up	5.045
225364_at		MALIGNANT NEOPLASM OF KIDNEY, NOS	CLEAR CELL ADENOCARCINOMA, NOS	1.683	Up	7.924
225364_at	LUNG, NOS	MALIGNANT NEOPLASM OF LUNG, NOS	SMALL CELL CARCINOMA, NOS	-1.79	Down	-7.071
53858_at	LYMPH NODE, NOS	HODGKIN'S DISEASE, NOS OF LYMPH NODES OF MULTIPLE SITES	HODGKIN'S DISEASE, NOS	1.539	Up	2.519
53858_at		MALIGNANT NEOPLASM OF LYMPHOID AND HISTIOCYTIC TISSUE, NOS	MALIGNANT LYMPHOMA, NOS	1.635	Up	3.243
53858_at		MALIGNANT NEOPLASM OF ISLETS OF LANGERHANS	ISLET CELL CARCINOMA	3.845	Up	7.929
53858_at	PANCREAS, NOS	MALIGNANT NEOPLASM OF PANCREAS, NOS	ADENOCARCINOMA, NOS	4.171	Up	7.165
225364_at		MALIGNANT NEOPLASM OF ISLETS OF LANGERHANS	ISLET CELL CARCINOMA	2.343	Up	3.551
225364_at		MALIGNANT NEOPLASM OF PANCREAS, NOS	ADENOCARCINOMA, NOS	2.278	Up	10.793
225364_at	PROSTATE, NOS	MALIGNANT NEOPLASM OF PROSTATE	ATYPIC SUSPICIOUS FOR MALIGNANCY	-1.641	Down	-4.8
53858_at	RECTUM, NOS	MALIGNANT NEOPLASM OF RECTUM	ADENOCARCINOMA, NOS	1.935	Up	5.416
53858_at		MALIGNANT LYMPHOMA, NOS OF UNSPECIFIED, EXTRANODAL OR SOLID ORGAN SITE	MALIGNANT LYMPHOMA, NOS	3.935	Up	3.535
53858_at	SMALL INTESTINE, NOS	MALIGNANT LYMPHOMA, NOS OF UNSPECIFIED, EXTRANODAL OR SOLID ORGAN SITE	MALIGNANT LYMPHOMA, NOS	3.024	Up	3.816
225364_at		MALIGNANT NEOPLASM OF STOMACH, NOS	SIGNET RING CELL CARCINOMA	1.507	Up	2.46
53858_at	STOMACH, NOS	MALIGNANT NEOPLASM OF STOMACH, NOS	ADENOCARCINOMA, NOS	2.076	Up	5.928
225364_at		MALIGNANT NEOPLASM OF STOMACH, NOS	SIGNET RING CELL CARCINOMA	1.524	Up	3.076
225364_at		MALIGNANT NEOPLASM OF STOMACH, NOS	ADENOCARCINOMA, NOS	1.637	Up	6.053

Table 1c

Affy ID	Tissue	Disease	Morphology	Fold Change	Dir	T-Stat
225364_at	THYROID GLAND, NOS	MALIGNANT LYMPHOMA, NOS OF UNSPECIFIED, EXTRANODAL OR SOLID ORGAN SITE	MALIGNANT LYMPHOMA, NOS	4.371	Up	9.429
225364_at		MALIGNANT NEOPLASM OF THYROID GLAND	PAPILLARY CARCINOMA, NOS	1.634	Up	3.22
53858_at	VULVA, NOS	MALIGNANT NEOPLASM OF VULVA, NOS	SQUAMOUS CELL CARCINOMA, NOS	1.505	Up	2.596

The GeneChip expression results, determined by sample binding to chip sequence
5 fragment no. 53858_at were validated by quantitative RT-PCR (Q-RT-PCR) using
Taqman® assay (Perkin-Elmer). PCR primers designed from the sequence information
file for the specific Affymetrix fragment (53858_at) were used in the assay. The target
gene in each RNA sample (ten ng of total RNA) was assayed relative to an exogenously

spiked reference gene. For this purpose, the tetracycline resistance gene was used as the exogenously added spike. This approach provides the relative expression as measured by cycle threshold (Ct) value of the target mRNA relative to a constant amount of Tet spike Ct values. The sample panel included normal and advanced gastric cancer tissue RNAs that were analyzed on U95 GeneChips. In addition, several new samples that were not analyzed on the GeneChip were used for the expression validations by Q-RT-PCR. The Q-RT-PCR data confirms the up-regulation of LBFL305 observed in advanced gastric cancer.

d) LBFL306 gene family

Analysis of the chip data showed that the expression of the marker LBFL306 was significantly up-regulated (3.27-fold, $p = 0.00217$ using the U133 GeneChip) in gastric carcinoma samples compared to samples from normal stomach tissue. These data indicate that up-regulation of LBFL306 may be diagnostic for stomach cancer.

The expression level of LBFL306 (SEQ ID NO: 17, 19 or 21) can be measured by chip sequence fragment nos. 57861_at and 223251_s_at on Affymetrix GeneChips® U95 and U133, respectively. Differential expression data were collected from experiments using Affymetrix GeneChips® by tissue type and were analyzed by the GX Scan algorithm, which is described in related applications 60/331,182, 60/388,745 and 60/390,608, all entitled "An Automated Computer-based Algorithm for Organizing and Mining Gene Expression Data Derived from Biological Samples with Complex Clinical Attributes," and all of which are herein incorporated by reference in their entirety. The expression levels of 223251_at in various malignant neoplasms, compared to normal control tissues, are shown in Table 1d, where the fold-change and the direction of the change (up- or down-regulation) are also indicated. A fold-change greater than 1.5 was considered to be significant. The data show that expression of LBFL306 is up-regulated in cancers of the bladder, colon, esophagus, kidney, omentum, pancreas, rectum and soft tissues, in addition to cancer of the stomach, and that expression of this gene family is down-regulated in cancers of the breast, endometrium and small intestine.

The full length cDNA having SEQ ID NO: 17 or 19 or 21 was obtained by using GeneTrapper® cDNA Positive Selection System Kits (Invitrogen). The resulting cDNA was converted to double-stranded plasmid DNA, used to transform *E. coli* cells (DH10B), and the longest cDNA was screened. After positive selection was confirmed by PCR using gene-specific primers, the cDNA clone was subjected to DNA sequencing.

Analysis by Northern blot was performed to determine the size of the mRNA transcripts that correspond to LBFL306. Northern blots containing total RNAs from various human tissues were used (ClonTech H12), and LBFL306-GE2 (SEQ ID NO: 21) was radioactively labeled by the random primer method and used to probe the blots. The blots were hybridized in Church and Gilbert buffer at 65 °C and washed with 0.1X SSC containing 0.1% SDS at room temperature. The Northern blots show a single transcript for this gene, which is approximately 1.5 kb in size. This corresponds to the size of the insert in full-length clones, which is also approximately 1.5 kb.

The GeneChip expression results, determined by sample binding to chip sequence fragment no. 223251_s_at were validated by quantitative RT-PCR (Q-RT-PCR) using Taqman® assay (Perkin-Elmer). PCR primers designed from the sequence information file for the specific Affymetrix fragment (223251_s_at) were used in the assay. The target gene in each RNA sample (ten ng of total RNA) was assayed relative to an exogenously spiked reference gene. For this purpose, the tetracycline resistance gene was used as the exogenously added spike. This approach provides the relative expression as measured by cycle threshold (Ct) value of the target mRNA relative to a constant amount of Tet spike Ct values. The sample panel included normal and advanced gastric cancer tissue RNAs that were analyzed on U133 GeneChips. In addition, several new samples that were not analyzed on the GeneChip were used for the expression validations by Q-RT-PCR. The Q-RT-PCR data confirms the up-regulation of LBFL306 observed in advanced gastric cancer.

Table 1d

Chip position no.	Tissue	Disease	Morphology	Fold change	Dir	T-Stat
223251_s_at	BLADDER, NOS	MALIGNANT NEOPLASM OF BLADDER, NOS	TRANSITIONAL CELL CARCINOMA, NOS	1.649	Up	2.572
223251_s_at	BREAST, NOS	MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INTRADUCTAL CARCINOMA, NOS	-1.701	Down	-5.202
223251_s_at	COLON, NOS	MALIGNANT NEOPLASM OF COLON, NOS	ADENOCARCINOMA, NOS	2.651	Up	8.164
223251_s_at	ENDOMETRIUM, NOS	MALIGNANT NEOPLASM OF ENDOMETRIUM	MULLERIAN MIXED TUMOR	-1.806	Down	-2.367
223251_s_at	ESOPHAGUS, NOS	MALIGNANT NEOPLASM OF ESOPHAGUS, NOS	ADENOCARCINOMA, NOS	5.016	Up	4.269
223251_s_at	KIDNEY, NOS	MALIGNANT NEOPLASM OF KIDNEY, NOS	TRANSITIONAL CELL CARCINOMA, NOS	1.755	Up	4.563
223251_s_at		MALIGNANT NEOPLASM OF KIDNEY, NOS	CLEAR CELL ADENOCARCINOMA, NOS	1.611	Up	4.054
223251_s_at		MALIGNANT NEOPLASM OF KIDNEY, NOS	WILMS' TUMOR	4.565	Up	3.891
223251_s_at	OMENTUM, NOS	MALIGNANT NEOPLASM OF THE OMENTUM	PAPILLARY SEROUS ADENOCARCINOMA	1.762	Up	3.398
223251_s_at	PANCREAS, NOS	MALIGNANT NEOPLASM OF PANCREAS, NOS	ADENOCARCINOMA, NOS	2.672	Up	7.13
223251_s_at	RECTUM, NOS	MALIGNANT NEOPLASM OF RECTUM	ADENOCARCINOMA, NOS	2.482	Up	6.042
223251_s_at	SMALL INTESTINE, NOS	MALIGNANT NEOPLASM OF SMALL INTESTINE, NOS	SARCOMA, NOS	-1.944	Down	-5.716
223251_s_at	SOFT TISSUES, NOS	MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUES, NOS	MYXOID LIPOSARCOMA	1.878	Up	3.894
223251_s_at	STOMACH, NOS	MALIGNANT NEOPLASM OF STOMACH, NOS	ADENOCARCINOMA, NOS	2.522	Up	5.101

Example 2

5 Cloning of Full Length human cDNAs (LBFL301, LBFL304, LBFL305 and LBFL306)

Corresponding to Differentially Expressed mRNA Species

The full length cDNA having SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 17, 19 or 21 was obtained by the oligo-pulling method. Briefly, a gene-specific oligo was designed based on the sequence of LBFL301, LBFL304, LBFL305 or LBFL306. The oligo was labeled with biotin and used to hybridize with 2 µg of single strand plasmid DNA (cDNA recombinants) from a fully differentiated stomach adenocarcinoma library (NCI CGAP Gas 4) or a library prepared from Jurkat cells following the procedures of Sambrook *et al.* The hybridized cDNAs were separated by streptavidin-conjugated beads and eluted by heating. The eluted cDNA was converted to double strand plasmid DNA and used to transform *E. coli* cells (DH10B) and the longest cDNA was screened. After positive selection was confirmed by PCR using gene-specific primers, the cDNA clone was subjected to DNA sequencing.

The nucleotide sequence of the full-length human cDNAs corresponding to the differentially regulated mRNA detected above is set forth in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 17, 19 and 21. In SEQ ID NO 1, the cDNA comprises 1272 base pairs (1255 base pairs and a polyA tail). In SEQ ID NO 3, the cDNA comprises 1355 base pairs (1334 base pairs and a polyA tail). There are several possible start codons for LBFL304, and they are designated in SEQ ID NOS: 5, 7, 9 and 11. The cDNA in SEQ ID NO: 13 comprises 6405 base pairs (6369 base pairs and a poly A tail). The cDNA corresponding to SEQ ID NO: 17 comprises 1299 base pairs (1284 base pairs and a polyA tail). The cDNA corresponding to SEQ ID NO: 19 comprises 2451 base pairs (2435 base pairs and a polyA tail). The cDNA corresponding to SEQ ID NO: 21 comprises 1194 base pairs (1178 base pairs and a polyA tail).

An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 1, at nucleotides 131-859 (131-862 including the stop codon), encodes a protein of 243 amino acids. The amino acid sequence corresponding to a predicted protein encoded by SEQ ID NO: 1 is set forth in SEQ ID NO: 2.

An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 3,

at nucleotides 174-584 (174-587 including the stop codon), encodes a protein of 137 amino acids. The amino acid sequence corresponding to a predicted protein encoded by SEQ ID NO: 3 is set forth in SEQ ID NO: 4. The protein sequence of SEQ ID NO: 4 is identical to that of SEQ ID NO: 2 for the first 124 amino acids, while the last 13 amino acids of
5 SEQ ID NO: 4 are unique. As shown in Figure 1, termination of the protein sequence corresponding to SEQ ID NO: 4 is produced by a 45-bp insertion which introduces a stop codon in the open reading frame.

SEQ ID NOS: 2 and 4 are weakly similar to the chymotrypsin serine protease family signature (S1) and the NUDIX hydrolase family signature. The chymotrypsin
10 serine protease family signature (S1) contains three domains, the third of which is absent in SEQ ID NO: 4. Additionally, both proteins contain a domain of collagen triple helix repeats.

Figures 2 and 3 show the results of a hydrophobicity analysis of the amino acid sequence of SEQ ID NOS: 2 and 4. Hydrophilic regions may be used to produce
15 antigenic peptides, as described above. Both sequences have hydrophobic N-termini, approximately 30 amino acids in length, with the most hydrophobic portion peaking at around amino acid no. 20. Further protein sequence analysis by SPScan (GCG Wisconsin Package) reveals that the hydrophobic regions from amino acid positions 1-30 are likely to be secretory signal peptides.

20 An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 5, at nucleotides 38-892 (38-895 including the stop codon), encodes a protein of 285 amino acids. The amino acid sequence corresponding to a predicted protein encoded by SEQ ID NO: 5 is set forth in SEQ ID NO: 6. SEQ ID NO: 6 is weakly similar to the chymotrypsin serine protease family (S1) signature. Figure 4 shows the results of a
25 hydrophobicity analysis of the amino acid sequence of SEQ ID NO: 6. Hydrophilic regions may be used to produce antigenic peptides, as described above.

An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 7, at nucleotides 53-892 (53-895 including the stop codon), encodes a protein of 280 amino

acids. The amino acid sequence corresponding to a predicted protein encoded by SEQ ID NO: 7 is set forth in SEQ ID NO: 8. The protein sequence of SEQ ID NO: 8 is identical to that of SEQ ID NO: 6, except that SEQ ID NO: 8 lacks the first five amino acids at the N-terminus of SEQ ID NO: 6.

5 An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 9, at nucleotides 65-892 (65-895 including the stop codon), encodes a protein of 276 amino acids. The amino acid sequence corresponding to a predicted protein encoded by SEQ ID NO: 9 is set forth in SEQ ID NO: 10. The protein sequence of SEQ ID NO: 10 is identical to that of SEQ ID NO: 6, except that SEQ ID NO: 10 lacks the first nine amino
10 acids at the N-terminus of SEQ ID NO: 6.

An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 11, at nucleotides 92-892 (92-895 including the stop codon), encodes a protein of 267 amino acids. The amino acid sequence corresponding to a predicted protein encoded by SEQ ID NO: 11 is set forth in SEQ ID NO: 12. The protein sequence of SEQ ID NO: 12 is
15 identical to that of SEQ ID NO: 6, except that SEQ ID NO: 12 lacks the first 18 amino acids at the N-terminus of SEQ ID NO: 6.

An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 13, at nucleotides 49-1434 (49-1437 including the stop codon), encodes a protein of 462 amino acids. The amino acid sequence corresponding to the protein encoded by SEQ ID NO: 13
20 is set forth in SEQ ID NO: 14.

BLAST search results and a high level of homology between the two sequences suggest that LBFL305 is a splice variant of Mst1 (e.g., of SEQ ID NO: 16). The underlined amino acid residues of the alignment indicate the differences between SEQ ID NO: 14 and SEQ ID NO: 18. Based on published studies of Mst1, SEQ ID NO: 14
25 contains a kinase domain (amino acid positions 1-299) (Creasy *et al.*, (1996) *J Biol Chem* 271:21049-21053), followed by a regulatory domain which acts to regulate kinase function (amino acid positions 300-462) (Creasy *et al.*, (1996) *J Biol Chem* 271:21049-21053). Also present are two caspase cleavage sites, between amino acid positions 326-327 and

349-350 (Graves *et al.*, (2001) *J Biol Chem* 276:14909-14915), and one NES domain (amino acid positions 361-370) (Ura *et al.*, (2002) *Proc Natl Acad Sci USA* 98: 10148-10153). Compared to SEQ ID NO: 16, SEQ ID NO: 14 is missing the second NES domain (amino acid positions 441-451 in SEQ ID NO: 16) (Ura *et al.*, (2002) *Proc Natl Acad Sci USA* 98: 10148-10153). Also, SEQ ID NO: 14 does not contain the multimerization domain (amino acid positions 431-487 in Mst1) that is required for self-association (Creasy *et al.*, (1996) *J Biol Chem* 271:21049-21053). Interestingly, the region in Mst1 that is required for its interaction with NORE, a putative Ras effector (amino acid positions 449-487 in SEQ ID NO: 16) (Khokhlatchev *et al.*, *Curr Biol* 12:253-265), is absent in SEQ ID NO: 14.

Figure 5 show the results of a hydrophobicity analysis of the amino acid sequence of SEQ ID NO: 14. Hydrophilic regions may be used to produce antigenic peptides, as described above.

15 An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 17, at nucleotides 75-572 (75-575 including the stop codon), encodes a protein of 166 amino acids. The amino acid sequence corresponding to the protein encoded by SEQ ID NO: 17 is set forth in SEQ ID NO: 18. Figure 7 shows the results of a hydrophobicity analysis of the amino acid sequence of SEQ ID NO: 18. Hydrophilic regions may be used to produce antigenic peptides, as described above.

20 An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 19, at nucleotides 78-1337 (78-1340 including the stop codon), encodes a protein of 420 amino acids. The amino acid sequence corresponding to the protein encoded by SEQ ID NO: 19 is set forth in SEQ ID NO: 20. Figure 8 shows the results of a hydrophobicity analysis of the amino acid sequence of SEQ ID NO: 20. Hydrophilic regions may be used to produce antigenic peptides, as described above.

25 An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 19, at nucleotides 78-737 (78-740 including the stop codon), encodes a protein of 220 amino

acids. The amino acid sequence corresponding to the protein encoded by SEQ ID NO: 21 is set forth in SEQ ID NO: 22. Figure 9 shows the results of a hydrophobicity analysis of the amino acid sequence of SEQ ID NO: 22. Hydrophilic regions may be used to produce antigenic peptides, as described above.

5 All three LBFL306 clones, EF3 (SEQ ID NO: 17), GC7 (SEQ ID NO: 19) and GE2 (SEQ ID NO: 21), contain multiple ankyrin repeats, as determined by hmmerpfam, using GCG Wisconsin Package software. The ankyrin repeats are from amino acid residues 57 to 89, 91 to 123 and 124 to 156 in EF3, GC7 and GE2. In addition to these three ankyrin repeats, GC7 contains an additional ankyrin repeat from residues 157 to 190.

10 Analysis by Northern blot was performed to determine the size of the mRNA transcripts that correspond to LBFL301, LBFL304 and LBFL305. Northern blots containing total RNAs from various human tissues were used (ClonTech), and clone CH4 (SEQ ID NO: 3), clone EA10 (SEQ ID NO: 5, 7, 9 or 11) and LBFL305 (SEQ ID NO: 13) were radioactively labeled by the random primer method and used to probe the blots. The
15 blots were hybridized in Church and Gilbert buffer at 65°C and washed with 0.1X SSC containing 0.1% SDS at room temperature. The Northern blots show a single transcript for each gene, which is approximately 1.57 kb (LBFL301), 2.6 kb (LBFL304) and 7.95 kb (LBFL305) in size. These correspond to the sizes of the inserts in clone CH4 (1.355 kb), clone EA10 (SEQ ID NO: 5, 7, 9 or 11), and LBFL305 (6.5 kb). When the sequence of
20 clone AD12 (SEQ ID NO: 1) was used as the probe, a transcript of 1.44 kb was detected, which corresponds to the size of the insert, 1.272 kb, in clone AD12.

To examine the expression of LBFL301, LBFL304, LBFL305 or LBFL306 in various normal tissues, an electronic Northern blot (e-Northern) was prepared as follows. Using the chips and the procedures in Example 1, mRNA from a panel of normal tissues,
25 as listed in Table 3, was hybridized to Affymetrix U95 human GeneChips. The results of these experiments is shown in Table 3. For each tissue type, the number of samples that are called present or absent are indicated, together with the total number of samples in that sample set. In addition, the median value and the 25th and 75th percentiles in each tissue

type are listed. Interestingly, although this gene is up-regulated in stomach cancer, expression of LBFL301 or LBFL304 could not be detected in most normal stomach samples. In addition, although LBFL305 and LBFL306 were found in most normal stomach samples tested, the level of expression was lower than in most other normal tissues tested. This observation indicates that LBFL301, LBFL304, LBFL305 or LBFL306 may be used as a diagnostic agent or marker to detect or screen for stomach cancer, as discussed below. Expression levels of LBFL301 appeared to be highest in skin tissue, followed by placental, adipose, arterial, bladder, bone, breast and soft tissues. Lower levels of expression were detected in most of the other tissues listed in Table 3a, although this gene was not detected in the liver or in most areas of the brain and heart. Expression levels of LBFL304 appeared to be highest in the arteries, omentum, uterus, endometrium, myometrium, and prostate. Expression levels of LBFL305 appeared to be highest in organs of the immune system (white blood cells, lymph nodes, spleen and thymus gland) followed by samples from the appendix, artery, bone and lung. Still lower levels of expression were detected in most of the other tissues listed in Table 3c. Expression levels of LBFL306 appeared to be highest in organs of the immune system (e.g., lymph nodes, spleen and thymus gland) and of the reproductive system (e.g., breast, endometrium, prostate and uterus).

Table 3a- e-Northern Data for 48774_at: LBFL301 Gene Expression in Normal Tissues

Global Present Freq.	Tissue	Present	Absent	Lower 25%	Median	Upper 75%
0.5492						
	Adipose	29 of 33	4 of 33	130.90	200.78	302.98
	Adrenal Gland	1 of 12	11 of 12	-4.10	8.75	22.07
	Appendix	1 of 3	2 of 3	21.54	31.31	71.81
	Artery	3 of 3	0 of 3	148.46	203.96	262.32
	Bladder	6 of 7	1 of 7	142.72	195.44	361.02
	Bone	2 of 4	2 of 4	75.00	240.38	412.62
	Breast	74 of 82	8 of 82	104.43	222.98	506.27
	Cerebellum	0 of 5	5 of 5	-7.51	-6.91	0.94
	Cervix	75 of 99	24 of 99	42.04	93.36	144.25
	Colon	36 of 148	112 of 148	1.75	12.16	29.05
	Cortex Frontal Lobe	1 of 7	6 of 7	5.96	14.07	18.05
	Cortex Temporal Lobe	0 of 3	3 of 3	-0.59	4.13	4.66
	Duodenum	9 of 51	52 of 51	3.99	11.54	20.62
	Endometrium	16 of 21	5 of 21	46.25	85.18	113.55
	Esophagus	14 of 27	13 of 27	17.91	42.08	81.58
	Fallopian Tube	21 of 51	30 of 51	7.97	20.39	33.96
	GallBladder	4 of 8	4 of 8	16.22	80.97	400.47
	Heart	0 of 3	3 of 3	-3.80	6.00	11.57
	Hippocampus	1 of 5	4 of 5	-6.49	-0.18	7.81
	Kidney	12 of 87	75 of 87	-14.80	-4.61	9.24
	Larynx	4 of 4	0 of 4	48.51	119.88	248.62
	Left Atrium	64 of 141	77 of 141	8.19	27.15	61.94
	Left Ventricle	2 of 15	13 of 15	-7.49	7.08	13.24
	Liver	0 of 33	33 of 33	-15.13	-8.62	0.03
	Lung	43 of 92	49 of 92	10.45	30.14	63.21
	Lymph Node	9 of 12	3 of 12	43.28	81.96	225.75
	Muscles	19 of 38	19 of 38	23.70	40.22	108.40
	Myometrium	68 of 106	38 of 106	19.39	56.42	99.78
	Omentum	12 of 16	4 of 16	76.26	148.41	236.54
	Ovary	26 of 75	49 of 75	4.20	21.96	47.43
	Pancreas	7 of 34	27 of 34	-12.61	0.83	17.69
	Placenta	5 of 5	0 of 5	284.63	361.07	414.51
	Prostate	7 of 32	25 of 32	0.03	12.08	36.90
	Rectum	17 of 44	27 of 44	3.23	12.57	37.41
	Right Atrium	60 of 171	111 of 171	2.99	15.73	53.22
	Right Ventricle	43 of 160	117 of 160	1.85	16.64	39.58
	Skin	56 of 59	3 of 59	321.45	906.78	1515.60
	Small Intestine	18 of 68	50 of 68	0.41	12.19	28.53
	Soft Tissues	5 of 6	1 of 6	148.50	202.33	794.03
	Spleen	5 of 29	24 of 29	-3.61	3.04	12.46
	Stomach	15 of 45	30 of 45	7.73	18.66	50.97
	Testis	3 of 5	2 of 5	14.11	27.34	64.24
	Thymus	19 of 71	52 of 71	4.06	25.61	40.45
	Thyroid Gland	7 of 19	12 of 19	12.43	32.64	40.31
	Uterus	35 of 56	21 of 56	32.20	44.73	143.10
	WBC	1 of 41	40 of 41	-18.91	-13.33	-6.24

Table 3b: e-Northern for 35832_at: LBFL304 Gene Expression in Normal Tissues

Fragment	Global Present Freq.	Tissue	Present	Absent	Lower 25%	Median	Upper 75%
35832_at	0.5228						
		Adipose	26 of 34	8 of 34	29.09	59.51	89.67
		Adrenal Gland	1 of 12	11 of 12	-11.00	-6.08	8.14
		Appendix	1 of 3	2 of 3	43.26	53.50	66.52
		Artery	3 of 4	1 of 4	182.70	291.81	428.36
		Bladder	5 of 7	2 of 7	56.36	62.71	64.68
		Bone	3 of 4	1 of 4	19.34	77.40	167.06
		Breast	65 of 82	17 of 82	33.67	63.19	108.61
		Cerebellum	0 of 5	5 of 5	-19.26	-14.78	-13.16
		Cervix	69 of 102	33 of 102	18.76	57.45	94.99
		Colon	85 of 146	61 of 146	10.73	35.22	87.91
		Cortex Frontal Lobe	1 of 7	6 of 7	-5.03	8.78	14.71
		Cortex Temporal Lobe	0 of 3	3 of 3	-16.73	-16.67	-15.85
		Duodenum	19 of 53	34 of 53	6.47	20.39	41.95
		Endometrium	15 of 21	6 of 21	31.44	93.20	137.68
		Esophagus	15 of 27	12 of 27	5.12	27.03	52.89
		Fallopian Tube	19 of 47	28 of 47	5.38	22.48	54.99
		GallBladder	2 of 7	5 of 7	8.71	28.94	50.85
		Heart	0 of 3	3 of 3	-35.98	-28.25	-6.72
		Hippocampus	2 of 5	3 of 5	-7.43	-3.64	5.68
		Kidney	28 of 89	61 of 89	1.67	20.45	45.18
		Larynx	4 of 4	0 of 4	36.13	54.20	79.75
		Left Atrium	80 of 141	61 of 141	8.32	25.37	52.28
		Left Ventricle	0 of 15	15 of 15	-21.85	-17.01	-8.17
		Liver	2 of 35	33 of 35	-10.51	0.02	8.05
		Lung	29 of 93	64 of 93	2.56	19.47	43.63
		Lymph Node	3 of 12	9 of 12	-17.58	-2.85	9.56
		Muscles	12 of 42	30 of 42	-13.74	3.99	23.23
		Myometrium	92 of 108	16 of 108	67.57	129.39	203.58
		Omentum	14 of 15	1 of 15	176.65	310.28	368.41
		Ovary	31 of 74	43 of 74	0.66	27.78	54.33
		Pancreas	4 of 33	29 of 33	-9.60	2.09	9.94
		Placenta	0 of 5	5 of 5	-21.32	-3.06	6.08
		Prostate	30 of 32	2 of 32	82.37	104.56	190.72
		Rectum	37 of 44	7 of 44	51.53	86.73	125.67
		Right Atrium	69 of 170	101 of 170	-3.30	8.80	33.56
		Right Ventricle	35 of 160	125 of 160	-11.65	-0.46	16.02
		Skin	28 of 61	33 of 61	4.22	25.33	67.56
		Small Intestine	36 of 67	31 of 67	10.76	33.92	64.75
		Soft Tissues	4 of 6	2 of 6	25.95	40.91	58.70
		Spleen	1 of 29	28 of 29	-19.20	-13.77	-6.69

Table 3b

Fragment	Global Present Freq.	Tissue	Present	Absent	Lower 25%	Median	Upper 75%
		Stomach	16 of 47	31 of 47	-8.30	13.38	47.93
		Testis	1 of 5	4 of 5	-18.20	5.01	37.66
		Thymus	1 of 73	72 of 73	-22.55	-12.50	-3.27
		Thyroid Gland	14 of 19	5 of 19	45.56	98.30	141.24
		Uterus	43 of 58	15 of 58	37.47	103.26	180.98
		WBC	0 of 43	43 of 43	-33.45	-25.32	-20.23

Table 3c- e-Northern Data for 48774_at: LBFL305 Gene Expression in Normal Tissues

Global Present Freq.	Tissue	Present	Absent	Lower 25%	Median	Upper 75%
0.9444						
	Adipose	31 of 32	1 of 32	221.82	286.63	380.88
	Adrenal Gland	12 of 12	0 of 12	162.12	214.21	310.82
	Appendix	3 of 3	0 of 3	352.94	506.01	633.71
	Artery	3 of 3	0 of 3	343.80	419.88	643.55
	Bladder	5 of 5	0 of 5	221.82	290.82	301.11
	Bone	3 of 3	0 of 3	410.63	508.38	662.78
	Breast	80 of 80	0 of 80	236.84	279.81	333.22
	Cerebellum	5 of 5	0 of 5	182.09	198.28	283.55
	Cervix	97 of 101	4 of 101	179.11	246.50	317.62
	Colon	146 of 151	5 of 151	247.18	314.49	389.23
	Cortex Frontal Lobe	7 of 7	0 of 7	222.19	230.28	268.13
	Cortex Temporal Lobe	3 of 3	0 of 3	305.66	365.62	377.16
	Duodenum	58 of 61	3 of 61	206.17	276.14	331.91
	Endometrium	21 of 21	0 of 21	158.91	193.40	257.17
	Esophagus	25 of 27	2 of 27	182.29	223.24	303.93
	Fallopian Tube	50 of 51	1 of 51	168.69	220.72	265.95
	GallBladder	7 of 8	1 of 8	237.67	270.08	312.45
	Heart	2 of 3	1 of 3	44.79	55.84	56.46
	Hippocampus	5 of 5	0 of 5	165.94	212.72	328.59
	Kidney	79 of 86	7 of 86	121.83	158.99	209.67
	Larynx	4 of 4	0 of 4	140.76	209.46	302.84
	Left Atrium	127 of 141	14 of 141	58.48	92.78	123.06
	Left Ventricle	9 of 15	6 of 15	50.50	74.69	101.06
	Liver	27 of 34	7 of 34	87.73	146.60	197.27
	Lung	92 of 93	1 of 93	365.58	454.87	550.48
	Lymph Node	11 of 11	0 of 11	493.34	943.95	1141.06
	Muscles	19 of 39	20 of 39	41.41	64.44	110.74
	Myometrium	104 of 106	2 of 106	188.94	263.73	322.65
	Omentum	15 of 15	0 of 15	198.02	244.56	334.75
	Ovary	70 of 74	4 of 74	133.44	181.39	246.40
	Pancreas	13 of 34	21 of 34	24.30	53.13	84.64
	Placenta	4 of 5	1 of 5	156.58	174.21	182.71
	Prostate	32 of 32	0 of 32	184.16	234.60	289.05
	Rectum	42 of 43	1 of 43	284.60	365.66	434.01
	Right Atrium	148 of 169	21 of 169	54.96	89.92	129.13
	Right Ventricle	132 of 160	28 of 160	55.58	78.85	114.70

Table 3c

Global Present Freq.	Tissue	Present	Absent	Lower 25%	Median	Upper 75%
	Skin	57 of 59	2 of 59	250.81	320.57	398.56
	Small Intestine	64 of 68	4 of 68	196.50	279.29	393.83
	Soft Tissues	6 of 6	0 of 6	234.21	307.07	363.66
	Spleen	31 of 31	0 of 31	775.25	879.84	1022.49
	Stomach	41 of 47	6 of 47	137.91	217.53	338.54
	Testis	5 of 5	0 of 5	326.62	358.69	377.26
	Thymus	71 of 71	0 of 71	691.12	802.96	984.42
	Thyroid Gland	18 of 18	0 of 18	121.11	162.16	238.53
	Uterus	57 of 58	1 of 58	157.19	202.53	265.91
	WBC	38 of 40	2 of 40	1663.06	2264.27	2743.82

Table 3d- e-Northern Data for 48774_at: LBFL306 Gene Expression in Normal Tissues

Global Present Freq.	Tissue	Present	Absent	Lower 25%	Median	Upper 75%
0.8143						
	Adipose	31 of 32	1 of 32	184.04	242.67	285.20
	Adrenal Gland	6 of 12	6 of 12	130.70	157.08	187.26
	Appendix	3 of 3	0 of 3	259.39	301.05	388.31
	Artery	4 of 4	0 of 4	168.95	207.06	295.97
	Bladder	7 of 8	1 of 8	196.52	239.43	374.54
	Bones	4 of 4	0 of 4	209.35	226.22	292.55
	Breast	60 of 61	1 of 61	238.09	315.29	421.47
	Cervix	92 of 102	10 of 102	180.90	224.31	342.25
	Colon	168 of 192	24 of 192	147.41	175.83	215.95
	Cortex Frontal Lobe	5 of 5	0 of 5	133.94	148.22	162.91
	Cortex Temporal Lobe	3 of 3	0 of 3	137.28	147.77	172.44
	Duodenum	68 of 68	0 of 68	186.24	218.73	336.00
	Endometrium	19 of 19	0 of 19	273.57	359.17	436.85

Table 3d

Global Present Freq.	Tissue	Present	Absent	Lower 25%	Median	Upper 75%
	Esophagus	14 of 25	11 of 25	105.83	140.56	195.89
	Gall Bladder	7 of 8	1 of 8	232.71	293.00	410.47
	Heart	1 of 3	2 of 3	86.39	100.48	129.68
	Hippocampus	9 of 10	1 of 10	125.62	140.94	194.06
	Kidney	53 of 91	38 of 91	108.29	147.35	186.69
	Larynx	3 of 4	1 of 4	160.96	190.50	219.55
	Left Atrium	65 of 143	78 of 143	100.94	128.86	157.57
	Left Ventricle	0 of 13	13 of 13	82.54	106.63	117.06
	Liver	15 of 44	29 of 44	145.82	204.77	244.58
	Lung	104 of 114	10 of 114	168.03	203.35	283.11
	Lymph Node	14 of 14	0 of 14	207.66	319.53	366.70
	Lymphocytes(B+T Cells)	24 of 24	0 of 24	224.46	292.01	348.07
	Muscles	31 of 40	9 of 40	183.43	240.15	329.99
	Myometrium	122 of 128	6 of 128	209.83	244.58	294.20
	Omentum	13 of 15	2 of 15	162.83	236.23	265.24
	Ovary	80 of 81	1 of 81	219.28	259.00	331.64
	Pancreas	8 of 40	32 of 40	97.07	136.80	174.54
	Prostate	47 of 47	0 of 47	318.31	397.81	525.43
	Rectum	38 of 46	8 of 46	143.79	188.95	232.42
	Right Atrium	87 of 162	75 of 162	104.22	132.56	161.54
	Skin	38 of 44	6 of 44	162.29	198.90	236.86
	Small Intestine	72 of 79	7 of 79	184.41	230.96	270.34
	Soft Tissues	5 of 5	0 of 5	240.30	258.33	499.21
	Spleen	36 of 36	0 of 36	253.03	322.87	390.61
	Stomach	32 of 54	22 of 54	139.62	174.76	239.47
	Thymus	70 of 70	0 of 70	352.12	438.94	511.11
	Thyroid Gland	25 of 25	0 of 25	177.32	211.27	276.25
	Uterus	54 of 56	2 of 56	243.74	312.71	387.50
	WBC	21 of 25	4 of 25	149.63	176.72	209.49

INDUSTRIAL APPLICAVILITY

5

Example 3

Detection of LBFL301, LBFL304, LBFL305 or LBFL306 mRNA for Stomach Cancer Screening

The expression level of mRNA corresponding to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 17, 19 or 21 is determined in stomach tissue biopsy samples, as described in Example 1, *i.e.*, by screening mRNA samples on a GeneChip, or as described in Example 2, *i.e.*, by screening mRNA samples on a Northern blot. Alternatively, samples from non-stomach hyperplastic tissues in malignant or non-malignant states may also be analyzed. Stomach tissue samples from patients with stomach cancer and from normal subjects may be used as positive and negative controls. Using any means of analyzing gene expression, a level of expression higher than that of the normal control is indicative of stomach cancer or a

likelihood of developing stomach cancer.

Although the present invention has been described in detail with reference to examples above, it is understood that various modifications can be made without departing
5 from the spirit of the invention. Accordingly, the invention is limited only by the following claims. All cited patents, patent applications and publications referred to in this application are herein incorporated by reference in their entirety.

What Is Claimed:

1. An isolated nucleic acid molecule selected from the group consisting of: (a) an isolated nucleic acid molecule comprising SEQ ID NO: 3, 5, 7, 9, 11, 13, 17 or 19; (b) an isolated nucleic acid molecule that encodes the amino acid sequence of SEQ ID NO: 4, 14 or 18; (c) an isolated nucleic acid molecule that encodes a protein that is expressed in stomach cancer and that exhibits at least about 92% nucleotide sequence identity over the entire length of SEQ ID NO: 3 or 17; (d) an isolated nucleic acid molecule that encodes a protein that is expressed in stomach cancer and that exhibits at least about 95% nucleotide sequence identity over the entire length of SEQ ID NO: 13; (e) an isolated nucleic acid molecule comprising the complement of a nucleic acid molecule of (a), (b), (c) or (d).

2. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises nucleotides 174-584 of SEQ ID NO: 3.

3. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule consists of nucleotides 174-584 of SEQ ID NO: 3.

4. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises nucleotides 174-587 of SEQ ID NO: 3.

5. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is selected from the group consisting of: a nucleic acid molecule consisting of nucleotides 38-892 of SEQ ID NO: 5 and a nucleic acid molecule consisting of nucleotides 38-895 of SEQ ID NO: 5.

6. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is selected from the group consisting of: a nucleic acid molecule consisting of nucleotides 53-

892 of SEQ ID NO: 7 and a nucleic acid molecule consisting of nucleotides 53-895 of SEQ ID NO: 7.

7. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is selected from the group consisting of: a nucleic acid molecule consisting of nucleotides 65-892 of SEQ ID NO: 9 and a nucleic acid molecule consisting of nucleotides 65-895 of SEQ ID NO: 9.

8. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is selected from the group consisting of: a nucleic acid molecule consisting of nucleotides 92-892 of SEQ ID NO: 11 and a nucleic acid molecule consisting of nucleotides 92-895 of SEQ ID NO: 11.

9. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises nucleotides 49-1434 of SEQ ID NO: 13.

10. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule consists of nucleotides 49-1437 of SEQ ID NO: 13.

11. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises nucleotides 49-1437 of SEQ ID NO: 13.

12. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises nucleotides 75-575 of SEQ ID NO: 17.

13. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule consists of nucleotides 75-575 of SEQ ID NO: 17.

14. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises nucleotides 75-572 of SEQ ID NO: 17.

15. The isolated nucleic acid molecule of any one of claims 1-14, wherein said nucleic acid molecule is operably linked to one or more expression control elements.

16. A vector comprising an isolated nucleic acid molecule of any one of claims 1-14.

17. A host cell transformed to contain the nucleic acid molecule of any one of claims 1-14.

18. A host cell comprising a vector of claim 16.

19. A host cell of claim 18, wherein said host cell is selected from the group consisting of prokaryotic host cells and eukaryotic host cells.

20. A method for producing a polypeptide or protein comprising culturing a host cell transformed with the nucleic acid molecule of any one of claims 1-14 under conditions in which the polypeptide or protein encoded by said nucleic acid molecule is expressed.

21. The method of claim 20, wherein said host cell is selected from the group consisting of prokaryotic host cells and eukaryotic host cells.

22. An isolated polypeptide or protein produced by the method of claim 21.

23. An isolated polypeptide or protein selected from the group consisting of: (a) an isolated polypeptide or protein comprising the amino acid sequence of SEQ ID NO: 4, 6, 8, 10, 12, 14 or 18; (b) an isolated polypeptide or protein exhibiting at least about 92% amino

acid sequence identity with SEQ ID NO: 4; (c) an isolated polypeptide or protein consisting of amino acids 31-137 of SEQ ID NO: 4; (d) an isolated polypeptide comprising a fragment of at least 10 amino acids of SEQ ID NO: 6, 8, 10 or 12; (e) an isolated polypeptide comprising conservative amino acid substitutions of SEQ ID NO: 6, 8, 10 or 12; (f) an isolated polypeptide comprising naturally occurring amino acid sequence variants of SEQ ID NO: 6, 8, 10 or 12; (g) an isolated polypeptide exhibiting at least about 75% amino acid sequence identity with SEQ ID NO: 6, 8, 10 or 12; (h) an isolated polypeptide or protein exhibiting at least about 95% amino acid sequence identity with SEQ ID NO: 14; and (i) an isolated polypeptide or protein exhibiting at least about 92% amino acid sequence identity with SEQ ID NO: 18.

24. An isolated antibody or antigen-binding antibody fragment that binds to a polypeptide or protein of claim 23 or to an isolated polypeptide or protein comprising the amino acid sequence of SEQ ID NO: 2.

25. An antibody of claim 24 wherein said antibody is a monoclonal or a polyclonal antibody.

26. A method of identifying an agent which modulates the expression of a nucleic acid encoding a protein of claim 23, a protein comprising the amino acid sequence of SEQ ID NO: 2, 20 or 22, or a Mst1 protein or a Mst1 splice variant protein, the method comprising:
exposing cells which express the nucleic acid to the agent; and
determining whether the agent modulates expression of said nucleic acid, thereby identifying an agent which modulates the expression of a nucleic acid encoding the protein.

27. A method of identifying an agent which modulates the level of or at least one activity of a protein of claim 23, or of a protein comprising the amino acid sequence of SEQ ID NO: 2, 20 or 22, or of a Mst1 protein or a Mst1 splice variant protein, the method

comprising:

exposing cells which express the protein to the agent;

determining whether the agent modulates the level of or at least one activity of said protein, thereby identifying an agent which modulates the level of or at least one activity of the protein.

28. The method of claim 27, wherein the agent modulates one activity of the protein.

29. A method of identifying binding partners for a protein of claim 23 or a protein comprising the amino acid sequence of SEQ ID NO: 2, the method comprising:

exposing said protein to a potential binding partner; and

determining if the potential binding partner binds to said protein, thereby identifying binding partners for the protein.

30. A method of modulating the expression of a nucleic acid encoding a protein of claim 23, a protein comprising the amino acid sequence of SEQ ID NO: 2, 20 or 22, or a Mst1 protein or a Mst1 splice variant protein, the method comprising:

administering an effective amount of an agent which modulates the expression of a nucleic acid encoding the protein.

31. A method of modulating at least one activity of a protein of claim 23, or of a protein comprising the amino acid sequence of SEQ ID NO: 2, 20 or 22, or of a Mst1 protein or a Mst1 splice variant protein, the method comprising:

administering an effective amount of an agent which modulates at least one activity of the protein.

32. A non-human transgenic animal modified to contain a nucleic acid molecule of any of claims 1-14.

33. The transgenic animal of claim 32, wherein the nucleic acid molecule contains a mutation that prevents expression of the encoded protein.

34. A method of diagnosing a disease state in a subject, comprising:

5 determining the level of expression of a nucleic acid molecule of any one of claims 1-14 or encoding a Mst1 protein or a Mst1 splice variant protein, or of a protein of claim 23, or of a protein comprising the amino acid sequence of SEQ ID NO: 2, 20 or 22 or of a Mst1 protein or a Mst1 splice variant protein.

10 35. The method of claim 34, wherein the disease state is stomach cancer.

36. The method of claim 34, wherein the disease state is advanced gastric cancer.

37. The method of claim 34, wherein the disease state is a malignant neoplasm.

15 38. The method of claim 37, wherein the malignant neoplasm occurs in soft tissue, bone, breast, cervix, colon, endometrium, esophagus, kidney, larynx, liver, lung, omentum, ovary, pancreas, rectum, thyroid, myometrium, prostate, skin, small intestine, bladder, spleen or stomach.


20 39. The method of any one of claims 16-21 or 24-25, wherein the splice variant is SEQ ID NO: 13 or SEQ ID NO: 14.

25 40. A composition comprising a diluent and a polypeptide or protein selected from the group consisting of: (a) an isolated polypeptide or protein comprising the amino acid sequence of SEQ ID NO: 4, 6, 8, 10, 12, 14, 18, 20 or 22 (b) an isolated polypeptide or protein exhibiting at least about 92% amino acid sequence identity with SEQ ID NO: 4 or 18, (c) an isolated polypeptide or protein consisting of amino acids 31-137 of SEQ ID NO:

4, (d) an isolated polypeptide comprising a fragment of at least 10 amino acids of SEQ ID NO: 6, 8, 10 or 12, (e) an isolated polypeptide comprising conservative amino acid substitutions of SEQ ID NO: 6, 8, 10 or 12, (f) an isolated polypeptide comprising naturally occurring amino acid sequence variants of SEQ ID NO: 6, 8, 10 or 12, (g) an
5 isolated polypeptide exhibiting at least about 75% amino acid sequence identity with SEQ ID NO: 6, 8, 10 or 12, (h) an isolated polypeptide exhibiting at least about 95% amino acid sequence identity with SEQ ID NO: 14.

Fig. 1

Differences Between CH4 and AD12



10/524258

Fig. 2

LBFL301-AD12





Fig. 3

LBFL301-CH4



10/524258

Fig. 4

LBFL304

PEPLOT of: ab029000_ea10_orfpep.pep ck: 3008, 1 to 285 June 19, 2002 14:18

TRANSLATE of: ab029000_ea10.seq check: 2851 from: 38 to 895






Fig. 5



10/524258

Fig. 6


EF3, GC7 and GE2 Alignment



10/524258

Fig. 7

LBFL306-EF3



10/524258

Fig. 8

LBFL306-GC7





Fig. 9

LBFL306-GE2



Sequence Listing

10/524258

DT01 Rec'd PCT/PTO 11 FEB 2005

<110> LG Life Sciences, Ltd.

<120> Gene families associated with stomach cancer

<130> PC03015-LG

<150> US 60/402,904

<151> 2002-08-14

<150> US 60/404,408

<151> 2002-08-20

<150> US 60/405,304

<151> 2002-08-23

<150> US 60/421,582

<151> 2002-10-28

<160> 22

<170> KopatentIn 1.71

<210> 1

<211> 1272

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (131)..(859)

<223> Gene LBFL301, Clone AD12

<400> 1

ggcgcgcggg tgaaaggcgc attgatgcag cctgcgcggg cctcggagcg cggcggagcc 60

agacgtgac cacgttcctc tctcgggtct cctccgcctc cagctccgcg ctgcccggca 120

gccgggagcc atg cga ccc cag ggc ccc gcc gcc tcc ccg cag cgg ctc cgc 172

Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg

Sequence Listing

1	5	10	
ggc ctc ctg ctg ctc ctg ctg ctg cag ctg ccc gcg ccg tcg agc gcc			220
Gly Leu Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala			
15	20	25	30
tct gag atc ccc aag ggg aag caa aag gcg cag ctc cgg cag agg gag			268
Ser Glu Ile Pro Lys Gly Lys Gln Lys Ala Gln Leu Arg Gln Arg Glu			
35	40	45	
gtg gtg gac ctg tat aat gga atg tgc tta caa ggg cca gca gga gtg			316
Val Val Asp Leu Tyr Asn Gly Met Cys Leu Gln Gly Pro Ala Gly Val			
50	55	60	
cct ggt cga gac ggg agc cct ggg gcc aat ggc att ccg ggt aca cct			364
Pro Gly Arg Asp Gly Ser Pro Gly Ala Asn Gly Ile Pro Gly Thr Pro			
65	70	75	
ggg atc cca ggt cgg gat gga ttc aaa gga gaa aag ggg gaa tgt ctg			412
Gly Ile Pro Gly Arg Asp Gly Phe Lys Gly Glu Lys Gly Glu Cys Leu			
80	85	90	
agg gaa agc ttt gag gag tcc tgg aca ccc aac tac aag cag tgt tca			460
Arg Glu Ser Phe Glu Glu Ser Trp Thr Pro Asn Tyr Lys Gln Cys Ser			
95	100	105	110
tgg agt tca ttg aat tat ggc ata gat ctt ggg aaa att gcg gag tgt			508
Trp Ser Ser Leu Asn Tyr Gly Ile Asp Leu Gly Lys Ile Ala Glu Cys			
115	120	125	
aca ttt aca aag atg cgt tca aat agt gct cta aga gtt ttg ttc agt			556
Thr Phe Thr Lys Met Arg Ser Asn Ser Ala Leu Arg Val Leu Phe Ser			
130	135	140	
ggc tca ctt cgg cta aaa tgc aga aat gca tgc tgt cag cgt tgg tat			604
Gly Ser Leu Arg Leu Lys Cys Arg Asn Ala Cys Cys Gln Arg Trp Tyr			
145	150	155	
ttc aca ttc aat gga gct gaa tgt tca gga cct ctt ccc att gaa gct			652
Phe Thr Phe Asn Gly Ala Glu Cys Ser Gly Pro Leu Pro Ile Glu Ala			

Sequence Listing

160	165	170	
ata att tat ttg gac caa gga agc cct gaa atg aat tca aca att aat			700
Ile Ile Tyr Leu Asp Gln Gly Ser Pro Glu Met Asn Ser Thr Ile Asn			
175	180	185	190
att cat cgc act tct tct gtg gaa gga ctt tgt gaa gga att ggt gct			748
Ile His Arg Thr Ser Ser Val Glu Gly Leu Cys Glu Gly Ile Gly Ala			
	195	200	205
gga tta gtg gat gtt gct atc tgg gtt ggc act tgt tca gat tac cca			796
Gly Leu Val Asp Val Ala Ile Trp Val Gly Thr Cys Ser Asp Tyr Pro			
	210	215	220
aaa gga gat gct tct act gga tgg aat tca gtt tct cgc atc att att			844
Lys Gly Asp Ala Ser Thr Gly Trp Asn Ser Val Ser Arg Ile Ile Ile			
	225	230	235
gaa gaa cta cca aaa t aaatgcttta attttcattt gctacctctt tttttattat			900
Glu Glu Leu Pro Lys			
	240		
gccttggaat gggttcactta aatgacattt taaataagtt tatgtataca tctgaatgaa			960
aagcaaagct aaatatgttt acagacccaaa gtgtgatttc aactgtttt taaatctagc			1020
attattcatt ttgcttcaat caaaagtggg ttcaatatatt tttttagttg gttagaatac			1080
tttcttcata gtcacattct ctcaacctat aatttggaat attgttgttg tcttttgttt			1140
tttctcttag tatagcattt ttaaaaaaat ataaaaagcta ccaatctttg tacaatttgt			1200
aaatgttaag aatttttttt atatctgtta aataaaaaatt attccaaca accttaaaaa			1260
aaaaaaaaaa aa			1272

<210> 2

<211> 243

<212> PRT

Sequence Listing

<213> Homo sapiens

<400> 2

Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu
1 5 10 15

Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu
20 25 30

Ile Pro Lys Gly Lys Gln Lys Ala Gln Leu Arg Gln Arg Glu Val Val
35 40 45

Asp Leu Tyr Asn Gly Met Cys Leu Gln Gly Pro Ala Gly Val Pro Gly
50 55 60

Arg Asp Gly Ser Pro Gly Ala Asn Gly Ile Pro Gly Thr Pro Gly Ile
65 70 75 80

Pro Gly Arg Asp Gly Phe Lys Gly Glu Lys Gly Glu Cys Leu Arg Glu
85 90 95

Ser Phe Glu Glu Ser Trp Thr Pro Asn Tyr Lys Gln Cys Ser Trp Ser
100 105 110

Ser Leu Asn Tyr Gly Ile Asp Leu Gly Lys Ile Ala Glu Cys Thr Phe
115 120 125

Thr Lys Met Arg Ser Asn Ser Ala Leu Arg Val Leu Phe Ser Gly Ser
130 135 140

Leu Arg Leu Lys Cys Arg Asn Ala Cys Cys Gln Arg Trp Tyr Phe Thr
145 150 155 160

Phe Asn Gly Ala Glu Cys Ser Gly Pro Leu Pro Ile Glu Ala Ile Ile
165 170 175

Tyr Leu Asp Gln Gly Ser Pro Glu Met Asn Ser Thr Ile Asn Ile His
180 185 190

Arg Thr Ser Ser Val Glu Gly Leu Cys Glu Gly Ile Gly Ala Gly Leu

Sequence Listing

195 200 205
 Val Asp Val Ala Ile Trp Val Gly Thr Cys Ser Asp Tyr Pro Lys Gly
 210 215 220
 Asp Ala Ser Thr Gly Trp Asn Ser Val Ser Arg Ile Ile Ile Glu Glu
 225 230 235 240
 Leu Pro Lys

<210> 3
 <211> 1355
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (174) .. (584)
 <223> Gene LBFL301, Clone CH4

<400> 3
 ctccgggtgt cgcgggggcg ggaggaatta agggaggag agaggcgcg gggtgaaagg 60
 cgcattgatg cagcctgcgg cggcctcgga gcgcggcgga gccagacgct gaccacgttc 120
 ctctctcggg tctctccgc ctccagctcc gcgctgcccg gcagccggga gcc 173
 atg cga ccc cag ggc ccc gcc gcc tcc ccg cag cgg ctc cgc ggc ctc 221
 Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu
 1 5 10 15
 ctg ctg ctc ctg ctg ctg cag ctg ccc gcg ccg tcg agc gcc tct gag 269
 Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu
 20 25 30
 atc ccc aag ggg aag caa aag gcg cag ctc cgg cag agg gag gtg gtg 317
 Ile Pro Lys Gly Lys Gln Lys Ala Gln Leu Arg Gln Arg Glu Val Val

Sequence Listing

35	40	45	
gac ctg tat aat gga atg tgc tta caa ggg cca gca gga gtg cct ggt			365
Asp Leu Tyr Asn Gly Met Cys Leu Gln Gly Pro Ala Gly Val Pro Gly			
50	55	60	
cga gac ggg agc cct ggg gcc aat ggc att ccg ggt aca cct ggg atc			413
Arg Asp Gly Ser Pro Gly Ala Asn Gly Ile Pro Gly Thr Pro Gly Ile			
65	70	75	80
cca ggt cgg gat gga ttc aaa gga gaa aag ggg gaa tgt ctg agg gaa			461
Pro Gly Arg Asp Gly Phe Lys Gly Glu Lys Gly Glu Cys Leu Arg Glu			
85	90	95	
agc ttt gag gag tcc tgg aca ccc aac tac aag cag tgt tca tgg agt			509
Ser Phe Glu Glu Ser Trp Thr Pro Asn Tyr Lys Gln Cys Ser Trp Ser			
100	105	110	
tca ttg aat tat ggc ata gat ctt ggg aaa att gcg aaa cac gtc aag			557
Ser Leu Asn Tyr Gly Ile Asp Leu Gly Lys Ile Ala Lys His Val Lys			
115	120	125	
agt caa tac gaa tgg aca gaa cta gtc tagaat gagggtacat ttacaaagat			610
Ser Gln Tyr Glu Trp Thr Glu Leu Val			
130	135		
gcgttcaa at agtgctctaa gaggtttggc cagggtgctca cttcggctaa aatgcagaaa			670
tgcatgctgt cagcgttggt atttcacatt caatggagct gaatgttcag gacctcttcc			730
cattgaagct ataatttatt tggaccaagg aagccctgaa atgaattcaa caattaatat			790
tcatgcact tcttctgtgg aaggactttg tgaaggaatt ggtgctggat tagtggatgt			850
tgctatctgg gttggcactt gttcagatta cccaaaagga gatgcttcta ctggatggaa			910
ttcagtttct cgcattcatta ttgaagaact accaaaataa atgctttaat tttcatttgc			970
tacctctttt tttattatgc cttggaatgg ttcacttaaa tgacatttta aataagttaa			1030

Sequence Listing

```

tgtatacatc tgaatgaaaa gcaaagctaa atatgtttac agaccaaagt gtgatttcac      1090
actgttttta aatctagcat tattcatttt gcttcaatca aaagtgggtt caatattttt      1150
tttagttggt tagaatactt tcttcatagt cacattctct caacctataa tttggaatat      1210
tgttgtggtc ttttggtttt tctcttagta tagcattttt aaaaaaatat aaaagctacc      1270
aatctttgta caatttgtaa atgttaagaa ttttttttat atctgttaaa taaaaattat      1330
ttccaacaaa aaaaaaaaaa aaaaaa                                           1355

```

<210> 4
 <211> 137
 <212> PRT
 <213> Homo sapiens

<400> 4
 Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu
 1 5 10 15
 Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu
 20 25 30
 Ile Pro Lys Gly Lys Gln Lys Ala Gln Leu Arg Gln Arg Glu Val Val
 35 40 45
 Asp Leu Tyr Asn Gly Met Cys Leu Gln Gly Pro Ala Gly Val Pro Gly
 50 55 60
 Arg Asp Gly Ser Pro Gly Ala Asn Gly Ile Pro Gly Thr Pro Gly Ile
 65 70 75 80
 Pro Gly Arg Asp Gly Phe Lys Gly Glu Lys Gly Glu Cys Leu Arg Glu
 85 90 95
 Ser Phe Glu Glu Ser Trp Thr Pro Asn Tyr Lys Gln Cys Ser Trp Ser
 100 105 110

Sequence Listing

Ser Leu Asn Tyr Gly Ile Asp Leu Gly Lys Ile Ala Lys His Val Lys
 115 120 125

Ser Gln Tyr Glu Trp Thr Glu Leu Val
 130 135

<210> 5
 <211> 2500
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (38)..(892)
 <223> Clone LBFL304, ORF1

<400> 5
 ggatataagc agtgcacccc aagacctaag aatcttg atg ttg gaa ata aag 52
 Met Leu Glu Ile Lys
 1 5

atg gag gaa gct atg acc tac aca gag gac agt tat ggg atg gat ggg 100
 Met Glu Glu Ala Met Thr Tyr Thr Glu Asp Ser Tyr Gly Met Asp Gly
 10 15 20

aag gtt aat cag ccc cgt ctc act gca gac atc aac tgg caa ggc cta 148
 Lys Val Asn Gln Pro Arg Leu Thr Ala Asp Ile Asn Trp Gln Gly Leu
 25 30 35

gag gag cta cac agt gtg aat gaa aac atc tat gag tac aga caa aac 196
 Glu Glu Leu His Ser Val Asn Glu Asn Ile Tyr Glu Tyr Arg Gln Asn
 40 45 50

tac aga ctt agt ctg gtg gac tgg act aat tac ttg aag gat tta gat 244
 Tyr Arg Leu Ser Leu Val Asp Trp Thr Asn Tyr Leu Lys Asp Leu Asp
 55 60 65

aga gta ttt gca ctg ctg aag agt cac tat gag caa aat aaa aca aat 292

Sequence Listing

Arg Val Phe Ala Leu Leu Lys Ser His Tyr Glu Gln Asn Lys Thr Asn			
70	75	80	85
aag act caa act gct caa agt gac ggg ttc ttg gtt gtc tct gct gag			340
Lys Thr Gln Thr Ala Gln Ser Asp Gly Phe Leu Val Val Ser Ala Glu			
90	95	100	
cac gct gtg tca atg gag atg gcc tct gct gac tca gat gaa gac cca			388
His Ala Val Ser Met Glu Met Ala Ser Ala Asp Ser Asp Glu Asp Pro			
105	110	115	
agg cat aag gtt ggg aaa aca cct cat ttg acc ttg cca gct gac ctt			436
Arg His Lys Val Gly Lys Thr Pro His Leu Thr Leu Pro Ala Asp Leu			
120	125	130	
caa acc ctg cat ttg aac cga cca aca tta agt cca gag agt aaa ctt			484
Gln Thr Leu His Leu Asn Arg Pro Thr Leu Ser Pro Glu Ser Lys Leu			
135	140	145	
gaa tgg aat aac gac att cca gaa gtt aat cat ttg aat tct gaa cac			532
Glu Trp Asn Asn Asp Ile Pro Glu Val Asn His Leu Asn Ser Glu His			
150	155	160	165
tgg aga aaa acc gaa aaa tgg acg ggg cat gaa gag act aat cat ctg			580
Trp Arg Lys Thr Glu Lys Trp Thr Gly His Glu Glu Thr Asn His Leu			
170	175	180	
gaa acc gat ttc agt ggc gat ggc atg aca gag cta gag ctg ggg ccc			628
Glu Thr Asp Phe Ser Gly Asp Gly Met Thr Glu Leu Glu Leu Gly Pro			
185	190	195	
agc ccc agg ctg cag ccc att cgc agg cac ccg aaa gaa ctt ccc cag			676
Ser Pro Arg Leu Gln Pro Ile Arg Arg His Pro Lys Glu Leu Pro Gln			
200	205	210	
tat ggt ggt cct gga aag gac att ttt gaa gat caa cta tat ctt cct			724
Tyr Gly Gly Pro Gly Lys Asp Ile Phe Glu Asp Gln Leu Tyr Leu Pro			
215	220	225	
gtg cat tcc gat gga att tca gtt cat cag atg ttc acc atg gcc acc			772

Sequence Listing

Val His Ser Asp Gly Ile Ser Val His Gln Met Phe Thr Met Ala Thr	
230	235 240 245
gca gaa cac cga agt aat tcc agc ata gcg ggg aag atg ttg acc aag	820
Ala Glu His Arg Ser Asn Ser Ser Ile Ala Gly Lys Met Leu Thr Lys	
250	255 260
gtg gag aag aat cac gaa aag gag aag tca cag cac cta gaa ggc agc	868
Val Glu Lys Asn His Glu Lys Glu Lys Ser Gln His Leu Glu Gly Ser	
265	270 275
gcc tcc tct tca ctc tcc tct gat tagatgaa actgttacct taccctaaac	920
Ala Ser Ser Ser Leu Ser Ser Asp	
280	285
acagtatttc tttttaactt ttttatttgt aaactaataa aggtaatcac agccaccaac	980
attccaagct accctgggta cctttgtgca gtagaagcta gtgagcatgt gagcaagcgg	1040
tgtgcacacg gagactcatc gttataattt actatctgcc aagagtagaa agaaaggctg	1100
gggatatttg ggttggttg gtttgattt ttgcttggt tgtttgttt gtactaaaac	1160
agtattatct ttggaatatc gtagggacat aagtatatac atgttatcca atcaagatgg	1220
ctagaatggt gcctttctga gtgtctaaaa cttgacaccc ctggtaaatc tttcaacaca	1280
cttccactgc ctgcgtaatg aagttttgat tcatttttaa ccaactggaat ttttcaatgc	1340
cgtcattttc agttagatga ttttgcaatt tgagattaaa atgccatgtc tatttgatta	1400
gtcttatttt tttattttta caggcttacc agtctcactg ttggctgtca ttgtgacaaa	1460
gtcaaataaa cccccaagga cgacacacag tatggatcac atattgtttg acattaagct	1520
tttgccagaa aatgttgcac gtgttttacc tcgacttgct aaaatcgatt agcagaaagg	1580
catggctaata aatgttggtg gtgaaaataa ataaataagt aaacaaaatg aagattgcct	1640
gctctctctg tgccatgcct caaagcgctc atcatatc ataccttaa gattgctata	1700

Sequence Listing

```

ttttgggtta ttttcttgac agggagaaaa gatctaaaga tcttttattt tcattctttt 1760
tggttttctt ggcattgacta agaagcttaa atgttgataa aatatgacta gttttgaatt 1820
tacaccaaga acttctcaat aaaagaaaat catgaatgct ccacaatttc aacataccac 1880
aagagaagtt aatttcttaa cattgtgttc tatgattatt tgtaagacct tcaccaagtt 1940
ctgatatctt ttaaagacat agttcaaaat tgcttttgaa aatctgtatt cttgaaaata 2000
tccttgttgt gtattagggt tttaaatacc agctaaagga ttacctcact gagtcacag 2060
taccctccta ttcagctccc caagatgatg tgtttttgct taccctaaga gaggttttct 2120
tcttattttt agataattca agtgcttaga taaattatgt tttctttaag tgcttatggt 2180
aaactctttt aaagaaaatt taatatgta tagctgaatc tttttggtta ctttaaactc 2240
ttatcataga ctctgtacat atgttcaaat tagctgcttg cctgatgtgt gtatcatcgg 2300
tgggatgaca gaacaaacat atttatgatc atgaataatg tgctttgtaa aaagatttca 2360
agttattagg aagcactatc tgttttttaa tcatgtataa tattccatga tacttttata 2420
gaacaattct ggcttcagga aagtctagaa gcaatatctt ttcaaataaa agtggtttta 2480
actttaaaaa aaaaaaaaaa 2500

```

<210> 6

<211> 285

<212> PRT

<213> Homo sapiens

<400> 6

Met Leu Glu Ile Lys Met Glu Glu Ala Met Thr Tyr Thr Glu Asp Ser

1

5

10

15

Tyr Gly Met Asp Gly Lys Val Asn Gln Pro Arg Leu Thr Ala Asp Ile

Sequence Listing

20	25	30
Asn Trp Gln Gly Leu Glu Glu Leu His Ser Val Asn Glu Asn Ile Tyr		
35	40	45
Glu Tyr Arg Gln Asn Tyr Arg Leu Ser Leu Val Asp Trp Thr Asn Tyr		
50	55	60
Leu Lys Asp Leu Asp Arg Val Phe Ala Leu Leu Lys Ser His Tyr Glu		
65	70	75 80
Gln Asn Lys Thr Asn Lys Thr Gln Thr Ala Gln Ser Asp Gly Phe Leu		
85	90	95
Val Val Ser Ala Glu His Ala Val Ser Met Glu Met Ala Ser Ala Asp		
100	105	110
Ser Asp Glu Asp Pro Arg His Lys Val Gly Lys Thr Pro His Leu Thr		
115	120	125
Leu Pro Ala Asp Leu Gln Thr Leu His Leu Asn Arg Pro Thr Leu Ser		
130	135	140
Pro Glu Ser Lys Leu Glu Trp Asn Asn Asp Ile Pro Glu Val Asn His		
145	150	155 160
Leu Asn Ser Glu His Trp Arg Lys Thr Glu Lys Trp Thr Gly His Glu		
165	170	175
Glu Thr Asn His Leu Glu Thr Asp Phe Ser Gly Asp Gly Met Thr Glu		
180	185	190
Leu Glu Leu Gly Pro Ser Pro Arg Leu Gln Pro Ile Arg Arg His Pro		
195	200	205
Lys Glu Leu Pro Gln Tyr Gly Gly Pro Gly Lys Asp Ile Phe Glu Asp		
210	215	220
Gln Leu Tyr Leu Pro Val His Ser Asp Gly Ile Ser Val His Gln Met		
225	230	235 240

Sequence Listing

Phe Thr Met Ala Thr Ala Glu His Arg Ser Asn Ser Ser Ile Ala Gly
 245 250 255

Lys Met Leu Thr Lys Val Glu Lys Asn His Glu Lys Glu Lys Ser Gln
 260 265 270

His Leu Glu Gly Ser Ala Ser Ser Ser Leu Ser Ser Asp
 275 280 285

<210> 7
 <211> 2500
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> CDS
 <222> (53)..(892)
 <223> Clone LBFL304, ORF2

<400> 7
 ggatataagc agtgcaaccc aagacctaag aatcttgatg ttggaaataa ag 52

atg gag gaa gct atg acc tac aca gag gac agt tat ggg atg gat ggg 100
 Met Glu Glu Ala Met Thr Tyr Thr Glu Asp Ser Tyr Gly Met Asp Gly
 1 5 10 15

aag gtt aat cag ccc cgt ctc act gca gac atc aac tgg caa ggc cta 148
 Lys Val Asn Gln Pro Arg Leu Thr Ala Asp Ile Asn Trp Gln Gly Leu
 20 25 30

gag gag cta cac agt gtg aat gaa aac atc tat gag tac aga caa aac 196
 Glu Glu Leu His Ser Val Asn Glu Asn Ile Tyr Glu Tyr Arg Gln Asn
 35 40 45

tac aga ctt agt ctg gtg gac tgg act aat tac ttg aag gat tta gat 244
 Tyr Arg Leu Ser Leu Val Asp Trp Thr Asn Tyr Leu Lys Asp Leu Asp
 50 55 60

aag gta ttt gca ctg aag agt cac tat gag caa aat aaa aca aat	292
Arg Val Phe Ala Leu Lys Ser His Tyr Glu Gln Asn Lys Thr Asn	
65 70 75 80	
aag act caa act gct caa agt gac ggg ttc ttg gtt gtc tct gct gag	340
Lys Thr Gln Thr Ala Gln Ser Asp Gly Phe Leu Val Val Ser Ala Glu	
85 90 95	
cac gct gtg tca atg gag atg gcc tct gct gac tca gat gaa gac cca	388
His Ala Val Ser Met Glu Met Ala Ser Ala Asp Ser Asp Glu Asp Pro	
100 105 110	
agg cat aag gtt ggg aaa aca cct cat ttg acc ttg cca gct gac ctt	436
Arg His Lys Val Gly Lys Thr Pro His Leu Thr Leu Pro Ala Asp Leu	
115 120 125	
caa acc ctg cat ttg aac cga cca aca tta agt cca gag agt aaa ctt	484
Gln Thr Leu His Leu Asn Arg Pro Thr Leu Ser Pro Glu Ser Lys Leu	
130 135 140	
gaa tgg aat aac gac att cca gaa gtt aat cat ttg aat tct gaa cac	532
Glu Trp Asn Asn Asp Ile Pro Glu Val Asn His Leu Asn Ser Glu His	
145 150 155 160	
tgg aga aaa acc gaa aaa tgg acg ggg cat gaa gag act aat cat ctg	580
Trp Arg Lys Thr Glu Lys Trp Thr Gly His Glu Glu Thr Asn His Leu	
165 170 175	
gaa acc gat ttc agt ggc gat ggc atg aca gag cta gag ctc ggg ccc	628
Glu Thr Asp Phe Ser Gly Asp Gly Met Thr Glu Leu Glu Leu Gly Pro	
180 185 190	
agc ccc agg ctg cag ccc att cgc agg cac ccg aaa gaa ctt ccc cag	676
Ser Pro Arg Leu Gln Pro Ile Arg Arg His Pro Lys Glu Leu Pro Gln	
195 200 205	
tat ggt ggt cct gga aag gac att ttt gaa gat caa cta tat ctt cct	724
Tyr Gly Gly Pro Gly Lys Asp Ile Phe Glu Asp Gln Leu Tyr Leu Pro	
210 215 220	

Sequence Listing

gtg cat tcc gat gga att tca gtt cat cag atg ttc acc atg gcc acc	772
Val His Ser Asp Gly Ile Ser Val His Gln Met Phe Thr Met Ala Thr	
225 230 235 240	
 gca gaa cac cga agt aat tcc agc ata gcg ggg aag atg ttg acc aag	820
Ala Glu His Arg Ser Asn Ser Ser Ile Ala Gly Lys Met Leu Thr Lys	
245 250 255	
 gtg gag aag aat cac gaa aag gag aag tca cag cac cta gaa ggc agc	868
Val Glu Lys Asn His Glu Lys Glu Lys Ser Gln His Leu Glu Gly Ser	
260 265 270	
 gcc tcc tct tca ctc tcc tct gat tagatgaa actgttacct taccctaaac	920
Ala Ser Ser Ser Ser Leu Ser Ser Asp	
275 280	
 acagtatttc tttttaactt ttttatttgt aaactaataa aggtaatcac agccaccaac	980
attccaagct accctgggta cctttgtgca gtagaagcta gtgagcatgt gagcaagcgg	1040
tgtgcacacg gagactcatc gttataattt actatctgcc aagagtagaa agaaaggctg	1100
gggatatattg gggttgcttg gttttgattt tttgcttggt tgtttgtttt gtactaaaac	1160
agtattatct tttgaatatc gtagggacat aagtatatac atgttatcca atcaagatgg	1220
ctagaatggg gcctttctga gtgtctaaaa cttgacaccc ctggtaaadc tttcaacaca	1280
cttccactgc ctgcgtaatg aagttttgat tcatttttaa ccactggaat ttttcaatgc	1340
cgtcattttc agttagatga ttttgcactt tgagattaaa atgccatgac tatttgatta	1400
gtcttattttt tttattttta caggcttacc agtctcactg ttggctgtca ttgtgacaaa	1460
gtcaaataaaa cccccaagga cgacacacag tatggatcac atattgtttg acattaagct	1520
tttgccagaa aatgttgcat gtgttttacc tcgacttgct aaaatcgatt agcagaaaag	1580
catggctaata aatqttgggt gtgaaaataa ataaaataagt aaacaaaatg aagattgcct	1640

Sequence Listing

```

gctctctctg tgccatgcct caaagcggtc atcatatc atacccttaa gattgctata      1700
ttttgggtta tttcttgac aggagaaaaa gatctaaaga tcttttattt tcatcttttt      1760
tggttttctt ggcatgacta agaagcttaa atgttgataa aatatgacta gttttgaatt      1820
tacaccaaga acttctcaat aaaagaaaat catgaatgct ccacaatttc aacataccac      1880
aagagaagtt aatttcttaa cattgtgttc tatgattatt tgtaagacct tcaccaagtt      1940
ctgatatctt ttaaagacat agttcaaaaat tgcttttgaa aatctgtatt cttgaaaaata      2000
tccttgttgt gtattaggtt tttaaatacc agctaaagga ttacctcact gagtcatcag      2060
taccctccta ttcagctccc caagatgatg tgtttttgct taccctaaga gaggttttct      2120
tcttattttt agataattca agtgcttaga taaattatgt tttctttaag tgtttatggt      2180
aaactctttt aaagaaaatt taatatgtta tagctgaatc tttttggtta ctttaaactt      2240
ttatcataga ctctgtacat atgttcaaat tagctgcttg cctgatgtgt gtatcatcgg      2300
tgggatgaca gaacaaacat atttatgatc atgaataatg tgctttgtta aaagatttca      2360
agttattagg aagcatactc tgttttttta tcatgtataa tattccatga tacttttata      2420
gaacaattct ggcttcagga aagtctagaa gcaatatttc ttcaaataaa aggtgtttta      2480
actttaaaaa aaaaaaaaaa                                         2500

```

<210> 8

<211> 280

<212> PRT

<213> Homo sapiens

<400> 8

Met Glu Glu Ala Met Thr Tyr Thr Glu Asp Ser Tyr Gly Met Asp Gly

1

5

10

15

Sequence Listing

Lys Val Asn Gln Pro Arg Leu Thr Ala Asp Ile Asn Trp Gln Gly Leu
20 25 30

Glu Glu Leu His Ser Val Asn Glu Asn Ile Tyr Glu Tyr Arg Gln Asn
35 40 45

Tyr Arg Leu Ser Leu Val Asp Trp Thr Asn Tyr Leu Lys Asp Leu Asp
50 55 60

Arg Val Phe Ala Leu Leu Lys Ser His Tyr Glu Gln Asn Lys Thr Asn
65 70 75 80

Lys Thr Gln Thr Ala Gln Ser Asp Gly Phe Leu Val Val Ser Ala Glu
85 90 95

His Ala Val Ser Met Glu Met Ala Ser Ala Asp Ser Asp Glu Asp Pro
100 105 110

Arg His Lys Val Gly Lys Thr Pro His Leu Thr Leu Pro Ala Asp Leu
115 120 125

Gln Thr Leu His Leu Asn Arg Pro Thr Leu Ser Pro Glu Ser Lys Leu
130 135 140

Glu Trp Asn Asn Asp Ile Pro Glu Val Asn His Leu Asn Ser Glu His
145 150 155 160

Trp Arg Lys Thr Glu Lys Trp Thr Gly His Glu Glu Thr Asn His Leu
165 170 175

Glu Thr Asp Phe Ser Gly Asp Gly Met Thr Glu Leu Glu Leu Gly Pro
180 185 190

Ser Pro Arg Leu Gln Pro Ile Arg Arg His Pro Lys Glu Leu Pro Gln
195 200 205

Tyr Gly Gly Pro Gly Lys Asp Ile Phe Glu Asp Gln Leu Tyr Leu Pro
210 215 220

Sequence Listing

Val His Ser Asp Gly Ile Ser Val His Gln Met Phe Thr Met Ala Thr
225 230 235 240

Ala Glu His Arg Ser Asn Ser Ser Ile Ala Gly Lys Met Leu Thr Lys
245 250 255

Val Glu Lys Asn His Glu Lys Glu Lys Ser Gln His Leu Glu Gly Ser
260 265 270

Ala Ser Ser Ser Leu Ser Ser Asp
275 280

<210> 9
<211> 2500
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (65)..(892)
<223> Clone LBFL304, ORF3

<400> 9
ggatataagc agtgcaaccc aagacctaag aatcttgatg ttggaaataa agatggagga 60

agct atg acc tac aca gag gac agt tat ggg atg gat ggg aag gtt 106
Met Thr Tyr Thr Glu Asp Ser Tyr Gly Met Asp Gly Lys Val
1 5 10

aat cag ccc cgt ctc act gca gac atc aac tgg caa ggc cta gag gag 154
Asn Gln Pro Arg Leu Thr Ala Asp Ile Asn Trp Gln Gly Leu Glu Glu
15 20 25 30

cta cac agt gtg aat gaa aac atc tat gag tac aga caa aac tac aga 202
Leu His Ser Val Asn Glu Asn Ile Tyr Glu Tyr Arg Gln Asn Tyr Arg
35 40 45

ctt agt ctg gtg gac tgg act aat tac ttg aag gat tta gat aga gta 250

Sequence Listing

Leu Ser Leu Val Asp Trp Thr Asn Tyr Leu Lys Asp Leu Asp Arg Val
 50 55 60

ttt gca ctg ctg aag agt cac tat gag caa aat aaa aca aat aag act 298
 Phe Ala Leu Leu Lys Ser His Tyr Glu Gln Asn Lys Thr Asn Lys Thr
 65 70 75

caa act gct caa agt gac ggg ttc ttg gtt gtc tct gct gag cac gct 346
 Gln Thr Ala Gln Ser Asp Gly Phe Leu Val Val Ser Ala Glu His Ala
 80 85 90

gtg tca atg gag atg gcc tct gct gac tca gat gaa gac cca agg cat 394
 Val Ser Met Glu Met Ala Ser Ala Asp Ser Asp Glu Asp Pro Arg His
 95 100 105 110

aag gtt ggg aaa aca cct cat ttg acc ttg cca gct gac ctt caa acc 442
 Lys Val Gly Lys Thr Pro His Leu Thr Leu Pro Ala Asp Leu Gln Thr
 115 120 125

ctg cat ttg aac cga cca aca tta agt cca gag agt aaa ctt gaa tgg 490
 Leu His Leu Asn Arg Pro Thr Leu Ser Pro Glu Ser Lys Leu Glu Trp
 130 135 140

aat aac gac att cca gaa gtt aat cat ttg aat tct gaa cac tgg aga 538
 Asn Asn Asp Ile Pro Glu Val Asn His Leu Asn Ser Glu His Trp Arg
 145 150 155

aaa acc gaa aaa tgg acg ggg cat gaa gag act aat cat ctg gaa acc 586
 Lys Thr Glu Lys Trp Thr Gly His Glu Glu Thr Asn His Leu Glu Thr
 160 165 170

gat ttc agt ggc gat ggc atg aca gag cta gag ctc ggg ccc agc ccc 634
 Asp Phe Ser Gly Asp Gly Met Thr Glu Leu Glu Leu Gly Pro Ser Pro
 175 180 185 190

agg ctg cag ccc att cgc agg cac ccg aaa gaa ctt ccc cag tat ggt 682
 Arg Leu Gln Pro Ile Arg Arg His Pro Lys Glu Leu Pro Gln Tyr Gly
 195 200 205

ggt cct gga aag gac att ttt gaa gat caa cta tat ctt cct gtg cat 730

Sequence Listing

Gly Pro Gly Lys Asp Ile Phe Glu Asp Gln Leu Tyr Leu Pro Val His	
210 215 220	
tcc gat gga att tca gtt cat cag atg ttc acc atg gcc acc gca gaa	778
Ser Asp Gly Ile Ser Val His Gln Met Phe Thr Met Ala Thr Ala Glu	
225 230 235	
cac cga agt aat tcc agc ata gcg ggg aag atg ttg acc aag gtg gag	826
His Arg Ser Asn Ser Ser Ile Ala Gly Lys Met Leu Thr Lys Val Glu	
240 245 250	
aag aat cac gaa aag gag aag tca cag cac cta gaa ggc agc gcc tcc	874
Lys Asn His Glu Lys Glu Lys Ser Gln His Leu Glu Gly Ser Ala Ser	
255 260 265 270	
tct tca ctc tcc tct gat tagatgaa actgttacct taccctaaac acagtatttc	930
Ser Ser Leu Ser Ser Asp	
275	
ttttaactt ttttatttgt aaactaataa aggtaatcac agccaccaac attccaagct	990
accctgggta cctttgtgca gtagaagcta gtgagcatgt gagcaagcgg tgtgcacacg	1050
gagactcatc gttataattt actatctgcc aagagtagaa agaaaggctg gggatatttg	1110
ggttggcttg gttttgattt tttgcttggt tgtttgtttt gtactaaaac agtattatct	1170
tttgaatatc gtagggacat aagtatatac atgttatcca atcaagatgg ctagaatggt	1230
gcctttctga gtgtctaaaa cttgacaccc ctggtaaatc tttcaacaca cttccactgc	1290
ctgcgtaatg aagttttgat tcatttttaa ccactggaat ttttcaatgc cgtcattttc	1350
agttagatga ttttgactt tgagattaaa atgcatgtc tatttgatta gtcttatttt	1410
tttattttta caggcttata agtctcactg ttggctgtca ttgtgacaaa gtcaaataaa	1470
ccccaagga cgacacacag tatggatcac atattgtttg acattaagct ttgcccagaa	1530
aatgttgcac gtgttttacc tcgacttgct aaaatcgatt agcagaaagg catggctaata	1590

Sequence Listing

aatgttggtg gtgaaaataa ataaataagt aaacaaaatg aagattgcct gctctctctg 1650
tgcctagcct caaagcggtc atcacatc ataccttaa gattgctata ttttgggtta 1710
ttttcttgac aggagaaaaa gatctaaaga tcttttattt tcatcttttt tggttttctt 1770
ggcatgacta agaagcttaa atgttgataa aatatgacta gttttgaatt tacaccaaga 1830
acttctcaat aaaagaaaat catgaatgct ccacaatttc aacataccac aagagaagtt 1890
aatttcttaa cattgtgttc tatgattatt tgtaagacct tcaccaagtt ctgatattctt 1950
ttaagacat agttcaaat tgcttttgaa aatctgtatt cttgaaaata tccttggtgt 2010
gtattaggtt ttaaatacc agctaaagga ttacctact gagtcacag taccctccta 2070
ttcagctccc caagatgatg tgtttttgct taccctaaga gaggttttct tcttattttt 2130
agataattca agtgcttaga taaattatgt tttctttaag tgtttatggt aaactctttt 2190
aaagaaaatt taatatgtta tagctgaatc tttttgtaa ctttaaactt ttatcataga 2250
ctctgtacat atgttcaa at tagctgcttg cctgatgtgt gtatcatcgg tgggatgaca 2310
gaacaaacat atttatgatc atgaataatg tgctttgtaa aaagatttca agttattagg 2370
aagcactctc tgttttttta tcatgtataa tattccatga tacttttata gaacaattct 2430
ggcttcagga aagtctagaa gcaatatttc ttcaaataaa aggtgtttta actttaaaaa 2490
aaaaaaaaa 2500

<210> 10

<211> 276

<212> PRT

<213> Homo sapiens

<400> 10

Sequence Listing

Met Thr Tyr Thr Glu Asp Ser Tyr Gly Met Asp Gly Lys Val Asn Gln
1 5 10 15

Pro Arg Leu Thr Ala Asp Ile Asn Trp Gln Gly Leu Glu Glu Leu His
20 25 30

Ser Val Asn Glu Asn Ile Tyr Glu Tyr Arg Gln Asn Tyr Arg Leu Ser
35 40 45

Leu Val Asp Trp Thr Asn Tyr Leu Lys Asp Leu Asp Arg Val Phe Ala
50 55 60

Leu Leu Lys Ser His Tyr Glu Gln Asn Lys Thr Asn Lys Thr Gln Thr
65 70 75 80

Ala Gln Ser Asp Gly Phe Leu Val Val Ser Ala Glu His Ala Val Ser
85 90 95

Met Glu Met Ala Ser Ala Asp Ser Asp Glu Asp Pro Arg His Lys Val
100 105 110

Gly Lys Thr Pro His Leu Thr Leu Pro Ala Asp Leu Gln Thr Leu His
115 120 125

Leu Asn Arg Pro Thr Leu Ser Pro Glu Ser Lys Leu Glu Trp Asn Asn
130 135 140

Asp Ile Pro Glu Val Asn His Leu Asn Ser Glu His Trp Arg Lys Thr
145 150 155 160

Glu Lys Trp Thr Gly His Glu Glu Thr Asn His Leu Glu Thr Asp Phe
165 170 175

Ser Gly Asp Gly Met Thr Glu Leu Glu Leu Gly Pro Ser Pro Arg Leu
180 185 190

Gln Pro Ile Arg Arg His Pro Lys Glu Leu Pro Gln Tyr Gly Gly Pro
195 200 205

Gly Lys Asp Ile Phe Glu Asp Gln Leu Tyr Leu Pro Val His Ser Asp

```

<400>      11
ggatataagc agtgcaacc aagacctaag aatcttgatg ttggaaataa agatggagga      60

agctatgacc tacacagagg acagttatgg g                atg gat ggg aag gtt      106
                Met Asp Gly Lys Val
                        1                5

aat cag ccc cgt ctc act gca gac atc aac tgg caa ggc cta gag gag      154
Asn Gln Pro Arg Leu Thr Ala Asp Ile Asn Trp Gln Gly Leu Glu Glu
                10                15                20

cta cac agt gtg aat gaa aac atc tat gag tac aga caa aac tac aga      202
Leu His Ser Val Asn Glu Asn Ile Tyr Glu Tyr Arg Gln Asn Tyr Arg
                25                30                35

```

Sequence Listing

ctt agt ctg gtg gac tgg act aat tac ttg aag gat tta gat aga gta	250
Leu Ser Leu Val Asp Trp Thr Asn Tyr Leu Lys Asp Leu Asp Arg Val	
40 45 50	
ttt gca ctg ctg aag agt cac tat gag caa aat aaa aca aat aag act	298
Phe Ala Leu Leu Lys Ser His Tyr Glu Gln Asn Lys Thr Asn Lys Thr	
55 60 65	
caa act gct caa agt gac ggg ttc ttg gtt gtc tct gct gag cac gct	346
Gln Thr Ala Gln Ser Asp Gly Phe Leu Val Val Ser Ala Glu His Ala	
70 75 80 85	
gtg tca atg gag atg gcc tct gct gac tca gat gaa gac cca agg cat	394
Val Ser Met Glu Met Ala Ser Ala Asp Ser Asp Glu Asp Pro Arg His	
90 95 100	
aag gtt ggg aaa aca cct cat ttg acc ttg cca gct gac ctt caa acc	442
Lys Val Gly Lys Thr Pro His Leu Thr Leu Pro Ala Asp Leu Gln Thr	
105 110 115	
ctg cat ttg aac cga cca aca tta agt cca gag agt aaa ctt gaa tgg	490
Leu His Leu Asn Arg Pro Thr Leu Ser Pro Glu Ser Lys Leu Glu Trp	
120 125 130	
aat aac gac att cca gaa gtt aat cat ttg aat tct gaa cac tgg aga	538
Asn Asn Asp Ile Pro Glu Val Asn His Leu Asn Ser Glu His Trp Arg	
135 140 145	
aaa acc gaa aaa tgg acg ggg cat gaa gag act aat cat ctg gaa acc	586
Lys Thr Glu Lys Trp Thr Gly His Glu Glu Thr Asn His Leu Glu Thr	
150 155 160 165	
gat ttc agt ggc gat ggc atg aca gag cta gag ctc ggg ccc agc ccc	634
Asp Phe Ser Gly Asp Gly Met Thr Glu Leu Glu Leu Gly Pro Ser Pro	
170 175 180	
agg ctg cag ccc att cgc agg cac ccg aaa gaa ctt ccc cag tat ggt	682
Arg Leu Gln Pro Ile Arg Arg His Pro Lys Glu Leu Pro Gln Tyr Gly	
185 190 195	

Sequence Listing

ggt cct gga aag gac att ttt gaa gat caa cta tat ctt cct gtg cat	730
Gly Pro Gly Lys Asp Ile Phe Glu Asp Gln Leu Tyr Leu Pro Val His	
200 205 210	
tcc gat gga att tca gtt cat cag atg ttc acc atg gcc acc gca gaa	778
Ser Asp Gly Ile Ser Val His Gln Met Phe Thr Met Ala Thr Ala Glu	
215 220 225	
cac cga agt aat tcc agc ata gcg ggg aag atg ttg acc aag gtg gag	826
His Arg Ser Asn Ser Ser Ile Ala Gly Lys Met Leu Thr Lys Val Glu	
230 235 240 245	
aag aat cac gaa aag gag aag tca cag cac cta gaa ggc agc gcc tcc	874
Lys Asn His Glu Lys Glu Lys Ser Gln His Leu Glu Gly Ser Ala Ser	
250 255 260	
tct tca ctc tcc tct gat tagatgaa actgttacct taccctaaac acagtatttc	930
Ser Ser Leu Ser Ser Asp	
265	
tttttaactt ttttatttgt aaactaataa aggtaatcac agccaccaac attccaagct	990
accctgggta cctttgtgca gtagaagcta gtgagcatgt gagcaagcgg tgtgcacacg	1050
gagactcatc gttataattt actatctgcc aagagtagaa agaaaggctg gggatatttg	1110
ggttggcctg gttttgattt ttgcttggt tgtttgttt gtactaaaac agtattatct	1170
tttgaatatc gtagggacat aagtatatac atgttatcca atcaagatgg ctagaatggt	1230
gcctttctga gtgtctaaaa cttgacaccc ctggtaaatc tttcaacaca cttccactgc	1290
ctgcgtaatg aagttttgat tcatttttaa cactggaat ttttcaatgc cgtcattttc	1350
agttagatga ttttgcactt tgagattaaa atgccatgtc tatttgatta gtcttatttt	1410
tttattttta caggcttatc agtctcactg ttggctgtca ttgtgacaaa gtcaaataaa	1470
cccccaagga cgacacacag tatggatcac atattgtttg acattaagct tttgccagaa	1530

Sequence Listing

aatgttgcat gtgttttacc tcgacttgct aaaatcgatt agcagaaaagg catggctaataat 1590

aatgttggtg gtgaaaataa ataaataagt aaacaaaatg aagattgcct gctctctctg 1650

tgcttagcct caaagcggtc atcatacatc ataccttaaa gattgctata ttttgggtta 1710

ttttcttgac aggagaaaaa gatctaaaga tcttttattt tcattctttt tggttttctt 1770

ggcatgacta agaagcttaa atgttgataa aatatgacta gttttgaatt tacaccaaga 1830

acttctcaat aaaagaaaat catgaatgct ccacaatttc aacataccac aagagaagtt 1890

aatttcttaa cattgtgttc tatgattatt tgtaagacct tcaccaagtt ctgatattctt 1950

ttaaagacat agttcaaaat tgcttttgaa aatctgtatt cttgaaaata tccttgttgt 2010

gtattagggt tttaaatacc agctaaagga ttacctcact gagtcatcag taccctccta 2070

ttcagctccc caagatgatg tggttttgct taccctaaga gaggttttct tcttattttt 2130

agataattca agtgcttaga taaattatgt tttctttaag tgtttatggt aaactctttt 2190

aaagaaaatt taatatgtta tagctgaatc tttttggtaa ctttaaatct ttatcataga 2250

ctctgtacat atgttcaaata tagctgcttg cctgatgtgt gtatcatcgg tgggatgaca 2310

gaacaaacat atttatgatc atgaataatg tgctttgtaa aaagatttca agttattagg 2370

aagcatactc tgtttttttaa tcattgtataa tattccatga tacttttata gaacaattct 2430

ggcttcagga aagtctagaa gcaatatttc ttcaaataaa aggtgtttta actttaaaaa 2490

aaaaaaaaa 2500

<210> 12

<211> 267

<212> PRT

<213> Homo sapiens

Sequence Listing

<400> 12

Met Asp Gly Lys Val Asn Gln Pro Arg Leu Thr Ala Asp Ile Asn Trp
1 5 10 15

Gln Gly Leu Glu Glu Leu His Ser Val Asn Glu Asn Ile Tyr Glu Tyr
20 25 30

Arg Gln Asn Tyr Arg Leu Ser Leu Val Asp Trp Thr Asn Tyr Leu Lys
35 40 45

Asp Leu Asp Arg Val Phe Ala Leu Leu Lys Ser His Tyr Glu Gln Asn
50 55 60

Lys Thr Asn Lys Thr Gln Thr Ala Gln Ser Asp Gly Phe Leu Val Val
65 70 75 80

Ser Ala Glu His Ala Val Ser Met Glu Met Ala Ser Ala Asp Ser Asp
85 90 95

Glu Asp Pro Arg His Lys Val Gly Lys Thr Pro His Leu Thr Leu Pro
100 105 110

Ala Asp Leu Gln Thr Leu His Leu Asn Arg Pro Thr Leu Ser Pro Glu
115 120 125

Ser Lys Leu Glu Trp Asn Asn Asp Ile Pro Glu Val Asn His Leu Asn
130 135 140

Ser Glu His Trp Arg Lys Thr Glu Lys Trp Thr Gly His Glu Glu Thr
145 150 155 160

Asn His Leu Glu Thr Asp Phe Ser Gly Asp Gly Met Thr Glu Leu Glu
165 170 175

Leu Gly Pro Ser Pro Arg Leu Gln Pro Ile Arg Arg His Pro Lys Glu
180 185 190

Leu Pro Gln Tyr Gly Gly Pro Gly Lys Asp Ile Phe Glu Asp Gln Leu
195 200 205

Sequence Listing

Tyr Leu Pro Val His Ser Asp Gly Ile Ser Val His Gln Met Phe Thr
 210 215 220

Met Ala Thr Ala Glu His Arg Ser Asn Ser Ser Ile Ala Gly Lys Met
 225 230 235 240

Leu Thr Lys Val Glu Lys Asn His Glu Lys Glu Lys Ser Gln His Leu
 245 250 255

Glu Gly Ser Ala Ser Ser Ser Leu Ser Ser Asp
 260 265

<210> 13
 <211> 6405
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (49)..(1434)
 <223> Gene LBFL305

<400> 13
 gcgggaggat ggagcagtga gcgggtctgg gcggctgctg gcagcgcc atg gag acg 57
 Met Glu Thr
 1

gta cag ctg agg aac ccg ccg cgc cgg cag ctg aaa aag ttg gat gaa 105
 Val Gln Leu Arg Asn Pro Pro Arg Arg Gln Leu Lys Lys Leu Asp Glu
 5 10 15

gat agt tta acc aaa caa cca gaa gaa gta ttt gat gtc tta gag aaa 153
 Asp Ser Leu Thr Lys Gln Pro Glu Glu Val Phe Asp Val Leu Glu Lys
 20 25 30 35

ctt gga gaa ggg tcc tat ggc agc gta tac aaa gct att cat aaa gag 201
 Leu Gly Glu Gly Ser Tyr Gly Ser Val Tyr Lys Ala Ile His Lys Glu

Sequence Listing

40	45	50	
acc ggc cag att gtt gct att aag caa gtt cct gtg gaa tca gac ctc			249
Thr Gly Gln Ile Val Ala Ile Lys Gln Val Pro Val Glu Ser Asp Leu			
55	60	65	
cag gag ata atc aaa gaa atc tct ata atg cag caa tgt gac agc cct			297
Gln Glu Ile Ile Lys Glu Ile Ser Ile Met Gln Gln Cys Asp Ser Pro			
70	75	80	
cat gta gtc aaa tat tac ggc agt tat ttt aag aac aca gac tta tgg			345
His Val Val Lys Tyr Tyr Gly Ser Tyr Phe Lys Asn Thr Asp Leu Trp			
85	90	95	
atc gtt atg gag tac tgt ggg gct ggt tct gta tct gat atc att cga			393
Ile Val Met Glu Tyr Cys Gly Ala Gly Ser Val Ser Asp Ile Ile Arg			
100	105	110	115
tta cga aat aaa acg tta aca gaa gat gaa ata gct aca ata tta caa			441
Leu Arg Asn Lys Thr Leu Thr Glu Asp Glu Ile Ala Thr Ile Leu Gln			
120	125	130	
tca act ctt aag gga ctt gaa tac ctt cat ttt atg aga aaa ata cac			489
Ser Thr Leu Lys Gly Leu Glu Tyr Leu His Phe Met Arg Lys Ile His			
135	140	145	
cga gat atc aag gca gga aat att ttg cta aat aca gaa gga cat gca			537
Arg Asp Ile Lys Ala Gly Asn Ile Leu Leu Asn Thr Glu Gly His Ala			
150	155	160	
aaa ctt gca gat ttt ggg gta gca ggt caa ctt aca gat acc atg gcc			585
Lys Leu Ala Asp Phe Gly Val Ala Gly Gln Leu Thr Asp Thr Met Ala			
165	170	175	
aag cgg aat aca gtg ata gga aca cca ttt tgg atg gct cca gaa gtg			633
Lys Arg Asn Thr Val Ile Gly Thr Pro Phe Trp Met Ala Pro Glu Val			
180	185	190	195
att cag gaa att gga tac aac tgt gta gca gac atc tgg tcc ctg gga			681
Ile Gln Glu Ile Gly Tyr Asn Cys Val Ala Asp Ile Trp Ser Leu Gly			

Sequence Listing

200	205	210	
ata act gcc ata gaa atg gct gaa gga aag ccc cct tat gct gat atc			729
Ile Thr Ala Ile Glu Met Ala Glu Gly Lys Pro Pro Tyr Ala Asp Ile			
215	220	225	
cat cca atg agg gca atc ttc atg att cct aca aat cct cct ccc aca			777
His Pro Met Arg Ala Ile Phe Met Ile Pro Thr Asn Pro Pro Pro Thr			
230	235	240	
ttc cga aaa cca gag cta tgg tca gat aac ttt aca gat ttt gtg aaa			825
Phe Arg Lys Pro Glu Leu Trp Ser Asp Asn Phe Thr Asp Phe Val Lys			
245	250	255	
cag tgt ctt gta aag agc cct gag cag agg gcc aca gcc act cag ctc			873
Gln Cys Leu Val Lys Ser Pro Glu Gln Arg Ala Thr Ala Thr Gln Leu			
260	265	270	275
ctg cag cac cca ttt gtc agg agt gcc aaa gga gtg tca ata ctg cga			921
Leu Gln His Pro Phe Val Arg Ser Ala Lys Gly Val Ser Ile Leu Arg			
280	285	290	
gac tta att aat gaa gcc atg gat gtg aaa ctg aaa cgc cag gaa tcc			969
Asp Leu Ile Asn Glu Ala Met Asp Val Lys Leu Lys Arg Gln Glu Ser			
295	300	305	
cag cag cgg gaa gtg gac cag gac gat gaa gaa aac tca gaa gag gat			1017
Gln Gln Arg Glu Val Asp Gln Asp Asp Glu Glu Asn Ser Glu Glu Asp			
310	315	320	
gaa atg gat tct ggc acg atg gtt cga gca gtg ggt gat gag atg ggc			1065
Glu Met Asp Ser Gly Thr Met Val Arg Ala Val Gly Asp Glu Met Gly			
325	330	335	
act gtc cga gta gcc agc acc atg act gat gga gcc aat act atg att			1113
Thr Val Arg Val Ala Ser Thr Met Thr Asp Gly Ala Asn Thr Met Ile			
340	345	350	355
gag cac gat gac acg ttg cca tca caa ctg ggc acc atg gtg atc aat			1161
Glu His Asp Asp Thr Leu Pro Ser Gln Leu Gly Thr Met Val Ile Asn			

Sequence Listing

360	365	370	
gca gag gat gag gaa gag gaa gga act atg aaa aga agg gat gag acc			1209
Ala Glu Asp Glu Glu Glu Glu Gly Thr Met Lys Arg Arg Asp Glu Thr			
375	380	385	
atg cag cct gcg aaa cca tcc ttt ctt gaa tat ttt gaa caa aaa gaa			1257
Met Gln Pro Ala Lys Pro Ser Phe Leu Glu Tyr Phe Glu Gln Lys Glu			
390	395	400	
aag gaa aac cag atc aac agc ttt ggc aag agt gta cct ggt cca ctg			1305
Lys Glu Asn Gln Ile Asn Ser Phe Gly Lys Ser Val Pro Gly Pro Leu			
405	410	415	
aaa aat tct tca gat tgg aaa ata cca cag gat gga gac tac gag ttt			1353
Lys Asn Ser Ser Asp Trp Lys Ile Pro Gln Asp Gly Asp Tyr Glu Phe			
420	425	430	435
aaa act agc caa gaa cag cag tct gga aaa gac ata tgt atc caa aat			1401
Lys Thr Ser Gln Glu Gln Gln Ser Gly Lys Asp Ile Cys Ile Gln Asn			
440	445	450	
tgc cag gga aac ctg ctg tgt aga tac gct ttc	tgagaa accacatgct		1450
Cys Gln Gly Asn Leu Leu Cys Arg Tyr Ala Phe			
455	460		
taagagttgg acagtggagg accttcagaa gaggctcttg gccctggacc ccatgatgga			1510
gcaggagatt gaagagatcc ggcagaagta ccagtccaag cggcagccca tcctggatgc			1570
catagaggct aagaagagac ggcaacaaaa cttctgagca aggccaggct gtgagggccc			1630
cagctccacc caggcttttg gtgaattctg gatggcttgc ctcattgttg ttagccagca			1690
cttctgctct gtcgtctctc cacagcacct ttgtgaactc aggaatgtgc gccagtggga			1750
agggctctct tgacagtcag cgtgccatct tgatgtgtgt atgtacattg gtcaggtata			1810
ttatctcaaa ggatttatat tggcgctttt aactcagagt tttaaaccac aggaacagag			1870

Sequence Listing

actcctagtt gagtgaatgc tgggaaagtt ttacattgtc tgtttttctt ctcccaatag	1930
ctttcaattg ttctttctgg aagactttta aaaaaatata aatatgcata tatatatata	1990
aattataaat agattcccca cgcagtgtgg tggcatctct gtacagggtac agttttaaac	2050
ggtttgccctc ttttctgtaa gattatggta ctgtggaaca tgagggcaga ggacaccggg	2110
aggctgttag ggggtcactg aatcccagga gccaacctcc ccctttgcag ggctgcattt	2170
aaaaattagg ttggggacag ttctgtgacc gtgggtttcag ccttgtgtgg tcatcactgg	2230
cttctggagc tattggtgat gtccaaggga aagctttgag agtttatgtt tactctttga	2290
gtcccaggag aagcctggca ccctctttgc aaattggcct ttgctcttcc aatgcctttc	2350
atccatctcc actctctcaa ctgcctaaag tcacagcaca gatactgcc agtgccttaa	2410
gaggagacat gatctctacc agggactctc agcaaacacg ggactgtgtt cagtcacaa	2470
aggaaaagcg tttttgaagc tctcattgtt catgtaaaaa tcatacacgt ggcatgttgc	2530
tccacattcc ttacacacag gggtagaggg gattgctttt gtgaccacg ttcaaatatg	2590
tgactgtttt cttttctctt ttactgctaa gcagcctgga aaggataaat gaatattaga	2650
ctaagatttg ttttccagga ggctcaatct gaacacacag aatgtcagag ctggaaggga	2710
ctatagagat catctgatct gatcctcttg tacggatgat cgcaaaactg aggtgtagag	2770
aggggaatgg ccaaaatcac aaagcaagtt agcgttaaga gctgagacta gaattcaggg	2830
tcctcactcc caggccaccg aaccatgcag cccttctttt gggggaagag acctgtgtca	2890
gtcttggtta attgttccag ggaaccttgc taacagaaac ttgctcttgc cttggctctt	2950
cagtagatga cctggctgta aagagattcc ctggacgagc cagatcattc agtttcagcg	3010
agtccttgag ctccacaaca tctaccagat atagcagaca agcaccatg gaggcaggtt	3070

Sequence Listing

tcgggcctga agcagatcag agggctttgc aaaagacagc atagagccat cttcctgcaa 3130

ctttacctct ttccctcaga tggggagcca tgactgggtt gcacctcagg atactgtaat 3190

ttgactccat aattgctttt gctcctgaaa cctgggaatc aatggaaagg cagggaatgt 3250

gcctcttctg tggccagatt ctgttatttg caattaaagc aagtttttaa aaaatgcaag 3310

aggcagttgt tagtcttcag ggcttgcaa ctgaaatagc tatgtggcgg atacggaaaa 3370

cagaggacaa tttgaggatc ttgctggaat aataaatgac agctaccatt tgttgagcac 3430

ctattatata tcaggcactg agctgggtag gctctaaact tcacaataac cctgtgactt 3490

aactacttta tctccatttt gtagttgaag aaataagttc agagagaaag attccttccc 3550

aaggctatgc agctagtaaa tgatagaatc aggattcata gcatcactat aggggggtcaa 3610

tatttacaca aaaaaggaaa gtcacaagcc tgtttaaaat gaagtgaaca ccttttcttg 3670

catagactaa ataactcgaa ctggcatttt taggttggaag agacagctga attagtagtt 3730

aagtctgata gccaaagtaag ttttaaaaac caaagcatcc aggatgcaca ccctgcacc 3790

atttgctgtg cgaattaata gttctgtctc tctctctctt tcttttttct ttttattctt 3850

tgagatggat ttctgctctt gtcgcccagg ctggagtaca atggcacgat cttggctcac 3910

tgcaacctcc gcctcccggg ttcaagcgat tcttctgctg ggattacagc atatgccacc 3970

atgcccagat tttttttttg tttttgtagt agagacgggg tttcaccatg tcagtcaggc 4030

tggtcttgaa ctctgacct caggtgatcc acccgctca gcctcccaca ctgctgggat 4090

tacaggcatg agccaccgct cctggcctct ctttcttttt taaacaaaga actttgcact 4150

tggccagaga ggaggagaaa gccattttc tcccttccta agctagatcc aaataaaaga 4210

aagttcagtt ttccccata actattcttg ggtcatgaac ttgatctgg agtttgtttt 4270

Sequence Listing

gtttcaggaa tgtgtgcacc cagcttgctg atccaacaaa gtctattgct taccagtcta 4330
gcttgatgaa gccttttggc cagaagtcaa tttgttttgg atcagagaaa tttcctgaca 4390
aggtatattt gttttctagt gacagaaagg caaaggaaca agtcctagtt gttgttggtg 4450
ttgttgaata ctaaatttaa gatatgtcag cttgctttca atgagccttg ggcttctgtt 4510
attgcttgag catttggaac tcgagcttcc agagaaattt gaggtcctcg cttgttctct 4570
gccttcaaga aacaatgacc tgattctgtc tttaaaaaaa aaatctcaga attctttttt 4630
tgtttgtgtt ttttttttgg agacagagtc tcactctgtt gccaggtg gagtgcagtg 4690
gcgccatctc ggctcactgc aacctccgcc tcccaggttc aagcaattct cctgcctcag 4750
cctcccaggt agctgccact acaggtgctg caccaccacg cccggctaatt tttgtattt 4810
ttagtagaga cagggtttca ccatattagc caggtgggtc ttgaactcct gaccttgta 4870
tccaccgcc tcggcctccc aaagtgtggt gattacaggtc gtgagccacc ttgcctggcc 4930
aaaaatctca gaattcttta agactgtttt aattgctcca tcagtaattt tgaagcactt 4990
tccttttttt ttttccctt tttgtccctt tccccagcc accaattgga tggatgaatg 5050
tttgacgggg aagaggaagg gtaggaggat gcatggatga gtggatgagt ggatcgatgg 5110
atgtattgat aaatagatag aaccagtcac ctgaagcaac ttaagaattg tagccttgac 5170
tccttgagac tgtagatttc gatccaggaa acatttattt agcacctgcc agatgccaga 5230
aatttatacc atttaaaact cagtaagtct tttaaatatc aggaaggaga gaagcgacat 5290
catgatacat cctatgggta ttaaaaagcc aatagaatat tatgaataat tttatgctaa 5350
taaatttaac aacttcaaca tcataaaca attccttgaa aaataaaaag taccaaaatt 5410
cattcaagaa gaaatagata ccagcctgag caacatggca aaatcccatc tctacaaaac 5470

Sequence Listing

```

atcaaaaaaa aaaaattagt cgggcatggt ggtgcacacc tgtaatccca gcttgtcagg      5530
aggctgaagt gggaggatca cctgagccca gggaggtcac ggatgcagtg agccatggtc      5590
tcaccactgc actctagcct aggtgacaga atgagacccc gtctcaaaaa aaaagaagaa      5650
gtagataatc tgaatagccc tatatctata gaaacttaac agtgctggga gatataggta      5710
ttattatcct catTTTtacag atgtgaaaat tgaggctcag agaagtaaag tctattgctc      5770
aaggtcatgt ggctagaata tggcagagcc atgattcaga tccaggctct ctgattctta      5830
ttccagtgtc ctttctagca taccatgttg cctctaaaga ttgcagctcc ttatttacta      5890
gaaaattggt cctgccaat ctacatctcc acctacccc atcttttctt aagcactatg      5950
tttgtgtttt tatcagtatt atattcattg tctttggaat acatgttctt gtttgtgttt      6010
ggaaaaaaaa tctcttttac cagcttgcac tcggaccaac ttggaaaaaaaa aaagcttaaa      6070
tgTTTTtgct atgtacagtt taaaaatgtg aagtttgtag ctttaacttt ttgtaagaaa      6130
atctaataac actggcttaa gtgctgactt gaaatgctat ttgtaaggt ttggatgtaa      6190
gtaatcaatt gaggtcagca gtttgtatga gacatagctt cctccattgc cccactcct      6250
tttttctttt ttaagtttga gatgcttcct gtgtttttat gttagaattg ttgttctcct      6310
tcttttcttc ttctataacc tcatcacgtt tgttttaaac aaactgtcct ttggaccaca      6370
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa      6405

```

<210> 14

<211> 462

<212> PRT

<213> Homo sapiens

<400> 14

Met Glu Thr Val Gln Leu Arg Asn Pro Pro Arg Arg Gln Leu Lys Lys

Sequence Listing

1	5	10	15
Leu Asp Glu Asp Ser Leu Thr Lys Gln Pro Glu Glu Val Phe Asp Val			
20	25	30	
Leu Glu Lys Leu Gly Glu Gly Ser Tyr Gly Ser Val Tyr Lys Ala Ile			
35	40	45	
His Lys Glu Thr Gly Gln Ile Val Ala Ile Lys Gln Val Pro Val Glu			
50	55	60	
Ser Asp Leu Gln Glu Ile Ile Lys Glu Ile Ser Ile Met Gln Gln Cys			
65	70	75	80
Asp Ser Pro His Val Val Lys Tyr Tyr Gly Ser Tyr Phe Lys Asn Thr			
85	90	95	
Asp Leu Trp Ile Val Met Glu Tyr Cys Gly Ala Gly Ser Val Ser Asp			
100	105	110	
Ile Ile Arg Leu Arg Asn Lys Thr Leu Thr Glu Asp Glu Ile Ala Thr			
115	120	125	
Ile Leu Gln Ser Thr Leu Lys Gly Leu Glu Tyr Leu His Phe Met Arg			
130	135	140	
Lys Ile His Arg Asp Ile Lys Ala Gly Asn Ile Leu Leu Asn Thr Glu			
145	150	155	160
Gly His Ala Lys Leu Ala Asp Phe Gly Val Ala Gly Gln Leu Thr Asp			
165	170	175	
Thr Met Ala Lys Arg Asn Thr Val Ile Gly Thr Pro Phe Trp Met Ala			
180	185	190	
Pro Glu Val Ile Gln Glu Ile Gly Tyr Asn Cys Val Ala Asp Ile Trp			
195	200	205	
Ser Leu Gly Ile Thr Ala Ile Glu Met Ala Glu Gly Lys Pro Pro Tyr			
210	215	220	

Sequence Listing

Ala Asp Ile His Pro Met Arg Ala Ile Phe Met Ile Pro Thr Asn Pro
225 230 235 240

Pro Pro Thr Phe Arg Lys Pro Glu Leu Trp Ser Asp Asn Phe Thr Asp
245 250 255

Phe Val Lys Gln Cys Leu Val Lys Ser Pro Glu Gln Arg Ala Thr Ala
260 265 270

Thr Gln Leu Leu Gln His Pro Phe Val Arg Ser Ala Lys Gly Val Ser
275 280 285

Ile Leu Arg Asp Leu Ile Asn Glu Ala Met Asp Val Lys Leu Lys Arg
290 295 300

Gln Glu Ser Gln Gln Arg Glu Val Asp Gln Asp Asp Glu Glu Asn Ser
305 310 315 320

Glu Glu Asp Glu Met Asp Ser Gly Thr Met Val Arg Ala Val Gly Asp
325 330 335

Glu Met Gly Thr Val Arg Val Ala Ser Thr Met Thr Asp Gly Ala Asn
340 345 350

Thr Met Ile Glu His Asp Asp Thr Leu Pro Ser Gln Leu Gly Thr Met
355 360 365

Val Ile Asn Ala Glu Asp Glu Glu Glu Gly Thr Met Lys Arg Arg
370 375 380

Asp Glu Thr Met Gln Pro Ala Lys Pro Ser Phe Leu Glu Tyr Phe Glu
385 390 395 400

Gln Lys Glu Lys Glu Asn Gln Ile Asn Ser Phe Gly Lys Ser Val Pro
405 410 415

Gly Pro Leu Lys Asn Ser Ser Asp Trp Lys Ile Pro Gln Asp Gly Asp
420 425 430

Sequence Listing

Tyr Glu Phe Lys Thr Ser Gln Glu Gln Gln Ser Gly Lys Asp Ile Cys
 435 440 445

Ile Gln Asn Cys Gln Gly Asn Leu Leu Cys Arg Tyr Ala Phe
 450 455 460

<210> 15
 <211> 1931
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (43)..(1503)
 <223> Mst1/STK4 gene

<400> 15
 cggcaccgaga gtgagcgggt ctgggcgggt gctggcagcg cc atg gag acg 51
 Met Glu Thr
 1

gta' cag ctg agg aac ccg ccg cgc cgg cag ctg aaa aag ttg gat gaa 99
 Val Gln Leu Arg Asn Pro Pro Arg Arg Gln Leu Lys Lys Leu Asp Glu
 5 10 15

gat agt tta acc aaa caa cca gaa gaa gta ttt gat gtc tta gag aaa 147
 Asp Ser Leu Thr Lys Gln Pro Glu Glu Val Phe Asp Val Leu Glu Lys
 20 25 30 35

ctt gga gaa ggg tcc tat ggc agc gta tac aaa gct att cat aaa gag 195
 Leu Gly Glu Gly Ser Tyr Gly Ser Val Tyr Lys Ala Ile His Lys Glu
 40 45 50

acc ggc cag att gtt gct att aag caa gtt cct gtg gaa tca gac ctc 243
 Thr Gly Gln Ile Val Ala Ile Lys Gln Val Pro Val Glu Ser Asp Leu
 55 60 65

Sequence Listing

cag gag ata atc aaa gaa atc tct ata atg cag caa tgt gac agc cct	291
Gln Glu Ile Ile Lys Glu Ile Ser Ile Met Gln Gln Cys Asp Ser Pro	
70 75 80	
cat gta gtc aaa tat tat ggc agt tat ttt aag aac aca gac tta tgg	339
His Val Val Lys Tyr Tyr Gly Ser Tyr Phe Lys Asn Thr Asp Leu Trp	
85 90 95	
atc gtt atg gag tac tgt ggg gct ggt tct gta tct gat atc att cga	387
Ile Val Met Glu Tyr Cys Gly Ala Gly Ser Val Ser Asp Ile Ile Arg	
100 105 110 115	
tta cga aat aaa acg tta aca gaa gat gaa ata gct aca ata tta caa	435
Leu Arg Asn Lys Thr Leu Thr Glu Asp Glu Ile Ala Thr Ile Leu Gln	
120 125 130	
tca act ctt aag gga ctt gaa tac ctt cat ttt atg aga aaa ata cac	483
Ser Thr Leu Lys Gly Leu Glu Tyr Leu His Phe Met Arg Lys Ile His	
135 140 145	
cga gat atc aag gca gga aat att ttg cta aat aca gaa gga cat gca	531
Arg Asp Ile Lys Ala Gly Asn Ile Leu Leu Asn Thr Glu Gly His Ala	
150 155 160	
aaa ctt gca gat ttt ggg gta gca ggt caa ctt aca gat acc atg gcc	579
Lys Leu Ala Asp Phe Gly Val Ala Gly Gln Leu Thr Asp Thr Met Ala	
165 170 175	
aag cgg aat aca gtg ata gga aca cca ttt tgg atg gct cca gaa gtg	627
Lys Arg Asn Thr Val Ile Gly Thr Pro Phe Trp Met Ala Pro Glu Val	
180 185 190 195	
att cag gaa att gga tac aac tgt gta gca gac atc tgg tcc ctg gga	675
Ile Gln Glu Ile Gly Tyr Asn Cys Val Ala Asp Ile Trp Ser Leu Gly	
200 205 210	
ata act gcc ata gaa atg gct gaa gga aag ccc cct tat gct gat atc	723
Ile Thr Ala Ile Glu Met Ala Glu Gly Lys Pro Pro Tyr Ala Asp Ile	
215 220 225	

Sequence Listing

cat cca atg agg gca atc ttc atg att cct aca aat cct cct ccc aca His Pro Met Arg Ala Ile Phe Met Ile Pro Thr Asn Pro Pro Pro Thr 230 235 240	771
ttc cga aaa cca gag cta tgg tca gat aac ttt aca gat ttt gtg aaa Phe Arg Lys Pro Glu Leu Trp Ser Asp Asn Phe Thr Asp Phe Val Lys 245 250 255	819
cag tgt ctt gta aag agc cct gag cag agg gcc aca gcc act cag ctc Gln Cys Leu Val Lys Ser Pro Glu Gln Arg Ala Thr Ala Thr Gln Leu 260 265 270 275	867
ctg cag cac cca ttt gtc agg agt gcc aaa gga gtg tca ata ctg cga Leu Gln His Pro Phe Val Arg Ser Ala Lys Gly Val Ser Ile Leu Arg 280 285 290	915
gac tta att aat gaa gcc atg gat gtg aaa ctg aaa cgc cag gaa tcc Asp Leu Ile Asn Glu Ala Met Asp Val Lys Leu Lys Arg Gln Glu Ser 295 300 305	963
cag cag cgg gaa gtg gac cag gac gat gaa gaa aac tca gaa gag gat Gln Gln Arg Glu Val Asp Gln Asp Asp Glu Glu Asn Ser Glu Glu Asp 310 315 320	1011
gaa atg gat tct ggc acg atg gtt cga gca gtg ggt gat gag atg ggc Glu Met Asp Ser Gly Thr Met Val Arg Ala Val Gly Asp Glu Met Gly 325 330 335	1059
act gtc cga gta gcc agc acc atg act gat gga gcc aat act atg att Thr Val Arg Val Ala Ser Thr Met Thr Asp Gly Ala Asn Thr Met Ile 340 345 350 355	1107
gag cac gat gac acg ttg cca tca caa ctg ggc acc atg gtg atc aat Glu His Asp Asp Thr Leu Pro Ser Gln Leu Gly Thr Met Val Ile Asn 360 365 370	1155
gca gag gat gag gaa gag gaa gga act atg aaa aga agg gat gag acc Ala Glu Asp Glu Glu Glu Gly Thr Met Lys Arg Arg Asp Glu Thr 375 380 385	1203

Sequence Listing

atg cag cct gcg aaa cca tcc ttt ctt gaa tat ttt gaa caa aaa gaa	1251
Met Gln Pro Ala Lys Pro Ser Phe Leu Glu Tyr Phe Glu Gln Lys Glu	
390 395 400	
aag gaa aac cag atc aac agc ttt ggc aag agt gta cct ggt cca ctg	1299
Lys Glu Asn Gln Ile Asn Ser Phe Gly Lys Ser Val Pro Gly Pro Leu	
405 410 415	
aaa aat tct tca gat tgg aaa ata cca cag gat gga gac tac gag ttt	1347
Lys Asn Ser Ser Asp Trp Lys Ile Pro Gln Asp Gly Asp Tyr Glu Phe	
420 425 430 435	
ctt aag agt tgg aca gtg gag gac ctt cag aag agg ctc ttg gcc ctg	1395
Leu Lys Ser Trp Thr Val Glu Asp Leu Gln Lys Arg Leu Leu Ala Leu	
440 445 450	
gac ccc atg atg gag cag gag att gaa gag atc cgg cag aag tac cag	1443
Asp Pro Met Met Glu Gln Glu Ile Glu Glu Ile Arg Gln Lys Tyr Gln	
455 460 465	
tcc aag cgg cag ccc atc ctg gat gcc ata gag gct aag aag aga cgg	1491
Ser Lys Arg Gln Pro Ile Leu Asp Ala Ile Glu Ala Lys Lys Arg Arg	
470 475 480	
caa caa aac ttc tgagcaa ggccaggctg tgagggcccc agtccacccc	1540
Gln Gln Asn Phe	
485	
aggctttggg tgaattctgg atggcttgcc tcatgtttgt tagccagcac ttctgctctg	1600
tcgtctctcc acagcacctt tgtgaactca ggaatgtgcg ccagtgggaa gggctctctt	1660
gacagtcagc gtgccatctt gatgtgtgta tgtacattgg tcaggtatat tatctcaaag	1720
gatttatatt ggcgctttta actcagagtt ttaaacccca ggaacagaga ctcttagttg	1780
agtgatagct gggaaagttt tacattgtct gtttttcttc tcccaatagc tttcaattgt	1840
tctttctgga agacttttaa aaaaatataa atatgcatat atatataata attataaata	1900

Sequence Listing

gattccccac gcaggtggtg gcattctctgt a

1931

<210> 16

<211> 487

<212> PRT

<213> Homo sapiens

<400> 16

Met Glu Thr Val Gln Leu Arg Asn Pro Pro Arg Arg Gln Leu Lys Lys
 1 5 10 15

Leu Asp Glu Asp Ser Leu Thr Lys Gln Pro Glu Glu Val Phe Asp Val
 20 25 30

Leu Glu Lys Leu Gly Glu Gly Ser Tyr Gly Ser Val Tyr Lys Ala Ile
 35 40 45

His Lys Glu Thr Gly Gln Ile Val Ala Ile Lys Gln Val Pro Val Glu
 50 55 60

Ser Asp Leu Gln Glu Ile Ile Lys Glu Ile Ser Ile Met Gln Gln Cys
 65 70 75 80

Asp Ser Pro His Val Val Lys Tyr Tyr Gly Ser Tyr Phe Lys Asn Thr
 85 90 95

Asp Leu Trp Ile Val Met Glu Tyr Cys Gly Ala Gly Ser Val Ser Asp
 100 105 110

Ile Ile Arg Leu Arg Asn Lys Thr Leu Thr Glu Asp Glu Ile Ala Thr
 115 120 125

Ile Leu Gln Ser Thr Leu Lys Gly Leu Glu Tyr Leu His Phe Met Arg
 130 135 140

Lys Ile His Arg Asp Ile Lys Ala Gly Asn Ile Leu Leu Asn Thr Glu
 145 150 155 160

Sequence Listing

Gly His Ala Lys Leu Ala Asp Phe Gly Val Ala Gly Gln Leu Thr Asp
165 170 175

Thr Met Ala Lys Arg Asn Thr Val Ile Gly Thr Pro Phe Trp Met Ala
180 185 190

Pro Glu Val Ile Gln Glu Ile Gly Tyr Asn Cys Val Ala Asp Ile Trp
195 200 205

Ser Leu Gly Ile Thr Ala Ile Glu Met Ala Glu Gly Lys Pro Pro Tyr
210 215 220

Ala Asp Ile His Pro Met Arg Ala Ile Phe Met Ile Pro Thr Asn Pro
225 230 235 240

Pro Pro Thr Phe Arg Lys Pro Glu Leu Trp Ser Asp Asn Phe Thr Asp
245 250 255

Phe Val Lys Gln Cys Leu Val Lys Ser Pro Glu Gln Arg Ala Thr Ala
260 265 270

Thr Gln Leu Leu Gln His Pro Phe Val Arg Ser Ala Lys Gly Val Ser
275 280 285

Ile Leu Arg Asp Leu Ile Asn Glu Ala Met Asp Val Lys Leu Lys Arg
290 295 300

Gln Glu Ser Gln Gln Arg Glu Val Asp Gln Asp Asp Glu Glu Asn Ser
305 310 315 320

Glu Glu Asp Glu Met Asp Ser Gly Thr Met Val Arg Ala Val Gly Asp
325 330 335

Glu Met Gly Thr Val Arg Val Ala Ser Thr Met Thr Asp Gly Ala Asn
340 345 350

Thr Met Ile Glu His Asp Asp Thr Leu Pro Ser Gln Leu Gly Thr Met
355 360 365

Val Ile Asn Ala Glu Asp Glu Glu Glu Glu Gly Thr Met Lys Arg Arg

Sequence Listing

```

370          375          380
Asp Glu Thr Met Gln Pro Ala Lys Pro Ser Phe Leu Glu Tyr Phe Glu
385          390          395          400
Gln Lys Glu Lys Glu Asn Gln Ile Asn Ser Phe Gly Lys Ser Val Pro
          405          410          415
Gly Pro Leu Lys Asn Ser Ser Asp Trp Lys Ile Pro Gln Asp Gly Asp
          420          425          430
Tyr Glu Phe Leu Lys Ser Trp Thr Val Glu Asp Leu Gln Lys Arg Leu
          435          440          445
Leu Ala Leu Asp Pro Met Met Glu Gln Glu Ile Glu Glu Ile Arg Gln
          450          455          460
Lys Tyr Gln Ser Lys Arg Gln Pro Ile Leu Asp Ala Ile Glu Ala Lys
          465          470          475          480
Lys Arg Arg Gln Gln Asn Phe
          485

```

```

<210> 17
<211> 1299
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> CDS
<222> (75)..(572)
<223> Clone no. LBFL306-EF3

```

```

<400> 17
gcggcgcgcg cttctcgagt cctccccgac gcgtcctcta ggccagcgag ccccgcgctc 60
tccggtgacg gacc          atg tcg gcg gcg gga gcg ggc gcg ggc gta gag 107
Met Ser Ala Ala Gly Ala Gly Ala Gly Val Glu

```

Sequence Listing

1	5	10	
gcg ggc ttc tcc agc gag gag ctg ctc tcg ctc cgt ttc ccg .ctg cac			155
Ala Gly Phe Ser Ser Glu Glu Leu Leu Ser Leu Arg Phe Pro Leu His			
15	20	25	
cgc gcc .tgc cgc gac ggg gac ctg gcc acg ctc tgc tcg ctg ctg cag			203
Arg Ala Cys Arg Asp Gly Asp Leu Ala Thr Leu Cys Ser Leu Leu Gln			
30	35	40	
cag aca ccc cac gcc cac ctg gcc tct gag gac tcc ttc tat ggc tgg			251
Gln Thr Pro His Ala His Leu Ala Ser Glu Asp Ser Phe Tyr Gly Trp			
45	50	55	
acg ccc gtg cac tgg gcc gcg cat ttc ggc aag ttg gag tgc tta gtg			299
Thr Pro Val His Trp Ala Ala His Phe Gly Lys Leu Glu Cys Leu Val			
60	65	70	75
cag ttg gtg aga gcg gga gcc aca ctc aac gtc tcc acc aca cgg tac			347
Gln Leu Val Arg Ala Gly Ala Thr Leu Asn Val Ser Thr Thr Arg Tyr			
80	85	90	
gcg cag acg cca gcc cac att gca gcc .ttt ggg gga cat cct cag tgc			395
Ala Gln Thr Pro Ala His Ile Ala Ala Phe Gly Gly His Pro Gln Cys			
95	100	105	
ctg gtc tgg ctg att caa gca gga gcc aac att aac aaa ccg gat tgt			443
Leu Val Trp Leu Ile Gln Ala Gly Ala Asn Ile Asn Lys Pro Asp Cys			
110	115	120	
gag ggt gaa act ccc att cac aag gca gct cgc tct ggg agc cta gaa			491
Glu Gly Glu Thr Pro Ile His Lys Ala Ala Arg Ser Gly Ser Leu Glu			
125	130	135	
tgc atc agt gcc ctt gtg gcg aat ggg gct cac gtc gat aac ccc aag			539
Cys Ile Ser Ala Leu Val Ala Asn Gly Ala His Val Asp Asn Pro Lys			
140	145	150	155
aaa ggc atc agg gtt ctg gag tgg ttg ttt gag	tgacacag cacaaggcct		590
Lys Gly Ile Arg Val Leu Glu Trp Leu Phe Glu			

Sequence Listing

160

165

```

tgatttcac atgcttttgc tgtggatgta gtgtagcttg ctgaacaggt ttatttcaca      650
gagcagtgtg cattcttgtc ttccagggga acttcaacat ggagttactt ttgatccctc      710
agttttaatt cagtgtctaa agcctgagaa atgccagtgg cctgacagca gcagacattg      770
cacaaaccca gggtttccaa gagtgtgccc agtttctctt gaacctccag aattgtcatc      830
tgaaccattt ctataacaat ggcattctaa atgggggtca tcagaatgta tttcctaatac      890
atattagtgt gggaacaaat cgaaagagat gcttggaaga ctcagaagac tttggagtaa      950
agaaagctag aactgaaggt gagaccgctt tgcgggtggg aagagcacac ttatttttcc     1010
tttctgtaat atgttttctt tttatggctg agcgcacctt cgagatgaga ccttcacttc     1070
aggtggtaat gcgcctgggtg gattgtgcgg tgacgggtgga gatttctcct gtactgccac     1130
tgcaagatg  ggacacttaa caaaaggga  tgtgaggga  atactgatgg cccaagtgt  1190
aatgtctatg tggaaacttt tgagcaccca tgtttacctg ccgtgaatta gattttttaa     1250
tttgtgttat ctgtttgaaa tatatctatt aaagaaaaaa aaaaaaaaaa     1299

```

<210> 18

<211> 166

<212> PRT

<213> Homo sapiens

<400> 18

```

Met Ser Ala Ala Gly Ala Gly Val Glu Ala Gly Phe Ser Ser
  1             5             10             15

```

```

Glu Glu Leu Leu Ser Leu Arg Phe Pro Leu His Arg Ala Cys Arg Asp
      20             25             30

```

```

Gly Asp Leu Ala Thr Leu Cys Ser Leu Leu Gln Gln Thr Pro His Ala

```

Sequence Listing

35

40

45

His Leu Ala Ser Glu Asp Ser Phe Tyr Gly Trp Thr Pro Val His Trp

50

55

60

Ala Ala His Phe Gly Lys Leu Glu Cys Leu Val Gln Leu Val Arg Ala

65

70

75

80

Gly Ala Thr Leu Asn Val Ser Thr Thr Arg Tyr Ala Gln Thr Pro Ala

85

90

95

His Ile Ala Ala Phe Gly Gly His Pro Gln Cys Leu Val Trp Leu Ile

100

105

110

Gln Ala Gly Ala Asn Ile Asn Lys Pro Asp Cys Glu Gly Glu Thr Pro

115

120

125

Ile His Lys Ala Ala Arg Ser Gly Ser Leu Glu Cys Ile Ser Ala Leu

130

135

140

Val Ala Asn Gly Ala His Val Asp Asn Pro Lys Lys Gly Ile Arg Val

145

150

155

160

Leu Glu Trp Leu Phe Glu

165

<210> 19

<211> 2451

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (78) .. (1337)

<223> Clone no. LBFL306-GC7

<400> 19

gctgcggcgg cggcttctcg agtcctcccc gacgcgtcct ctaggccagc gagccccgcg

60

Sequence Listing

```

ctctccggtg acggacc      atg tcg gcg gcg gga gcg ggc gcg ggc gta gag      110
                        Met Ser Ala Ala Gly Ala Gly Ala Gly Val Glu
                          1              5              10

gcg ggc ttc tcc agc gag gag ctg ctc tcg ctc cgt ttc ccg ctg cac      158
Ala Gly Phe Ser Ser Glu Glu Leu Leu Ser Leu Arg Phe Pro Leu His
                   15                   20                   25

cgc gcc tgc cgc gac ggg gac ctg gcc acg ctc tgc tcg ctg ctg cag      206
Arg Ala Cys Arg Asp Gly Asp Leu Ala Thr Leu Cys Ser Leu Leu Gln
                   30                   35                   40

cag aca ccc cac gcc cac ctg gcc tct gag gac tcc ttc tat ggc tgg      254
Gln Thr Pro His Ala His Leu Ala Ser Glu Asp Ser Phe Tyr Gly Trp
                   45                   50                   55

acg ccc gtg cac tgg gcc gcg cat ttc ggc aag ttg gag tgc tta gtg      302
Thr Pro Val His Trp Ala Ala His Phe Gly Lys Leu Glu Cys Leu Val
                   60                   65                   70                   75

cag ttg gtg aga gcg gga gcc aca ctc aac gtc tcc acc aca cgg tac      350
Gln Leu Val Arg Ala Gly Ala Thr Leu Asn Val Ser Thr Thr Arg Tyr
                   80                   85                   90

gcg cag acg cca gcc cac att gca gcc ttt ggg gga cat cct cag tgc      398
Ala Gln Thr Pro Ala His Ile Ala Ala Phe Gly Gly His Pro Gln Cys
                   95                   100                  105

ctg gtc tgg ctg att caa gca gga gcc aac att aac aaa ccg gat tgt      446
Leu Val Trp Leu Ile Gln Ala Gly Ala Asn Ile Asn Lys Pro Asp Cys
                   110                  115                  120

gag ggt gaa act ccc att cac aag gca gct cgc tct ggg agc cta gaa      494
Glu Gly Glu Thr Pro Ile His Lys Ala Ala Arg Ser Gly Ser Leu Glu
                   125                  130                  135

tgc atc agt gcc ctt gtg gcg aat ggg gct cac gtc gac ctg aga aat      542
Cys Ile Ser Ala Leu Val Ala Asn Gly Ala His Val Asp Leu Arg Asn
                   140                  145                  150                  155

```

Sequence Listing

gcc agt ggc ctg aca gca gca gac att gca caa acc cag ggt ttc caa Ala Ser Gly Leu Thr Ala Ala Asp Ile Ala Gln Thr Gln Gly Phe Gln 160 165 170	590
gag tgt gcc cag ttt ctc ttg aac ctc cag aat tgt cat ctg aac cat Glu Cys Ala Gln Phe Leu Leu Asn Leu Gln Asn Cys His Leu Asn His 175 180 185	638
ttc tat aac aat ggc atc tta aat ggg ggt cat cag aat gta ttt cct Phe Tyr Asn Asn Gly Ile Leu Asn Gly Gly His Gln Asn Val Phe Pro 190 195 200	686
aat cat att agt gtg gga aca aat cga aag aga tgc ttg gaa gac tca Asn His Ile Ser Val Gly Thr Asn Arg Lys Arg Cys Leu Glu Asp Ser 205 210 215	734
gaa gac ttt gga gta aag aaa gct aga act gaa gct caa agc ttg gat Glu Asp Phe Gly Val Lys Lys Ala Arg Thr Glu Ala Gln Ser Leu Asp 220 225 230 235	782
tct gcc gtg cca ctc acg aat ggc gac aca gaa gac gat gct gac aaa Ser Ala Val Pro Leu Thr Asn Gly Asp Thr Glu Asp Asp Ala Asp Lys 240 245 250	830
atg cac gtt gat agg gag ttt gct gtt gta aca gat atg aaa aac agt Met His Val Asp Arg Glu Phe Ala Val Val Thr Asp Met Lys Asn Ser 255 260 265	878
agc tcc gta tcg aat aca ttg aca aat gga tgt gtc atc aat gga cat Ser Ser Val Ser Asn Thr Leu Thr Asn Gly Cys Val Ile Asn Gly His 270 275 280	926
ttg gac ttc ccc tcc acg acc ccg ctc agt ggg atg gaa agc agg aat Leu Asp Phe Pro Ser Thr Thr Pro Leu Ser Gly Met Glu Ser Arg Asn 285 290 295	974
ggc cag tgc ttg aca gga act aac gga att agc agt gga tta gcc cca Gly Gln Cys Leu Thr Gly Thr Asn Gly Ile Ser Ser Gly Leu Ala Pro 300 305 310 315	1022

Sequence Listing

gga cag ccg ttt ccg agt agc cag ggt tct ctc tgc att agt ggg act	1070
Gly Gln Pro Phe Pro Ser Ser Gln Gly Ser Leu Cys Ile Ser Gly Thr	
320 325 330	
gag gag cca gag aag acc ctg aga gct aac cct gag ttg tgc ggt tct	1118
Glu Glu Pro Glu Lys Thr Leu Arg Ala Asn Pro Glu Leu Cys Gly Ser	
335 340 345	
ctg cac ctg aac ggg agt cca agt agc tgc ata gcc agt agg cct tcc	1166
Leu His Leu Asn Gly Ser Pro Ser Ser Cys Ile Ala Ser Arg Pro Ser	
350 355 360	
tgg gtg gaa gac att ggg gat aac ctg tac tat gga cac tac cac ggg	1214
Trp Val Glu Asp Ile Gly Asp Asn Leu Tyr Tyr Gly His Tyr His Gly	
365 370 375	
ttt ggg gac act gct gaa agc atc cca gaa ctg aac agt gtg gtc gag	1262
Phe Gly Asp Thr Ala Glu Ser Ile Pro Glu Leu Asn Ser Val Val Glu	
380 385 390 395	
cat tcc aag tcc gtg aag gtg cag gag cgg tac gac agt gcc gtg ctg	1310
His Ser Lys Ser Val Lys Val Gln Glu Arg Tyr Asp Ser Ala Val Leu	
400 405 410	
ggc acc atg cac ctg cac cac ggc tcc tag agacgctgac ctggctctcg	1360
Gly Thr Met His Leu His His Gly Ser	
415 420	
gaaacgcagg agtccttcct ggtagccagc tcagaatacc catgtagcag caacttgaac	1420
gaatgtcaca acttgtacgt tttttatata cttcaacttt ctgaaaaagt aaacttcgac	1480
aagttcccag caactgcttg tttgtgcatg agtagggctt actaagtgca tagatgtttc	1540
tacagtgagg tgtccttttt ataaggtgca cttttggagt tcttctgatg ccaatctcaa	1600
cattgtcttt ttaatactgt caccagatat tgccattttt ctttttgtta aaagattata	1660
tgatcaagat aaattggggg ggtaaatacag gtgccttgga atttatctct ttgcacatgg	1720

Sequence Listing

```

gcatcatttt aaaaagcttg cttccactct tttctgtaga atttgacgga acacagctat      1780
ttccctatgc aaggtacagc cttacaaaga tttctgcagt gatttgtgtg aagaagagaa      1840
cgtttgtctt tttcaatgaa gctttgcaga tcaccatgtg gttgaagggt ttagttgttg      1900
acacagtggg ccttccttaa tgatgaagat cactgccttg ggcttcattg aaaacaggcc      1960
cagcctgggg ctgcgttttg atttattgtt tttattccac acttctact tggctctctg      2020
aagttttacc acatgtaaca gattccttta tatgtagtgg aaatcactat ttgtagaaac      2080
tgtcagggtca aaatatttaa ctgactgttg acatgtatct tcttttttcc ttgtttttgt      2140
tttttagggg tttctgcttt aagatatata ccactatgta tatccagtta actgagagaa      2200
ttttgactct cttaataaaa ctgcattaag tttttgattt tgtagaaatt agcttttctc      2260
taggcaacta gtggttatac tctgcaaata ttgtaatgaa tttttacttt ttgatttttt      2320
gtaataaaaa ttggtgcaga taaaatgtca aatgaacaaa ccagtgttct aagagtgtta      2380
ctaacatttt gttctaaaac tgtccttcac aaattgaata aaaaactctc acactcaaaa      2440
aaaaaaaaa a                                                                2451

```

<210> 20

<211> 420

<212> PRT

<213> Homo sapiens

<400> 20

Met Ser Ala Ala Gly Ala Gly Ala Gly Val Glu Ala Gly Phe Ser Ser

1

5

10

15

Glu Glu Leu Leu Ser Leu Arg Phe Pro Leu His Arg Ala Cys Arg Asp

20

25

30

Sequence Listing

Gly Asp Leu Ala Thr Leu Cys Ser Leu Leu Gln Gln Thr Pro His Ala
 35 40 45

His Leu Ala Ser Glu Asp Ser Phe Tyr Gly Trp Thr Pro Val His Trp
 50 55 60

Ala Ala His Phe Gly Lys Leu Glu Cys Leu Val Gln Leu Val Arg Ala
 65 70 75 80

Gly Ala Thr Leu Asn Val Ser Thr Thr Arg Tyr Ala Gln Thr Pro Ala
 85 90 95

His Ile Ala Ala Phe Gly Gly His Pro Gln Cys Leu Val Trp Leu Ile
 100 105 110

Gln Ala Gly Ala Asn Ile Asn Lys Pro Asp Cys Glu Gly Glu Thr Pro
 115 120 125

Ile His Lys Ala Ala Arg Ser Gly Ser Leu Glu Cys Ile Ser Ala Leu
 130 135 140

Val Ala Asn Gly Ala His Val Asp Leu Arg Asn Ala Ser Gly Leu Thr
 145 150 155 160

Ala Ala Asp Ile Ala Gln Thr Gln Gly Phe Gln Glu Cys Ala Gln Phe
 165 170 175

Leu Leu Asn Leu Gln Asn Cys His Leu Asn His Phe Tyr Asn Asn Gly
 180 185 190

Ile Leu Asn Gly Gly His Gln Asn Val Phe Pro Asn His Ile Ser Val
 195 200 205

Gly Thr Asn Arg Lys Arg Cys Leu Glu Asp Ser Glu Asp Phe Gly Val
 210 215 220

Lys Lys Ala Arg Thr Glu Ala Gln Ser Leu Asp Ser Ala Val Pro Leu
 225 230 235 240

Thr Asn Gly Asp Thr Glu Asp Asp Ala Asp Lys Met His Val Asp Arg

Sequence Listing

245	250	255
Glu Phe Ala Val Val Thr Asp Met Lys Asn Ser Ser Ser Val Ser Asn		
260	265	270
Thr Leu Thr Asn Gly Cys Val Ile Asn Gly His Leu Asp Phe Pro Ser		
275	280	285
Thr Thr Pro Leu Ser Gly Met Glu Ser Arg Asn Gly Gln Cys Leu Thr		
290	295	300
Gly Thr Asn Gly Ile Ser Ser Gly Leu Ala Pro Gly Gln Pro Phe Pro		
305	310	315 320
Ser Ser Gln Gly Ser Leu Cys Ile Ser Gly Thr Glu Glu Pro Glu Lys		
325	330	335
Thr Leu Arg Ala Asn Pro Glu Leu Cys Gly Ser Leu His Leu Asn Gly		
340	345	350
Ser Pro Ser Ser Cys Ile Ala Ser Arg Pro Ser Trp Val Glu Asp Ile		
355	360	365
Gly Asp Asn Leu Tyr Tyr Gly His Tyr His Gly Phe Gly Asp Thr Ala		
370	375	380
Glu Ser Ile Pro Glu Leu Asn Ser Val Val Glu His Ser Lys Ser Val		
385	390	395 400
Lys Val Gln Glu Arg Tyr Asp Ser Ala Val Leu Gly Thr Met His Leu		
405	410	415
His His Gly Ser		
420		

<210> 21
 <211> 1194
 <212> DNA
 <213> Homo sapiens

Sequence Listing

<220>

<221> CDS

<222> (78)..(737)

<223> Clone no. LBFL-306-GE2

<400> 21

gctgcggcgg cggtttctcg agtcctcccc gacgcgtcct ctaggccagc gagccccgcg 60

ctctccggtg acggacc atg tcg gcg gcg gga gcg ggc gcg ggc gta gag 110
Met Ser Ala Ala Gly Ala Gly Ala Gly Val Glu
1 5 10

gcg ggc ttc tcc agc gag gag ctg ctc tcg ctc cgt ttc ccg ctg cac 158
Ala Gly Phe Ser Ser Glu Glu Leu Leu Ser Leu Arg Phe Pro Leu His
15 20 25

cgc gcc tgc cgc gac ggg gac ctg gcc acg ctc tgc tcg ctg ctg cag 206
Arg Ala Cys Arg Asp Gly Asp Leu Ala Thr Leu Cys Ser Leu Leu Gln
30 35 40

cag aca ccc cac gcc cac ctg gcc tct gag gac tcc ttc tat ggc tgg 254
Gln Thr Pro His Ala His Leu Ala Ser Glu Asp Ser Phe Tyr Gly Trp
45 50 55

acg ccc gtg cac tgg gcc gcg cat ttc ggc aag ttg gag tgc tta gtg 302
Thr Pro Val His Trp Ala Ala His Phe Gly Lys Leu Glu Cys Leu Val
60 65 70 75

cag ttg gtg aga gcg gga gcc aca ctc aac gtc tcc acc aca cgg tac 350
Gln Leu Val Arg Ala Gly Ala Thr Leu Asn Val Ser Thr Thr Arg Tyr
80 85 90

gcg cag acg cca gcc cac att gca gcc ttt ggg gga cat cct cag tgc 398
Ala Gln Thr Pro Ala His Ile Ala Ala Phe Gly Gly His Pro Gln Cys
95 100 105

ctg gtc tgg ctg att caa gca gga gcc aac att aac aaa ccg gat tgt 446
Leu Val Trp Leu Ile Gln Ala Gly Ala Asn Ile Asn Lys Pro Asp Cys

Sequence Listing

110	115	120	
gag ggt gaa act ccc att cac aag gca gct cgc tct ggg agc cta gaa			494
Glu Gly Glu Thr Pro Ile His Lys Ala Ala Arg Ser Gly Ser Leu Glu			
125	130	135	
tgc atc agt gcc ctt gtg gcg aat ggg gct cac gtc gag ttt att tca			542
Cys Ile Ser Ala Leu Val Ala Asn Gly Ala His Val Glu Phe Ile Ser			
140	145	150	155
cag agc agt gta cat tct tgt ctt cca ggg gaa ctt caa cat gga gtt			590
Gln Ser Ser Val His Ser Cys Leu Pro Gly Glu Leu Gln His Gly Val			
160	165	170	
act ttt gat ccc tca gtt tta att cag tgt cta aag cct gag aaa tgc			638
Thr Phe Asp Pro Ser Val Leu Ile Gln Cys Leu Lys Pro Glu Lys Cys			
175	180	185	
cag tgg cct gac agc agc aga cat tgc aca aac cca ggg ttt cca aga			686
Gln Trp Pro Asp Ser Ser Arg His Cys Thr Asn Pro Gly Phe Pro Arg			
190	195	200	
gtg tgc cca gtt tct ctt gaa cct cca gaa ttg tca tct gaa cca ttt			734
Val Cys Pro Val Ser Leu Glu Pro Pro Glu Leu Ser Ser Glu Pro Phe			
205	210	215	
cta taa caatggcatc ttaaattgggg gtcattcagaa tgtatttcct aatcatatta			790
Leu			
220			
gtgtgggaac aaatcgaaag agatgcttgg aagactcaga agactttgga gtaaagaaag			850
ctagaactga aggtgagacc gctttgcggg tgggaagagc acacttattt ttcctttctg			910
taatattgttt tctttttatg gctgagcgca ccttcgagat gagaccttca cttcaggtgg			970
taatgcgcct ggtggattgt gcggtgacgg tggagatttc tcctgtactg ccactgcgaa			1030
gatgggacac ttaacaaaag ggaatgtgag ggaaatactg atggcccaag tgtaaatgtc			1090

Sequence Listing

tatgtggaac tttttgagca cccatgttta cctgccgtga attagatttt ttaatttgtt 1150

gtatctgttt gaaatatatc tattaaagaa aaaaaaaaaa aaaa 1194

<210> 22

<211> 220

<212> PRT

<213> Homo sapiens

<400> 22

Met Ser Ala Ala Gly Ala Gly Ala Gly Val Glu Ala Gly Phe Ser Ser
1 5 10 15

Glu Glu Leu Leu Ser Leu Arg Phe Pro Leu His Arg Ala Cys Arg Asp
20 25 30

Gly Asp Leu Ala Thr Leu Cys Ser Leu Leu Gln Gln Thr Pro His Ala
35 40 45

His Leu Ala Ser Glu Asp Ser Phe Tyr Gly Trp Thr Pro Val His Trp
50 55 60

Ala Ala His Phe Gly Lys Leu Glu Cys Leu Val Gln Leu Val Arg Ala
65 70 75 80

Gly Ala Thr Leu Asn Val Ser Thr Thr Arg Tyr Ala Gln Thr Pro Ala
85 90 95

His Ile Ala Ala Phe Gly Gly His Pro Gln Cys Leu Val Trp Leu Ile
100 105 110

Gln Ala Gly Ala Asn Ile Asn Lys Pro Asp Cys Glu Gly Glu Thr Pro
115 120 125

Ile His Lys Ala Ala Arg Ser Gly Ser Leu Glu Cys Ile Ser Ala Leu
130 135 140

Val Ala Asn Gly Ala His Val Glu Phe Ile Ser Gln Ser Ser Val His
145 150 155 160

Sequence Listing

Ser Cys Leu Pro Gly Glu Leu Gln His Gly Val Thr Phe Asp Pro Ser
165 170 175

Val Leu Ile Gln Cys Leu Lys Pro Glu Lys Cys Gln Trp Pro Asp Ser
180 185 190

Ser Arg His Cys Thr Asn Pro Gly Phe Pro Arg Val Cys Pro Val Ser
195 200 205

Leu Glu Pro Pro Glu Leu Ser Ser Glu Pro Phe Leu
210 215 220

